Microfluidics-Based Single-Cell Functional Proteomics Microchip for Portraying Protein Signal Transduction Networks within the Framework of Physicochemical Principles, with Applications in Fundamental and Translational Cancer Research by Wei, Wei
MICROFLUIDICS-BASED SINGLE-CELL FUNCTIONAL 
PROTEOMICS MICROCHIP FOR PORTRAYING 
PROTEIN SIGNAL TRANSDUCTION NETWORKS 
WITHIN THE FRAMEWORK OF PHYSICOCHEMICAL 
PRINCIPLES, WITH APPLICATIONS IN 
FUNDAMENTAL AND TRANSLATIONAL CANCER 
RESEARCH 
 
 
Thesis by 
Wei Wei 
 
In Partial Fulfillment of the Requirements for the degree 
of 
Doctor of Philosophy 
 
 
 
 
 
 
 
CALIFORNIA INSTITUTE OF TECHNOLOGY 
Pasadena, California 
2014 
(Defended  February 12, 2014)
 ii 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 2014 
Wei Wei 
All Rights Reserved
 iii 
 
 
 
 
 
 
 
To my dearest wife, 
Bing Shu 
 
 iv 
ACKNOWLEDGEMENTS 
It would not have been possible to finish this doctoral thesis without the constant help 
and support from the talented and kind people around me during my study at Caltech, to 
only some of whom it is possible to give a particular mention here. 
Foremost, I would like to express my deepest appreciation to my advisor, Professor 
Jim Heath. His boundless enthusiasm for science and persistent pursuit of truth 
exceptionally inspire and enrich me all the time, not to mention his advice, insight and 
supreme knowledge in the field. He offers everyone in the group sufficient academic 
freedom, supports and resources, allowing me to pursue my own scientific ideas and 
shaping me from a knowledge absorber to an independent scientist. Jim's unlimited 
support, trust and friendship have been invaluable to me on both an academic and a 
personal level, for which I am extremely grateful. I could not have imagined having a better 
advisor and mentor for my PhD study. 
I have been so fortunate to have had the great opportunity to work with many 
intelligent collaborators through Jim's organization among Caltech, UCLA, and the 
Institute for Systems Biology (ISB).  I would like to express my sincere gratitude to many 
senior collaborators, including Professor Paul Mischel, Professor Raphael Levine, 
Professor Tim Cloughesy, Professor Francoise Remacle, Professor Antoni Ribas, and 
Professor Leroy Hood for their unsurpassed knowledge and great support in the 
collaborative projects. 
 v 
I would like to thank the members of my thesis committee, Professor William 
Goddard, Professor Julia Greer, Professor William Johnson and Professor Mark Davis, for 
their time, encouragement and insightful comments. 
I would like to thank my friends and colleagues whom I have had the pleasure of 
working with over the years. Specifically, I am most grateful to Dr. Qihui Shi and Dr. 
Lidong Qin, who trained me when I joined into Jim's lab as a fresh PhD. Qihui and I 
worked closely to develop the single-cell functional proteomic microchip and successfully 
applied it to address fundamental cancer biology problems. We also become very close 
friends. I thank my great collaborators and good friends, Dr. Young Shik Shin and Dr. 
Beatrice Gini. We worked closely to apply our microchip technology to the preclinical 
cancer research. I thank my fellow labmates, Dr. Heather Agnew, Dr. Rosemary Rohde, 
Dr. Ann Cheung, Dr. Min Xue, Dr. Kiwook Hwang, Dr. Jing Zhou, Dr. Jing Yu, Dr. Chao 
Ma, Dr. Peigen Cao, Dr. Nataly Balasha, Dr. Jun Wang, Alex Sutherland, and all other 
current and past members of the Heath group, for all the fun we have had in the last four 
years. I thank my friends Michael Amori, Ke Sun, and Chenguang Ji for sharing personal 
lives as well as scientific ideas. I am very grateful to Kevin Kan and Elyse Garlock for their 
effort in lab management and administration. 
My sincere thanks also go to my past and current option representatives, Professor 
Brent Fultz and Professor Sossina Haile for their mentoring and useful advice in academic 
affairs. I thank Pam Albertson, Christy Jenstad, Natalie Gilmore, and Laura Flower Kim for 
their kind help in administrative affairs. 
Last, but by no means least, I owe much to my beautiful wife, Bing Shu, for her 
unlimited love, care and support that enrich my life with joy and happiness throughout. I 
 vi 
thank my parents and parents-in-law for letting me pursue my dream for so long and so 
far away from home, and supporting me spiritually all the time.  
 
 vii 
ABSTRACT 
Single-cell functional proteomics assays can connect genomic information to 
biological function through quantitative and multiplex protein measurements. Tools for 
single-cell proteomics have developed rapidly over the past 5 years and are providing 
unique opportunities. This thesis describes an emerging microfluidics-based toolkit for 
single cell functional proteomics, focusing on the development of the single cell barcode 
chips (SCBCs) with applications in fundamental and translational cancer research.  
The microchip designed to simultaneously quantify a panel of secreted, cytoplasmic 
and membrane proteins from single cells will be discussed at the beginning, which is the 
prototype for subsequent proteomic microchips with more sophisticated design in 
preclinical cancer research or clinical applications. The SCBCs are a highly versatile and 
information rich tool for single-cell functional proteomics. They are based upon isolating 
individual cells, or defined number of cells, within microchambers, each of which is 
equipped with a large antibody microarray (the barcode), with between a few hundred to 
ten thousand microchambers included within a single microchip. Functional proteomics 
assays at single-cell resolution yield unique pieces of information that significantly shape 
the way of thinking on cancer research. An in-depth discussion about analysis and 
interpretation of the unique information such as functional protein fluctuations and protein-
protein correlative interactions will follow. 
The SCBC is a powerful tool to resolve the functional heterogeneity of cancer cells. It 
has the capacity to extract a comprehensive picture of the signal transduction network from 
single tumor cells and thus provides insight into the effect of targeted therapies on protein 
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signaling networks. We will demonstrate this point through applying the SCBCs to 
investigate three isogenic cell lines of glioblastoma multiforme (GBM).   
The cancer cell population is highly heterogeneous with high-amplitude fluctuation at 
the single cell level, which in turn grants the robustness of the entire population. The 
concept that a stable population existing in the presence of random fluctuations is 
reminiscent of many physical systems that are successfully understood using statistical 
physics. Thus, tools derived from that field can probably be applied to using fluctuations to 
determine the nature of signaling networks. In the second part of the thesis, we will focus 
on such a case to use thermodynamics-motivated principles to understand cancer cell 
hypoxia, where single cell proteomics assays coupled with a quantitative version of Le 
Chatelier's principle derived from statistical mechanics yield detailed and surprising 
predictions, which were found to be correct in both cell line and primary tumor model. 
The third part of the thesis demonstrates the application of this technology in the 
preclinical cancer research to study the GBM cancer cell resistance to molecular targeted 
therapy. Physical approaches to anticipate therapy resistance and to identify effective 
therapy combinations will be discussed in detail. Our approach is based upon elucidating 
the signaling coordination within the phosphoprotein signaling pathways that are 
hyperactivated in human GBMs, and interrogating how that coordination responds to the 
perturbation of targeted inhibitor. Strongly coupled protein-protein interactions constitute 
most signaling cascades. A physical analogy of such a system is the strongly coupled atom-
atom interactions in a crystal lattice. Similar to decomposing the atomic interactions into a 
series of independent normal vibrational modes, a simplified picture of signaling network 
coordination can also be achieved by diagonalizing protein-protein correlation or 
 ix 
covariance matrices to decompose the pairwise correlative interactions into a set of 
distinct linear combinations of signaling proteins (i.e. independent signaling modes). By 
doing so, two independent signaling modes – one associated with mTOR signaling and a 
second associated with ERK/Src signaling have been resolved, which in turn allow us to 
anticipate resistance, and to design combination therapies that are effective, as well as 
identify those therapies and therapy combinations that will be ineffective. We validated our 
predictions in mouse tumor models and all predictions were borne out. 
In the last part, some preliminary results about the clinical translation of single-cell 
proteomic chips will be presented. The successful demonstration of our work on human-
derived xenografts provides the rationale to extend our current work into the clinic. It will 
enable us to interrogate GBM tumor samples in a way that could potentially yield a 
straightforward, rapid interpretation so that we can give therapeutic guidance to the 
attending physicians within a clinical relevant time scale. The technical challenges of the 
clinical translation will be presented and our solutions to address the challenges will be 
discussed as well. A clinical case study will then follow, where some preliminary data 
collected from a pediatric GBM patient bearing an EGFR amplified tumor will be 
presented to demonstrate the general protocol and the workflow of the proposed clinical 
studies. 
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1 
C h a p t e r  1  
Introduction 
1.1 NANOTECHNOLOGY INNOVATIVE TOOLS FOR CANCER RESEARCH 
Cancer is the leading cause of death worldwide. The early detection and treatment of 
cancer has been a long-term bottleneck in the clinic. Over the past decade, however, 
nanotechnology offers a wealth of innovative tools that lead to advances in early detection
1
, 
molecular imaging
2, 3
, assessment of therapeutic efficacy
4, 5
, targeted and multifunctional 
therapeutics
6, 7
, and prevention and control of this complex disease
8, 9
.  
Nanotechnology is being applied to cancer in two broad areas: the development of 
nanovectors, such as nanoparticles, which can be loaded with drugs or imaging agents and 
then targeted to tumors, and high-throughput biomolecular profiling devices that can detect 
a large number of different molecular species at the same time
10
.  
Thousands of nanovectors are currently under study, which include but not limited to 
liposomes
11, 12
, nanoparticles
13-15
, polymeric micelles
16, 17
, dendrimers
18
 and quantum dots
2, 
3
. Fundamental advantage of nanovectors is the multifunctionality that combines the 
avoidance of biobarriers, tumor targeting and controlled release. On the other hand, various 
micro- or nanofabrication technologies, such as photolithography, soft lithography, etc. 
enable high precision patterning of biological molecules on substrates, which in turn 
become the technological foundation of high-throughput and multiplexed platform for 
biomolecule detection
19-27
. Microarrays
19, 20, 23
, as a prime example, are used for molecular 
diagnostics, genotyping and biomarker-guided therapeutic targeting. Microfluidic-based 
  
2 
microchips further integrate highly versatile and extremely miniaturized microfluidic 
platform with biomolecule microarray and therefore enable quantitative measurements of 
large numbers of biological signatures from minuscule amount of blood
1
 or even single 
cells taken from disease tissues
4, 24-27
.  
Combined, such technologies opens up new avenues for studying, diagnosing and 
treating cancer at a systems-level to facilitate predictive, preventive and personalized 
medicine in which early and accurate tumor detection and subsequent identification of 
effective therapy strategies lead to rapid initiation of smart treatment tailored to each 
patient's tumor molecular profile
9, 28
. 
  
3 
1.2 CELLULAR HETEROGENEITY AND SINGLE-CELL TECHNOLOGY 
Cancer is a highly heterogeneous disease
29
. Phenotypic and functional heterogeneity 
arise among cancer cells within the same tumor as a consequence of genetic change, 
environmental differences, and reversible changes in cell properties
30
. Much of our 
knowledge of biology is based upon ensemble measurements under the assumption that 
ensemble averages reflect the dominant biological mechanism operating within individual 
cells in a population
31
. After decades of research on single cells, however, it has been 
widely recognized that cell-to-cell variations are always present in any population of 
"seemingly identical" cells
32
, and the traditional ensemble average measurements may not 
correctly present the behaviors of any individual cell when the measured properties are of 
binary nature
33, 34
, cell-cycle dependent
35, 36
 or dominated by a small subset of cells
37-40
. 
Although this heterogeneity is often ascribed to some process (such as stochastic gene 
expression), it is also intrinsic to the finite nature of a single cell
41
. Some cell-to-cell 
variations are due to biochemical noise and may not have functional significance
42, 43
. This 
heterogeneity, however, is not always without consequences; for example, it can contribute 
to the diversity of an immune response
44
 or to the emergence of therapeutic resistance in 
cancers
39, 45
.  
Determining whether observed heterogeneity has functional significance requires a 
framework for quantifying heterogeneity and assessing its information content
31
. 
Measuring parameters of interest at single cell resolution is therefore desired, especially for 
cancer cells which are genetically unstable and usually comprised of multiple 
subpopulations of cells with different functional activities
40, 46
.  
  
4 
1.3 ONCOGENIC SIGNALING NETWORK IN CANCER CELLS. 
Cellular activities and functions are governed by a complex system of communication 
mechanism called cell signaling which ensures cells to perceive and correctly respond to 
their microenvironment and serves as the basis of development, tissue repair and immunity 
as well as normal tissue homeostasis. Alterations and errors in cell signaling processes are 
responsible for disease such as cancer, autoimmunity and diabetes
47
. Traditional biology 
has focused on studying individual parts of cell signaling pathways. The advancements in 
systems biology and "omics" (proteomics, genomics, transcripomics, metabolomics, etc.) 
technologies have yielded large inventories of genes, transcripts, proteins and metabolites 
and have shaped our views on signal transduction
48
. The signaling pathways are not simple 
linear paths that pipe the signal from cell surface to nucleus, but are organized as networks. 
Portraying the underlying structure of the signaling networks, understanding how changes 
in these networks may affect the transmission and flow of information and exploring how 
these networks will respond to external perturbations are crucial to transform how disease 
is understood, attached and possibly prevented.  
For many cancers, genomic surveys are revealing a landscape of altered signal 
transduction cascades that often cluster along a set of druggable core pathways. In fact, 
these pathways contain molecular targets for newer generations of cancer therapies
49
. 
However, the translation of genomic data into effective clinical treatments has been 
confounded because non-genetic cell-to-cell variability is profound in drug responses and 
resistance development. A recent editorial
50
 has pointed out that capturing the functional 
protein signaling network may prove valuable for this purpose, because those signaling 
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proteins, "not the genes per se, are responsible for the phenotypes of tumors and for the 
emergence of therapeutic resistance." Single cell proteomics therefore provides the most 
direct approach for elucidating protein signaling network structure and coordination, and 
builds the natural bridge connecting signaling events to biological functions
27
. 
 
Figure 1.1 Scheme of traditional and systems views of receptor tyrosine kinase 
signaling. Left panel is a traditional view of linear signaling pathway. The right 
panel indicates intracellular pathways are organized as network structure. 
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1.4 MICROFLUIDIC-BASED MICROCHIP PLATFORMS FOR SINGLE-CELL PROTEOMICS 
Single cell proteomics has evolved over more than 50 years, dating back to the 
invention of the Coulter counter
51
, which is the precursor of the first cytometer
52
. The 
increasing availability of lasers, photon detectors, high speed electronics, bioconjugation 
chemistries, and dye molecules fed into the development of fluorescence flow cytometry 
(FFC)
53
, fluorescence activated cell sorting (FACS)
54
 and Enzyme-linked immunosorbent 
spot (ELISpot)
55
. Most recently, mass spectrometry have been harnessed for the 
development of mass cytometry
56
. Excepting ELISpot, the dominant applications of these 
tools have been sorting or enumerating cellular phenotypes based upon labeling and 
measurements of surface marker (membrane) proteins. Intracellular staining (ICS) 
techniques
57
 have opened FFC and mass cytometry up to the analysis of at least a few 
cytoplasmic functional proteins per cells. Each of those techniques has strongly influenced 
the development and/or specific application of the more recent microchip tools. 
Over the past 25 years, microfluidic techniques
58
 have emerged for the manipulation, 
sorting and analysis of small biological samples, ranging from microliters of blood
1
 to 
single cells
59, 60
. On-chip assays range from cell counting to molecular measurements, with 
applications that span broadly across the field of biology and biomedicine
27, 61, 62
. Common 
advantages of microfluidic tools are that they can often be cheaply manufactured in large 
quantities, they can handle very small amount numbers of cells and require only tiny 
quantities of expensive reagents, and they are highly versatile for meeting different 
purposes, and so on. Many of these features are briefly characterized and compared against 
other non-microchip single cell proteomics tools in Table 1.1
27
.  
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One of the newer technologies to emerge, and to be adapted to microchip platforms, 
is that of single cell functional proteomics. Functional proteins include the secreted 
cytokines, chemokines, proteases, and granulocytes that are commonly associated with 
immune cell function, but also include catalytically active (phosphorylated) kinases and 
associated effector proteins that participate in intracellular signaling cascades. Examples of 
such cascades involve the hyper-activated phosphoprotein signaling pathways that are 
commonly associated with tumorigenic activity in cancer cells, and are consequently 
targeted by anticancer therapies. In their active states, these signaling pathways have 
functional consequences that can be associated with the various hallmarks of cancer.  
For single cell functional proteomics, microfluidic-based platforms fall into two 
groups: those in which the cells are stained to identify specific proteins, and those for 
which proteins are released from the cells and measured using surface immunoassays. 
Table 1.1 Single-cell functional proteomics tools27 
Technique Number and 
types of protein 
assayed 
Throughput Detection 
limit 
Statistical accuracy 
and signal 
quantification 
Notes and features 
Flow cytometry methods 
Fluorescence 
flow 
cytometry53 
Around 15 
proteins (mostly 
membrane 
proteins, a few 
cytoplasmic 
proteins) 
104 cells/s 500 copies 
per cell 
90% phenotyping 
accuracy; relative 
protein abundance 
Standard for sorting 
and enumeration of 
cellular phenotypes. 
Secretion blocked and 
cell fixed for 
cytoplasmic proteins 
Mass flow 
cytometry56 
Around 35 
membrane and 
intracellular 
proteins, likely 
expandable 
103 cells/s >103 copies 
per cell 
Good cell counting 
statistics; relative 
protein abundance 
Cells handled in bulk 
prior to analysis. 
Secretion blocked and 
cells fixed for 
cytoplasmic proteins 
Surface methods 
ELISpot55 1-3 secreted 
proteins 
Not available 6 spots per 
105 cells 
Quantitative for 
percentage active cells 
Cells secrete proteins 
onto antibody coated 
surface; secretion 
activity correlated with 
cell location 
Microfluidics technologies 
Image 
cytometry63, 
64 
3-4 membrane or 
intracellular 
proteins and cell 
size 
103-104 cells 
per chip 
105 
fluorophores 
per μm2 
Good cell counting 
statistics; relative 
protein abundance 
Cell are fixed and 
stained (in bulk) with 
fluorescent antibodies; 
protein assay and cell 
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location spatially 
correlated 
Cell array65-
68 
1 intracellular 
proteins 
<103 cells per 
chip 
Not available Good cell counting; 
relative protein 
abundance 
Single cells separated 
and imaged on chip; 
continuous monitoring 
of cell physiology 
Micro-
droplet69-71 
1 membrane or 
intracellular 
protein 
102μdrops/s Not defined Good cell sampling 
statistics 
Cells entrained in 
microdroplets; 
microdroplet 
composition control 
permits screening cells 
Micro-
engraving72-
75 
3 secreted plus 3 
membrane 
proteins 
104-105 cells 
per chip 
Not available Very good cell 
number statistics; 
relative protein 
abundance 
Cells isolated in 
microwells; surface 
immunoassays; proteins 
colorimetrically 
detected; secretome 
kinetics from single 
cells; proteomic and 
functional assays from 
same cell. 
Single cell 
barcode 
chips1, 4, 24, 26, 
27, 44, 76-78 
About 20 
secreted, 
membrane or 
cytoplasmic 
proteins, 
expandable 
103-105 cells 
per chip 
102 copies Good cell counting 
statistics; absolute 
quantification; 10% 
measurement error per 
protein per cell 
Cells insolated in 
microchambers; 
miniature antibody 
arrays yield spatial 
separation of specific 
protein assays; 
proteomic and 
functional assays from 
the same cell; single 
cells or defined small 
cell populations 
accessed 
 
The first group includes a image cytometry, cell-array, and micro-droplet techniques. 
Early variations of such tools detected proteins from single cells by imaging stained cells, 
or by following the labeled cells or cell-encapsulation droplets through a microfluidic 
channel designed to allow fluorescence detection. These were basically microchip versions 
of FFC or FACS
79
. More recent approaches have significantly diverged to take advantage 
of some of the unique aspects of microfluidics. For example, cells can be spatially 
segregated into large arrays
65-68
, or they can be entrained within arrays of drops
69-71
. Such 
manipulations are followed by immunostaining of membrane proteins, followed by 
automated imaging to quantify single cell fluorescence signals. These approaches can offer 
control over the cell environment before analysis, which make them attractive screening 
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tools
63, 64
. One disadvantage of these and other cell-staining approaches is that they have 
limited multiplexing capacity, which might be overcome through integrating super 
resolution imaging
80
 with a conceptual extension of optical barcodes
81
. 
The most advanced microfluidic single cell proteomics tools use surface-immobilized 
antibodies for separating protein detection from cell manipulation. This approach is 
conceptually similar to ELISpot, but has capabilities that can in many ways surpass those 
cytometry tools. Separating protein assays from the cells implies that individual proteins 
can be spatially, rather than colorimetrically, identified, and that sandwich ELISA-type 
assays can be used. Of course, cell staining of proteins can be still simultaneously carried 
out. The result is a significantly higher level of multiplexing and, for some proteins, 
absolute quantification. Moreover, intracellular, membrane and secreted proteins may be 
assayed from the same cell. The chambers in which the cells are isolated can potentially 
accommodate multiple cells and/or cell types, thus permitting measurements of cellular 
interactions. Finally, these platforms allow the integration of functional assays (e.g. cell 
mobility) with protein assays.  
One of base technologies in this class of platforms is the microengraving approach 
developed by Love's group
72-74
 uses small volume microwells in an array format to isolate 
and culture single cells. A "microengraved" (antibody-coated) substrate is used to cap the 
microwell array and to capture secreted proteins. Proteins are detected using sandwich-type 
ELISA immunoassays. Different fluorophores colorimetrically distinguish between 
different detection antibodies to allow the simultaneous detection of about three secreted 
proteins. The microengraved substrate can be replaced multiple times in situ, thus enabling 
kinetic studies at the single cell level. The multiplexing capacity of the microengraving 
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method can be increased using fluorophore-labeled antibody staining of membrane 
proteins; fluorescence imaging of the captured cells yields information on membrane 
protein levels (to identify cellular phenotypes), and the microengraved substrate assays for 
secreted proteins (to assess cellular function). 
A related approach is the single cell barcode chips (SCBCs) which are a highly 
versatile and information rich tool for single cell functional proteomic analysis. SCBCs are 
based upon isolating individual cells, or defined numbers of cells, within microchambers, 
each of which is equipped with a large antibody microarray (the barcode), with between a 
few hundred to 10
4
 individual microchambers included within a single microchip. 
Depending upon the application, SCBC microchamber volume are designed to be between 
0.1–2 nanoliters25, 26, 44, and microchamber design and operation protocols can permit 
sandwich-type ELISA immunoassay of cytoplasmic, secreted, or membrane proteins with a 
measurement error of ~10% for a given protein level
24, 82
. The development and 
applications of SCBCs is the central topic of this thesis and will be discussed in detail in the 
subsequent chapters. 
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1.5 PHYSICAL APPROACHES TOWARD UNDERSTANDING CANCER 
The advent of the “omics” age has not only triggered a revolution in technology, but 
also the way of thinking
48
. The ability to routinely study thousands of genes and proteins 
enables physical scientists to consider complex biological events as systems of interacting 
units which can be understood through statistical mechanics, thermodynamics and 
chemical kinetics. In this perspective, human body can be viewed as a highly coordinated 
system of interacting molecular networks, among which protein signaling networks provide 
the most direct access to understand diseases such as cancer since proteins are actual 
performers of a vast array of functions within living organisms.  
Recently developed single cell functional proteomic microchips further grant people to 
quantify functional proteins, which are often transient and low-abundance targets, in a 
high-throughput and multiplex fashion at single cell resolution. Functional protein are 
typically generated, released or activated following stimulation, and their production is 
closely relevant to how cells process information and respond to perturbation and is often 
the end results of a series of stochastic events. In other words, they are the opposite of 
housekeeping proteins such as actin that are always present in abundant and reasonably 
stable concentrations. As a result, the abundances, kinetics and their statistical distributions 
of functional proteins contains ample information of molecular interactions within cells and 
can reflect changes in cellular activity, such as immune-cell activation or the activation or 
inhibition of protein signaling. Many physical approaches, such as fluctuation dissipation 
theorem, linear noise approximation, potential landscape, etc. have been developed to 
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understand functional protein fluctuations. A mean-field model
26
 will also be introduced 
in Chapter 3 to better demonstrate the biological significance of functional protein 
fluctuation. 
Single cell functional proteomics allow simultaneously probing a panel of key 
functional proteins relevant to the problem of study. By analogy with the concept of phase 
space in statistical mechanics, the collections of such extracted features (protein levels) 
allow an individual cell to be represented as a point in (often high-dimensional) feature 
space, with each axis representing a different measurement. Therefore, populations of cells 
are transformed into distributions of points in feature space
31
, which allows to identify the 
steady-state of the cell population (or more rigorously, the steady-state of the signaling 
coordination) through establishing a single cell ensemble and seeking the probability 
distribution function that is of maximum entropy
82
. The functional protein interactions can 
be quantified by protein covariance matrices, which may further couple with linear 
perturbation theory to predict how the levels of protein would respond to a weak 
perturbation
26
. These will be discussed in detail in Chapter 3. 
On the other hand, studying cancer cells from different patients or from the same 
patient but, under different states during the course of therapy (such as treatment naive, 
drug responsive, drug resistant) is thus reduced to the problem of identifying patterns of 
distinct cellular behaviors in feature space. A couple of analytical and computational 
approaches of decomposing heterogeneous distributions and identifying dominative 
patterns can be used to extract a set of collective behaviors of functional proteins in the 
cancer cells, which is similar to decompose the strongly coupled atomic interactions in a 
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crystal into a series of normal vibrational modes. This has important implications on how 
to design effective targeted therapy and will be included in Chapter 4. 
Cancer cells are highly heterogeneous. Population heterogeneity can arise from factors 
such as the stochastic nature of intracellular events controlled by low-copy-number 
transcription factors
83
 or through cell-cell interactions
37, 84
. From a traditional biology 
perspective, this heterogeneity causes cancer to be viewed as a complex (or "hard to 
understand") disease. Biologists seek to classify the population into different phenotypes 
and study them separately. However, both phenotypical and functional heterogeneity may 
be highly dynamic. Even if one starts with a homogeneous phenotype of a cancer cell 
population, cell-cell interactions can rapidly render the population heterogeneous
85, 86
 just 
like collisions render the velocity distribution of gas molecules Maxwellian.  
A heterogeneous tumor, however, as viewed by a physical scientist, might appear as a 
stable ‘organ’, with a stability that emerges exactly because of the heterogeneity of the 
cellular components. Thus, fluctuation measurements can capture cellular heterogeneity, 
while simultaneously providing a measure of the stability of the organelle, tumor, etc., that 
is comprised of those cells, and providing a bridge to statistical physics models with 
predictive capacity. This picture, in turn, can provide insight into how to disrupt that robust 
state by targeting the signaling networks essential for tumor maintenance, as well as 
anticipating mechanisms of resistance. These approaches, which are unique to single cell 
measurements and are one of the central topics of this thesis, contrasts with traditional 
biology thinking that discards the heterogeneity of the system in favor of a more 
streamlined (but ultimately non-predictive) description.  
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1.6 THESIS OVERVIEW 
Single-cell functional proteomics assay connect genomic information to biological 
function through quantitative and multiplex protein measurements. This thesis will focus 
on the development of microfluidic-based single-cell functional proteomics microchip and 
its applications in fundamental cancer biology and preclinical cancer research. Preliminary 
attempts of translating this microfluidic-based microchip into a valuable clinical toolkit 
with diagnostic and prognostic capacities will also be included.  
Parallel proteomic assays across many different single cells yield unique pieces of 
information that are not readily disclosed by traditional biology methods. They also 
significantly shape the way of thinking on cancer itself. The availability of large proteomic 
dataset allows us to understand cancer using fundamental physicochemical principles such 
as statistical mechanics, thermodynamics and chemical kinetics. This in turn fosters the 
development of physical and computational approaches to make predictions on, for 
example, targeted therapy resistance and effective drug combinations. 
Starting from Chapter 2, I will describe a microchip designed to quantify the levels of 
a dozen secreted, cytoplasmic and membrane proteins from single cells. We use the 
platform to assess protein-protein interactions associated with the EGF-receptor-mediated 
PI3K signaling pathway. Single-cell sensitivity is achieved by isolating a defined number 
of cells in 2nL volume chamber, each of which is patterned with a miniature antibody 
array. The cells are lysed on-chip, and the levels of released proteins are assayed using the 
antibody microarrays. We investigate three isogenic cell lines representing the cancer 
glioblastoma multiforme (GBM), at the basal level, under EGF stimulation, and under 
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erlotinib inhibition plus EGF stimulation. The measured protein abundances are 
consistent with previous work, and single-cell analysis uniquely reveals single-cell 
heterogeneity, and different types of strength of protein-protein interactions. This platform 
helps provide a comprehensive picture of altered signal transduction networks in tumor 
cells and provides insight into the effect of targeted therapies on protein signaling 
networks. (Chapter 2 has been taken in part from Proc Natl Acad Sci USA 109, 419-424 
(2012)). 
Chapter 3 further applies the single-cell microchip to the study the transition of tumor 
hypoxia. Hypoxia is a near-universal feature of cancer, promoting glycolysis, cellular 
proliferation, and angiogenesis. The molecular mechanisms of hypoxic signaling have been 
intensively studied, but the impact of changes in oxygen partial pressure (pO2) on the state 
of signaling network is less clear. In GBM cancer cell model, we examined the response of 
signaling networks to targeted pathway inhibition between 21% and 1% pO2. We used a 
microchip technology that facilitates quantification of a panel of functional proteins from 
statistical number of single cells. We find that near 1.5% pO2, the signaling network 
associated with mammalian target of rapamycin (mTOR) complex 1 (mTORC1)––a critical 
component of hypoxic signaling and a compelling cancer drug target––is deregulated in a 
manner such that it will be unresponsive to mTOR kinase inhibitors near 1.5% pO2, but 
will respond at higher or lower pO2 values. These predictions were validated through 
experiments on bulk GBM cell line cultures and on neurosphere cultures of a human-origin 
GBM xenograft tumor. We attempt to understand this behavior through the use of a 
quantitative version of Le Chatelier's principle derived from statistical mechanics, as well 
as through a steady-state kinetic model of protein interactions, both of which indicate that 
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hypoxia can influence mTORC1 signaling as a switch. The Le Chatelier approach also 
indicates that this switch may be thought of as a type of phase transition. Our analysis 
indicates that certain biologically complex cell behaviors may be understood using 
fundamental, thermodynamics-motivated principles. (Chapter 3 has been taken in part from 
Proc Natl Acad Sci USA 110, E1352-1360 (2013)). 
Chapter 4 demonstrates the application of this technology in the preclinical cancer 
research to study the cancer cell resistance to molecular targeted therapy and corresponding 
physical approaches to anticipate therapy resistance and identify effective therapy 
combinations. GBM is an aggressive tumor for which there are no effective surgical or 
pharmacologic treatments. GBM also serves as a prototype of advanced stage cancer. 
While GBM tumors contain druggable targets, resistance to single-agent targeted therapy is 
rapid and almost universal. Combination therapies that can anticipate resistance may 
provide a solution, but identifying effective combinations is largely an unmet challenge. 
We empirically derived signaling network inferences from quantitative functional 
proteomic analysis of statistical numbers of single cell separated from the glioblastoma-
derived mouse model of mTOR kinase inhibitor resistance. Our approach is based upon 
elucidating the detailed signaling coordination within the phosphoprotein signaling 
pathways that are hyperactivated in human GBMs, and interrogating how that coordination 
responds to the perturbation of targeted inhibitor. We assayed for key elements of the 
phosphoprotein signaling pathways associated with GBM tumor growth and maintenance. 
Analysis of how the signaling coordination responses to the targeted inhibitor reveals a 
rapid adaptation to the presence of the drug, with compensation that occurs via the 
activation of alternative signaling pathways. The analysis allows us to anticipate resistance, 
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and to design combination therapies that are effective, as well as identify those therapies 
and therapy combinations that will be ineffective. The analysis also unveils a general and 
very fast-acting resistance mechanism. 
The human-derived GBM model recapitulates the heterogeneity, invasive growth, and 
a drug response profile reflective of clinical behavior. We sought to elucidate the general 
mechanism of resistance by considering two resistance mechanisms. The first, Darwinian-
like selection, occurs when a drug targeted at the dominant tumor cell population generates 
an environment suitable for a sub-population of cancer cells to flourish. The second 
mechanism is one in which the same tumor cells that initially respond to the drug adapt by 
altering their protein signaling networks. We analyzed the tumor model at 3 stages: control, 
responding to an mTOR kinase inhibitor, and resistant to that inhibitor. Analysis of the 
effect of the mTOR inhibitor resolves two independent signaling modes – one associated 
with mTOR signaling and a second associated with ERK/Src signaling. This suggested that 
drugging one target from each mode would provide an effective treatment. We tested 3 
therapy combinations expected to be effective, and 4 expected to be ineffective, in mouse 
tumor models. All predictions were borne out: the effective therapy combinations 
completely halted tumor growth until the point of drug release, with no apparent side 
effects. We also identified that cellular adaption, rather than Darwinian evolution, led to 
resistance. This finding increases the clinical relevance of this work; this resistance 
mechanism is not readily identified via deep sequencing, but it can be detected via a few-
day in vitro analysis using single cell functional proteomics. A retrospective analysis of 
tumor tissues from all treatment combinations further revealed that the mTOR signaling 
mode was driving tumor growth, while ERK/Src signaling was the dominant resistance 
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mechanism. We also show that this type of analysis can be done on a clinically relevant 
time-scale (Chapter 4 has been taken in part from a manuscript that is currently under 
review in Nature Medicine). 
In Chapter 5, some preliminary results about the clinical translation of single cell 
proteomic chips will be presented. The hypothesis is that there exists a sufficient pharmacy 
to treat many GBM patients, and appropriately designed assays can inform, at the 
individual patient level, how those drugs can be combined for effective therapy.  A key 
challenge is that those diagnostic assays must resolve the functional heterogeneity within a 
given patient’s tumor. Single cell functional proteomics on statistical numbers of single 
cells therefore becomes a perfect candidate. Compared to model cell lines, clinical samples 
always have a low purity and weak functional protein expression. To meet the clinical 
challenges, the surface chemistries of the SCBCs has been intensively optimized to 
improve the assay sensitivity. This includes the use of on-chip poly-L-lysine (PLL) 
treatment and a covalent binding method to immobilize the DNAs to the PLL surface. A 
protocol on the single cell proteomic analysis of patient biopsy samples has also been 
developed, tested and standardized to ensure the assay reproducibility and robustness. A 
case study of a pediatric GBM patient sample will be discussed in detail for demonstrating 
the process of anticipating potential resistance and identifying the effective therapy 
combination within a clinical relevant time-scale.  
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C h a p t e r  2  
Development of the microchip: single-cell functional proteomics chips 
for profiling cancer cell signal transduction pathways 
2.1 INTRODUCTION 
Although signal transduction inhibitors occasionally offer clinical benefit for cancer 
patients
1
, signal flux emanating from oncogenes is often distributed through multiple 
pathways
2
, potentially underlying the failure of most such inhibitors
3
. Measuring signal 
flux through multiple pathways, in response to signal transduction inhibitors, may help 
uncover network interactions that contribute to therapeutic resistance, and which are not 
predicted by analyzing pathways in isolation
4
. The cellular and molecular complexity of a 
solid tumor microenvironment
5
 suggests the need to study signaling in individual cancer 
cells.  
Protein-protein interactions within signaling pathways are often elucidated by 
assessing the levels of relevant pathway proteins in model and tumor-derived cell lines, and 
with various genetic and molecular perturbations. Such interactions, and the implied 
signaling networks, may also be elucidated via quantitative measurements of multiple 
pathway related proteins within single cells
6
. At the single cell level, inhibitory and 
activating protein-protein relationships, as well as stochastic (single-cell) fluctuations, are 
revealed. However, most techniques for profiling signaling pathways
7, 8
 require large 
numbers of cells. Single-cell immunostaining
9
 is promising, and some flow cytometry
6
 
techniques are relevant, as discussed below.  
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We describe quantitative, multiplex assays of intracellular signaling proteins from 
single cancer cells using a platform called the single-cell barcode chip (SCBC).  The SCBC 
simple in concept: a single or defined number of cells, is isolated within a 1~2 nanoliter 
volume microchamber that contains an antibody array
10
 for the capture and detection of a 
panel of proteins. The SCBC design
11
 permits on chip culture and on chip lysis of each 
individual trapped cell.   
Intracellular staining flow cytometry can assay up to 11 phosphoproteins from single 
cells
6
. Our SCBC can profile a panel of up to 20 proteins, but this limit is not fundamental 
and may be extendable.  Depending on the design, several hundred to several thousand 
single cells per chip can be measured simultaneously, yielding some statistical assessment 
for each experiment. The SCBC is a relatively simple platform, and only requires a few 
hundred cells per assay.  
In this chapter, we will describe in detail the enabling technologies, the design and 
fabrication of SCBCs. The protocol of the single cell proteomic assay and the result 
extraction, calibration, and statistical analysis will also be covered. We will focus on the 
unique pieces of information disclosed from single cell analysis and how the information 
endows us with the capacity of employing physicochemical approaches to understand 
cancer at a systems level. 
To illustrate the process, we used the SCBC to study signal transduction in 
Glioblastoma Multiforme (GBM), a primary malignant brain tumor
12
. GBM has been 
genetically characterized, yet the nature of signaling pathways downstream of key 
oncogenic mutations, such as EGFR activating mutation (EGFRvIII) and PTEN tumor 
  
30 
suppressor gene loss associated with Receptor Tyrosine Kinase (RTK)/PI3K signaling, 
are incompletely understood
13-15
. Single cell experiments may also help resolve the 
characteristic heterogeneity of GBM.  
We interrogated eleven proteins directly or potentially associated with PI3K signaling 
through three isogenic GBM cell lines: U87 (expressing wild-type p53, mutant PTEN and 
low levels of wild-type EGFR, no EGFRvIII)
16, 17
, U87 EGFRvIII (U87 cells stably 
expressing EGFRvIII deletion mutant), and U87 EGFRvIII PTEN (U87 cells co-expressing 
EGFRvIII and PTEN)
18
. Fig. 2.1 diagrams this biology. Each cell line was investigated 
under conditions of standard cell culture, in response to EGF stimulation, and after erlotinib 
treatment followed by EGF stimulation. The proteins assayed represented receptor tyrosine 
kinases (RTKs) and proteins signifying activation of PI3k and MAPK signaling. They were 
(p-denotes phosphorylation): p-Src, p-mammalian target of rapamycin (p-mTOR), p-p70 
ribosomal protein S6 kinase (p-p70S6K), p-glycogen synthase kinase-3 (p-GSK-3α/β), p-
p38 mitogen activated protein kinase (p-p38α), p-extracellular regulated kinase (p-ERK), p-
c-Jun N-terminal kinase (p-JNK2), p-Platelet Derived Growth Factor Receptor β (p-
PDGFRβ), p-Vascular Endothelial Growth Factor Receptor 2 (p-VEGFR2), tumor protein 
53 (P53) and total EGFR. 
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Figure 2.1 The PI3K pathway activated by EGF-stimulated EGFR or the constitutively 
activated EGFRvIII. All proteins in light blue with central yellow background were 
assayed. Orange background proteins were expressed in the cell lines U87 EGFRvIII or 
U87 EGFRvIII PTEN. The oval, yellow background components are the investigated 
molecular perturbations. 
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2.2 EXPERIMENTAL METHODS 
2.2.1 Enabling technologies: DNA Encoded Antibody Library (DEAL) and DNA 
barcode microarray 
The basic concept of SCBCs is to pattern a many-element capture antibody array in 
each single-cell microwell so that different proteins are detected at different designated 
array spots. The key enabling technologies of SCBCs is the miniature antibody arrays. The 
patterning approach for the antibody barcode arrays has unique constraints. Due to the 
instability of antibody for long term storage, or towards microchip processing conditions, 
the barcodes are initially patterned as single strand DNA (ssDNA) barcodes, with each 
barcode stripe having a unique ssDNA label. A cocktail of antibodies labeled with 
complementary ssDNA' oligomers (DEAL) is used to convert the DNA barcode into an 
antibody barcode, just prior to running an proteomic assay. The microchamber surface area 
 
Figure 2.2 Quality assessments of the DNA barcode microarrays used for SCBC 
assays. At left are fluorescence images of the DNA barcode stripes across the slide 
surface, with an intensity profile shown at right. This data reflects the uniform DNA 
loading across the whole slide. An Axon Genepix 4400A (Molecular Device) array 
scanner is used to obtain this image in the 532nm channel with a laser power set at 
15% and an optical gain of 450. 
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for a typical 20-element barcode is between 150×150 μm2 to 1000×150 μm2, implying 
each array element needs to be around 10-20 μm wide at a 20-40 μm pitch. Such 
dimensions may be read with a standard microarray scanner, but are beyond the resolution 
of standard spotting tools. Molecular patterning tools that can approach these dimensions 
include molded elastomer stamping, dip pen lithography, and microfluidic flow patterning. 
Of these choices, stamping does not permit the required level of multiplexing, while dip 
pen does not yield a surface coverage sufficient for stable and sensitive assays. We have 
therefore developed microfluidic flow patterning into the method of choice for SCBCs, 
including even building robotics systems to automate the task. Specifically, an elastomer 
film is molded so that it contains a series of long, serpentine channels. It is adhered to the 
top of a glass slide. Solutions containing a different ssDNAs oligomer are flowed through 
each channel. After solution evaporation, the molded elastomer is then removed, leaving a 
series of 10 to 20 μm wide stripes of different ssDNA oligomers across the glass substrate 
(Fig. 2.2). The influence of various barcoding surface chemistries on assay sensitivity are 
described in detail in our previous work. The details of microfluidic flow patterning of 
DNA barcode microarray and the synthesis of ssDNA oligomers and antibody conjugates 
can be found in Appendix A: Supplementary Methods.  
2.2.2 Design and fabrication of single-cell proteomic chip 
The PDMS microfluidic chip for the single-cell proteomic experiment is comprised of 
a two-layer microfluidic network and fabricated by soft lithography
11
 (Fig. 2.3 A and B). 
Valves isolate the chip into 120 microchambers for cell compartmentalization, cell lysis, 
and protein assays (Fig 2.3 C-F). A push-down valve configuration was utilized with a 
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thick control layer bonded together with a thin flow layer. The molds for the control 
layer and flow layer were fabricated with SU8 2010 negative photoresist (~23 μm 
thickness) and SPR 220 positive photoresist (~15 μm), respectively. The photoresist 
patterns for the flow layer were rounded via thermal treatment. The thick control layer was 
molded with 10:1 mixture of GE RTV 615 PDMS prepolymer part A and part B (w/w) and 
the flow layer was formed by spin-coating a 20:1 mixture of GE RTV 615 part A and part 
 
Figure 2.3 Single-cell barcode chip design and operation. (A) Design of the SCBC 
microfluidic chip for on-chip cell lysis and multiplex phosphoprotein detection. V1 to V6 
represent valves. V3 isolates chambers from channel and V4 control the diffusion 
between cell chamber and lysis buffer chamber. V1, V2, V5 and V6 control flow within 
the microchannels. (B) A photograph of an SCBC. The flow layer (red) and the control 
valve layer (blue) are delineated with food dyes. (C) A single measurement unit of the 
SCBC. Single or few cells are isolated in the 2 nL microchamber. Intracellular proteins 
are assayed by introducing a pre-aliquoted lysis buffer, whereupon the released proteins 
bind to the antibody microarray within the chamber. (D) A photograph of a single 
microchamber. (E) Visualization of on-chip lysis buffer diffusion. Red food dye is used to 
visualize the diffusion process. The chip is sitting on ice and titled to accelerate on-chip 
diffusion. (F) A drawing of a single cell chamber with critical parts labeled. A cell is 
isolated in the cell chamber by the valves. The neighboring chamber contains cell lysis 
buffer. The duplicate DNA barcode copies are converted into an antibody microarray 
prior to cell loading, counting, and lysis. 
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B (w/w) on the flow layer mold at 2000rpm for 60 seconds. Both layers were cured at 
80°C for 1 hour, whereupon the control layer was cut from its mold and aligned to the flow 
layer. An additional 60 minutes of thermal treatment at 80°C ensured that the two layers 
bonded into a monolithic device, which was then peeled from its mold and punched to 
create appropriate access holes. Finally, the PDMS chip was thermally bonded to the DNA 
barcode slide to form the working device. 
2.2.3 Protocol of single-cell proteomic assays. 
The cell determines the copy numbers of a given protein, while the microchamber 
volume is minimized so those copy numbers are at a detectable level using standard 
sandwich ELISA immunoassays with fluorescent readouts.  At the beginning of the 
experiment, all SCBC microchannels are blocked with blocking buffer for 60 minutes. A 
cocktail of all DNA-antibody conjugates is flowed through the channels for 60 minutes, 
transforming the DNA barcode microarrays into antibody microarrays. Unbound 
 
Figure 2.4 The relationship between on-chip incubation time and obtained intensity: 2 hr 
incubation is sufficient to capture more than 95% of the released protein following cell lysis. 
 
  
36 
conjugates are removed with washing buffer. Then, 3× lysis buffer is loaded into the 
lysis buffer chambers and cells are loaded in the cell chamber while keeping the valves 
between these chambers closed. Upon cell loading, each microchamber contains zero to a 
few cells, which are counted through the transparent chip under microscope. The valves are 
then opened to allow on-chip diffusion of lysis buffer to the neighboring cell chambers for 
20 min on ice. Cell are lysed via diffusion of lysis buffer which contains phosphatase 
protease inhibitors. The SCBC was then incubated 20 min on ice and 2 hour at room 
temperature with gentle shaking to allow capturing the proteins released from the cells.  
The two hours incubation used here reaches >95% of maximal intensity for all assays 
(Fig. 2.4). Cell lysate is quickly removed by washing buffer after incubation. Captured 
proteins are developed by applying biotinylated detection antibodies and fluorescent dye-
labeled streptavidin for visualization. The barcode glass slide is then detached for scanning. 
A detailed step by step protocol can be found in Appendix A: Supplementary Methods. 
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2.2.4 Results extraction, calibration and conversion 
Once an SCBC assay is complete, an array scanner (Axon Genepix 4400A, Molecular 
Devices) is utilized to digitize the fluorescent levels from the antibody arrays associated 
with each microchamber. One array element has a distinct fluorophore to serve as an 
alignment marker; this permits individual proteins to be identified via their spatial location 
(Fig. 2.5).  The digitized data is then loaded into a table (using custom written algorithms).  
Each table row corresponds to a specific microchamber address.  The columns contain the 
numbers and locations of the cells in each microchamber, plus the fluorescence intensities 
corresponding to each of the assayed proteins. Those intensities are background normalized 
(using 0 cell data) and converted into protein copy numbers using calibrations (Fig. 2.6). 
 
Figure 2.5 Representative fluorescence images, and resultant heat maps, from on-chip 
intracellular protein profiling in the model GBM cell lines. The y-axis labels indicate the 
stimulation conditions, and the x-axis labels indicate the numbers of cells per microchamber 
assay. The barcodes shown are from a single barcode assay from a single microchamber 
containing U87 EGFRvIII PTEN cells (A) All images have been equally contrast enhanced 
to more clearly illustrate which proteins are detected. (B) Complete heat maps of 
cytoplasmic protein profiling in all cell lines and conditions. All heat maps have been 
equally contrast enhanced to better illustrate which proteins are and are not detected. 
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Unlike other single cell proteomic tools, SCBC assays can yield absolute protein 
level quantification in copy number per cell, which allows clinical studies or investigations 
in which statistical cell behaviors are compared across a perturbation series or patients. 
This is achieved by generating calibration curves against standard (recombinant) proteins 
when available. 
The calibration experiments are performed within an SCBC and under exact the same 
condition as the single-cell proteomic assay described above, except that standard proteins 
are used, rather than cells. A mixture of standard proteins from the SCBC assayed panel is 
serially diluted in 1× PBS and flowed into the SCBC microchannels. Fluorescence signals 
are collected to generate the calibration curves. Because the volume of the microchamber is 
known, these calibration curves enable a transformation from the fluorescence intensity to 
number of molecules for each protein assayed, under the caveat that the standard protein 
may not be exactly the same as their counterparts from the cells. 
2.2.5 Cell culture, stimulation and drug treatment 
 
Figure 2.6 Protein calibration test. (A) Fluorescence images used to extract calibration 
data for the SCBC assays, and representing a serial dilution of assayed proteins. Standard 
protein are serially diluted in 1× PBS and flwoed into the SCBC microchannels. (B) 
Calibration curves for several assayed proteins. 
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The human GBM cell lines U87 was purchased from American Tissue Culture 
Collection. U87 EGFRvIII and U87 EGFRvIII PTEN cells were constructed as previously 
described
14,18
. Cell lines were routinely maintained in DMEM (ATCC) containing 10% 
fetal bovine serum in a humidified atmosphere of 5% CO2, 95% air at 37
o
C. For EGF 
stimulation, cells were serum-starved for 24 hours and then stimulated by EGF at 50 ng/mL 
for 10 min before harvest. For erlotinib treatment, serum-starved cells were treated with 10 
μM enlotinib for 24 hours, followed by EGF stimulation (50 ng/mL) for 10 min before 
harvest. The treated cells were dissociated with trypsin and EDTA and suspended in cold 
PBS with a concentration of 1000 cell/μL prior to loading to the device.  
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2.3 RESULTS AND DISCUSSION 
2.3.1 Unique information disclosed from single-cell analysis 
Single cell proteomics provides the most direct approach for elucidating protein 
signaling network structure and coordination, and information from such measurements 
emerges at many levels. An SCBC cell dataset, which is comprised of a statistical number 
of single-cell assays, yield three types of independent observables. The first observables are 
averaged level of each assayed protein from single cells, which can be compared against 
results from assays on bulk cell populations such as Western blotting or sandwich ELISA.  
The second and third observables are unique to single-cell multiplex proteomics 
assays. A measurement of the average level of a protein requires many single-cell 
measurements. Such measurements, if compiled as a histogram of the frequency of 
observation versus the measured protein levels, reflect the fluctuations of that protein. 
Similar to spectroscopy that is the outcome from interactions between matter and radiation 
energy, single cell protein fluctuations are spectra involving all the protein interactions 
within a single cell. As a result, they are highly informative toward understanding protein 
functional activity. A straightforward example is to identify subpopulations of cells by 
looking at the fluctuation profiles of a single protein marker or a combination of markers 
(Fig. 2.7)
19
. This information has been intensively used in flow cytometry and flow-
activated cell sorting (FACS). A deeper analysis of the protein fluctuation line shapes by a 
mean field model (See Chapter 3 for details) provides a context for discussing how the 
average effect of other proteins influences the fluctuations of a specific protein in question. 
It offers predictive capacity of fluctuation profiles that a widely dispersed fluctuation can 
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indicate a highly active protein that is involved in multiple functional processes. A 
narrow, sharp fluctuation, by contrast, represents a protein with limited interactions. The 
protein fluctuation, namely the spread in copy number of a given protein as measured 
across each of many otherwise identical single cells, can represent the functional 
heterogeneity of that protein, which further contributes the population heterogeneity of 
those seemingly identical single cells. The concept of a stable population existing in the 
presence of random fluctuations is reminiscent of many physical systems that are 
successfully understood using statistical physics. Thus, tools derived from that field can 
probably be applied to using fluctuations to determine the nature of signaling networks. 
 
Figure 2.7 Single-cell functional protein fluctuations. (i) An illustration of single cell 
protein fluctuations across many parallel single cell measurements. (ii) An example of two 
subpopulations identified from single cell measurements. A small subpopulation (at right) 
may differ from the remainder of the population or from the "main" behavior (left peak). 
(iii) The connections between the line shapes and signaling activities. 
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The third unique observations are the protein-protein correlations between the 
various assayed proteins across all the single cell measurements. Correlations and anti-
correlations can imply activating and inhibitory interactions. By connecting assayed 
proteins (network nodes) with different weights of lines to reflect the strength of 
correlations, a correlation network map can be established and serve as a signature of the 
signaling network activity. This also means that measurements with higher multiplexing 
capacity will capture larger number of such interactions, and thus increasingly resolve the 
associated protein signaling network. In the context of cancer cells, comparing the 
correlation network of single cancer cells following stimulus, plus a drug treatment with 
those with stimulus alone could identify how the signaling profiles are affected by the drug. 
Similarly, comparing the correlation network at initial, drug responsive and drug resistant 
stages to analyze the evolution of the cancer cell signaling following the drug treatment 
could yield insight into how tumor cells develop therapeutic resistance to evade the 
targeted therapy. 
2.3.2. Stripping experimental uncertainty out of the biological variation 
The protein fluctuations, namely the spread (variance) in copy number of given 
proteins as measured across each of many otherwise identical single cells, represents the 
functional heterogeneity of the proteins. However, experimental errors can also contribute 
the measured variance and thus must be compared against the measured variations for 
extracting the true biological fluctuations. 
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The experimental errors mainly include the variation from non-uniform DNA 
barcode patterns which in turn transfers to the final protein signal, and the variation due to 
the randomly distributed cell location in the chamber. The former one can be estimated by 
the histogram of the fluorescence intensity from the calibration experiment with 
recombinant proteins. Since a recombinant protein has fixed concentration over the entire 
channel, it represents a uniform protein level without any heterogeneity and location 
dependence. As a result, the distribution of the fluorescence intensity of a specific 
 
Figure 2.8 Monte Carlo simulation for evaluating experimental error. (A) Representative 
histograms of p-mTOR and p-p38α measurements, showing a coefficient of variation of ~8%. 
(B) The experimentally measured fluorescence intensity ratio versus barcode interspace for 3 
proteins indicates a systematic error that can be accounted for. (C) Average signals are 
simulated by accounting for protein diffusion within the microchamber to the two duplicate 
barcode stripes L. The histogram is the average of 5000 single cell cases, each with the cell 
located randomly within the microchamber. The blue curve is the Gaussian fit. (D) Illustration 
of barcode intensity (#L) versus cell location in three single cell chamber generated by the 
simulation. The yellow dots represent the location of the cell in each chamber and the 
brightness of the barcode corresponds to the signal intensity as in the experiment. The 
chambers yielded average signal between 161 and 184. This means that although a strong cell 
location dependence is reflected in the individual barcode stripe, the average value of the 
duplicate stripes is not sensitive to the cell location. (E) Estimation of single cell biological 
variation of U87 EGFRvIII cells for different proteins. The CV of the assay is directly 
adopted from the experiment data. 
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recombinant protein reflects the detection profile of the DNA barcode. In Fig. 2.8 A, 
histograms are provided for the protein p-mTOR and p-p38α, and the coefficient of 
variation (CV) of those histograms is ~8%. These histograms are generated from the 
calibration measurements that utilized the cocktail of recombinant proteins, and are 
representative of all of the proteins assayed here over a broad range of concentrations (Fig. 
2.8). In general, basically the intensities of all the recombinant proteins at detectable 
concentration follow a Gaussian distribution with CVs typically lower than 10%.  
The cell location within a microchamber, relative to the barcode positions, is another 
factor for the system error. This error arises because of the competition between 
antibody/protein binding kinetics, and protein diffusion. In order to minimize this effect, 
we utilized two sets of barcodes in a chamber and used the averaged signal intensity from 
two barcodes as the final signal value. Thus, the barcode close to the cell will undergo a 
higher local protein concentration than its compartment during the course of protein 
diffusion. Since the cells are randomly distributed in the microchambers, this adds an error 
to the SCBC system. However, we can record the positions of the cells, as well as the 
fluorescence intensities from the duplicate barcode arrays. So we can investigate whether 
this error is systematic. If yes, then it can be accounted for, and its contribution to the 
experiment error subtracted. 
For evaluating experimental errors, a Monte Carlo simulation was carried out by R (R 
Foundation for Statistical Computing, version 2.10.1). Depending on the processes of the 
protein release, there are two kinetic scenarios that need to be considered. One is for 
cytoplasmic and membrane proteins which are fully released from the cell location during 
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the cell lysis. The other one is for secreted proteins that are gradually secreted by the cell 
during the incubation. For the former one, we examined the fluorescence signals of the two 
barcodes within microchambers containing single cells. The intensity ratio of the barcode 
copies versus the location of the cell can be approximated by a linear relationship (Fig. 2.8 
B). The closer the cell is to one barcode, the higher is that barcode signal, while the more 
distant barcode signal is proportionately weaker. For the latter case, we back-calculate the 
secretion rate of a single cell for each secreted protein based upon the experiment results. 
With the exact chamber size and shape, as well as the diffusivity and the secretion rate of a 
specific protein in hand, the simulation should correctly capture the physics of the 
measurement since the equations for protein diffusion are known and typical 
antibody/protein binding kinetics can also be modeled.  
To investigate the influence of cell locations on signal variation, we assumed, for the 
simulation, that each single cell releases a fixed amount of specific amount of a 
cytoplasmic protein. This assumption removes the effect of biological variation and allows 
us to focus on the experimental error. The parameters used in the simulation match our 
experimental environment. The chamber is 2000 μm in length and 100 μm in width, with 
two sets of DNA barcode M-A and A-M from left to right. Excluding the 200 μm wide 
valves at each microchamber ends, the effective length of the chamber is 1800 μm. Each 
barcode stripe is 20 μm wide, and are patterned at 50 μm pitch. For the simulation, a single 
cell is randomly placed in a chamber. 
Fig. 2.8 C is the simulated distributions of fluorescence signal per chamber for 5000 
single-cell cases with proteins conjugated to ssDNA oligomers L. The maximum protein 
  
46 
intensity, which is assigned to the case for which a cell sits directly on a given barcode 
stripe, is set as 200. The barcode variability for a given protein was set as 10%, which is a 
representative value of the experimental determined uncertainty from the calibration data. 
The blue curves are the Gaussian fitting with the sample average and sample standard 
deviation obtained from the simulation. The fits indicate that the average signal per 
chamber follows a Gaussian distribution after including the randomness of cell locations. 
This is, then the statistical distribution of the measurements for single cells after accounting 
for the barcode variations and variations arising from cell locations, but with zero cell 
heterogeneity, which constitutes the system error. 
Fig. 2.8 D shows three representative cases generated from the simulation for the 
ssDNA L. The average protein signal measured from these chambers ranges from 161 to 
184, indicating that a similar average signal (limited by the intrinsic barcode variations) is 
measured, regardless of cell locations. 
By matching the concentration close to the actual level in the experiment, the Monte 
Carlo simulation can yield the system error of our measurement. Consequently, the single 
cell biological variation can be calculated by the formula below: 
 
2 2
experiment biologicalCV CV +CVtotal   
where the CVtotal refers to the total CV of the experiment data and CVexperiment is 
dominated by the uncertainty of the barcode variation. An estimation of the biological 
variation is shown in Fig. 2.8 E where it can be noticed that the biological variation is 
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dominant in the total variation of the assay and the experimental error is around 10% for 
this fashion of measurement. 
2.3.3 Validation of SCBC technology with conventional methods 
Fig. 2.9 shows heat map data from SCBC experiments on U87 EGFRvIII PTEN cells, 
and from measurements on bulk populations of those cells. Individual microchamber data 
are shown in Fig. 2.5 B. Fig. 2.9 B shows protein assays measured from a population of 
EGF stimulated U87 EGFRvIII PTEN cells. These assays used similar cell lysis and assay 
protocols as the SCBC assays. Comparison across Fig. 2.9 A and B reveals that the bulk 
 
Figure 2.9 SCBC and bulk cell measurements of U87 EGFRvIII PTEN cells. (A) Heat 
maps of SCBC protein level assays. Each column represents 1 microchamber assay, 
each row represents a protein.  (B) Protein assays from a population of U87 EGFRvIII 
PTEN cells under EGF stimulation. The contrast of these images has been equally 
adjusted, and the intensity of EGFR is divided by 5 in the heat maps. 
  
48 
assays and SCBC measurements are self-consistent. Comparisons between bulk cell assays, 
SCBC single cell measurements, and literature results
18, 20-23
 were also done to detect 
distinct phosphorylation states of EGFR under the influence of EGF and erlotinib 
stimulation. Those results again formed a self consistent data set. 
Data, such as is shown in Fig. 2.9, was first averaged to recapitulate measurements of 
proteins from cell populations for comparison with known biology. It was then more fully 
analyzed to yield a statistical representation of fluctuations at the single cell level.  
 
Figure 2.10 Averaged responses for all three cell lines to EGF and erlotinib (eb) + EGF 
exposures. (A, Left) Measured protein expression profiles, in fluorescent intensity units, 
averaged over the 3-cell measurements (n~20). The signal of EGFR/EGFRvIII is divided by 
10. Results are shown as mean ± SD. SD represents the combined experimental error and 
intrinsic biological variation, but is dominated by the biological variation. (Right) Western 
blot analysis of p-EGFR, p-ERK, p-mTOR, p-Src, p-p70S6K, p-GSK3β and p-Akt 
expression in U87 EGFRvIII and U87 EGFRvIII PTEN cell lines at the basal, EGF 
stimulation and eb + EGF treatment states. (B) Heat map of relative expression fold changes 
of proteins, normalized by unperturbed U87 cells (eb = erlotinib). (C, Left) Mean fold change 
of phosphorylation levels of p-ERK and p-mTOR in different cell lines and conditions, 
relative to unperturbed U87 cells. (E: EGF; e+E: erlotinib + EGF). (Right) Western blot 
analysis of p-ERK and p-mTOR expression in response to EGF stimulation in U87 
EGFRvIII and U87 EGFRvIII PTEN cell lines. These cells were cultured in DMEM medium 
containing 10% FBS for 24 hours, then in serum free medium for 24 hours or (+) erlotinib 
(10 μM) treatment in serum free medium, followed by stimulation (+) with EGF (20 ng/ml) 
for 15 min. Cells were lysed and the listed proteins were detected by western blotting. 
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Fig. 2.10 A presents the protein abundances (averaged over all 3-cell experiments), 
measured for each cell line and for all conditions (mean intensities and standard deviations 
are presented in Appendix B: Supplementary Tables). We compared these SCBC results 
with literature findings that used conventional bulk cell assays, as well as with our own 
Western blot assays (Fig. 2.10). In the following discussion, literature citations following 
the protein names provide validation of our SCBC results.  
At basal level, U87 cells (Fig. 2.10 A, top) showed low EGFR phosphorylation
23
 and 
modest activation of signaling proteins, including p-Src
22
, p-mTOR
24
, p-p70S6K
23, 25
, p-
GSK3α/β23, 26, 27, p-p38α24, and p-ERK18, 22, 26, while p-JNK2 was not detected23. U87 
EGFRvIII cells (Fig. 2.10 A, middle) exhibited increased baseline levels of 
phosphorylation compared with cells expressing wild-type EGFR, including p-Src
22
, p-
mTOR, p-p70S6K
25
, p-ERK
18
 and p-JNK2
28
. In U87 EGFRvIII PTEN cells (Fig. 2.10 A, 
bottom), PTEN coexpression diminished baseline phosphorylation of p-Src, p-mTOR, p-
p70S6K
25
, p-ERK
18
 and p-JNK2 compared with U87 EGFRvIII.  
EGF stimulation induced EGFR phosphorylation (Fig. 2.13)
18, 27, 28
 and promoted 
downstream pathway activation in all 3 cell lines, irrespective of PTEN status, including 
activation of p-p70S6K
25
 and p-ERK
18
. The increase of levels of p-ERK in response to 
EGF stimulation in U87 EGFRvIII and U87 EGFRvIII PTEN cells are demonstrated by the 
Western blots shown in Fig. 2.10. The level of p-GSK3α/β in response to EGF stimulation 
was increased in U87
27
 and U87 EGFRvIII cells, but remained relatively unchanged in U87 
EGFRvIII PTEN cells (consistent with Western  
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Erlotinib inhibition + EGF stimulation diminished phosphorylation of both EGFR 
and EGFRvIII (Fig. 2.10)
18
 relative to EGF stimulation. It led to decreased phosphorylation 
levels in U87, although those levels are higher than in the unstimulated cells. One 
previously identified example of this effect is p-p70S6K
14, 18
. Erlotinib + EGF showed little 
impact on U87 EGFRvIII cells, indicating that PTEN loss confers resistance to EGFR 
tyrosine kinase inhibitors
14, 21
. The phosphoprotein expression levels decrease, but are 
above the unstimulated levels. Representative proteins include p-Src
22
 and p-p70S6K
14, 18, 
25
. Erlotinib significantly diminished phosphorylation levels of p-ERK, p-p70S6K
14, 18
, p-
mTOR and p-Src only for the U87 EGFRvIII PTEN cells. Those phosphorylation levels are 
below those observed for unperturbed cells; p-p70S6k and p-mTOR drop to below the 
detection limit. These results are consistent with previous findings that co-expression of 
EGFRvIII and PTEN protein by GBM cells is associated with clinical response to EGFR 
kinase inhibitor therapy
14
. 
Fig. 2.10 B shows the heat map of relative mean-fold changes in the expression levels 
of proteins and phosphoproteins for the different cell lines and conditions, normalized by 
the protein levels measured from unperturbed U87 cells. This plot was calculated as 
follows. For a microchamber i containing n cells, the fluorescence levels recorded from the 
two barcode assays for a given protein ρ were averaged to yield ρi,n. The fluorescence 
intensity for ρ, averaged over all 0-cell measurements, was subtracted as 
background: , 0( )i n  . This value was then normalized against the background-
subtracted, fluorescence levels of ρ averaged over all n cell measurements for unperturbed 
U87:    
1
, 0 87i n nU  

  . These fold-changes were then averaged over all microchambers 
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containing 2-5 cells, and combined to produce the heat map of Fig. 2.10 B. This map 
provides a relative comparison of the pathway activation states in different cell lines and 
conditions, but it also emphasizes that the phosphorylation of p-ERK (representative of 
MAPK signaling) exhibits correlation with the phosphorylation of mTOR (PI3K signaling).  
Recent work suggests cross talk between the RAS/MAPK and PI3K signaling 
pathways
3, 29
. Recent work has also uncovered a negative regulatory feedback loop by 
which mTOR complex 1 signaling through S6K1 suppresses PI3K-mediated activation of 
MAPK activity, so that inhibition of mTOR signaling through S6K1 can activate MAPK
30, 
31
. This implied correlation between PI3K and MAPK signaling can be estimated by 
comparing the phosphorylation levels of ERK and mTOR in varying genetic contexts that 
regulate PI3K signaling, and in response to ligand stimulation and/or inhibition. The mean 
fold changes of p-ERK and p-mTOR in U87 EGFRvIII and U87 EGFRvIII PTEN cell lines 
are shown in Fig. 2.10 C (left). In U87 EGFRvIII cells, the fold change of p-ERK under 
basal level, EGF stimulation and erlotinib + EGF treatment are statistically lower than that 
of p-mTOR (Table 2.3). However, in U87 EGFRvIII PTEN cells, the situation is reversed. 
Obviously, PTEN expression sensitizes GBM cells to MAPK signaling stimulated by EGF. 
This preferential activation of MAPK signaling pathways in response to EGF activation in 
GBM cells containing PTEN was validated by immunoblot analysis (Fig. 2.10 C, right), 
and is consistent with recent findings that minimal levels of ERK signaling are required for 
optimal EGFRvIII-mediated tumor cell growth in PTEN null glioblastomas
15
. These data 
demonstrate that SCBC measurements can uncover feedback loops and pathway cross talk 
in situations where the connectivity is less well defined. 
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2.3.4 Constructing protein-protein correlation networks to reveal the signaling 
coordination 
 
Figure 2.11 Graphical representation of the information that is uniquely extracted at the single 
cell level. All data are collected using the SCBC platform. Representative error bars, based 
upon the measured standard deviations, are provided. (A) Relative abundance levels of P53, 
recorded for 0, 1, 2, and 3 cell experiments. Note that the lowest abundance levels correlate 
linearly with numbers of cells in the chamber, and that a small fraction of cells with high p53 
levels begin to dominate the measured signal in the 3 cell experiments. (B) Abundance 
histograms of p-ERK levels measured from single U87 EGFRvIII PTEN cells. The single cell 
data reveal that the erlotinig+EGF stimulated cells exhibit a much more homogeneous behavior 
than do the unstimulated cells (biological coefficient of variation of 28% versus 57%). (C-D) 
Characteristic protein-protein correlations. (C) Plot showing a strong correlation between p-
p70S6K and p-mTOR in U87 EGFRvIII cells, regardless of the numbers of cells in the 
microchamber, for 1-5 cell experiments (note the 0-cell baseline). (D) Plot showing the anti-
correlation between p-GSK3α/β and p-ERK in U87 EGFRvIII PTEN cells. The listed % values 
indicate the fraction of cells in a particular quadrant. Percentages in black font include 1 and 2 
cell data; grey font values include 1-4 cell data. Note that the 1 and 2 cell experiments exhibit a 
similarly high level of anti-correlation, but that the anti-correlation begins to be masked by 
population effects once the 3 and 4 cell data is included in the scatter plot. 
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Profiles that reveal the relative importance of the measured biological fluctuations 
versus the experimental errors are shown in Fig. 2.11 A and B. Two points are relevant for 
comparing bulk cell assays and single cell measurements. Fig. 2.11 A which plots p53 
intensity versus experiment number, for the sets of 1, 2, and 3 cell experiments, illustrates 
how a small fraction of cells can dominate an assay. Fig. 2.11 B provides histograms of the 
number of p-ERK molecules detected, versus frequency of detection, for single U87 
EGFRvIII PTEN cells under all three conditions. Those histograms may be compared 
against the averaged p-ERK intensities presented at the bottom of Fig. 2.10 A. According 
to Fig. 2.10 A, the p-ERK level for the unperturbed cells is only slightly higher than for the 
EGF + erlotinib exposed cells. However, the coefficient of variation of p-ERK levels is 
much larger (57%) than in the EGF+erlotinib perturbed cells (28%). This effect, which is 
not captured in bulk assays, may represent an increased amount of regulation for p-ERK in 
the EGF+erlotinib perturbed cells
32
.  
The levels of several proteins associated with PI3K signaling should exhibit 
coordinated behaviors
6
.  A typical protein-protein positive correlation (p-mTOR vs p-
p70S6K for unstimulated U87 EGFRvIII cells), and an anti-correlation (p- GSK3α/β vs p-
ERK for unstimulated U87 EGFRvIII PTEN) are shown in Supplementary Fig. 2.10 C and 
D. The positive correlation is independent of the numbers of cells per microchamber assay, 
while the negative correlation begins to be masked for populations as low as 3 cells. Fig. 
2.12 provides 9 SCBC-derived protein correlation networks. The line weight defines the 
strength of the correlation (see key). We used the Bonferroni method
33
, which limits 
correlations to those that exhibit a p-value ≤ 0.05; correlation coefficients above 0.4, or 
  
54 
below -0.4, are significant. Perturbation by ligand stimulation and/or receptor inhibition 
reveal new relationships, and the genetic context of those relationships. EGF stimulation of 
EGFRvIII-expressing GBM cells greatly enhances network connectivity in a way that is 
very different from what would be expected from simply summing the effects of EGF 
treatment (U87 + EGF, top middle) and EGFRvIII expression (U87 EGFRvIII, middle 
left). This represents a clinically and biologically relevant result, since wild type EGFR is 
always present in EGFRvIII expressing cells
14
. The greatly enhanced network 
interconnectivity for the EGF stimulated U87 EGFRvIII cells may suggest a mechanism 
underlying the difficulty of inhibiting downstream signaling in EGFRvIII expressing, 
PTEN null tumor cells, potentially providing one mechanism for their striking 
tumorigenicity and their established role in promoting therapeutic resistance. This is 
consistent with the clinical failure and the lack of p70S6K inhibition observed in 
EGFRvIII-expressing, PTEN deficient GBM patients treated with erlotinib
14
, and suggests 
that clinically relevant insights may potentially be derived from these types of single cell 
experiments. Classical genetics is also often used to combine perturbations and phenotypic 
responses to infer functional relationships between genes
34
, but specific interactions are 
difficult to extract because intermediate interacting partners may contribute combinations 
of positive and/or negative interactions. 
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Figure 2.12 Protein correlation maps under different genetic and environmental 
perturbations. All indicated correlations pass a Bonferroni corrected p-value test (p=0.05). 
Underlined proteins are below detection limit. 
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2.4 CONCLUSION 
The SCBC provides certain advantages for assaying cytoplasmic proteins. The ability 
to normalize protein levels to numbers of cells permits for the SCBC data to recapitulate 
qualitative protein measurements from bulk cell populations, but in a quantitative fashion. 
One example relates towards interrogating cross talk between the RAS/MAPK and 
Receptor Tyrosine Kinase (RTK)/PI3K signaling in GBM
3, 29, 30
. Using the SCBC, we 
found that for U87 EGFRvIII PTEN cells, stimulation with EGF (associated with 
RTK/PI3K signaling) led to a sharp increase in levels or p-ERK (associated with the 
RAS/MAPK pathway), a result that was confirmed using Western Blot analysis of the bulk 
cell lines. Exposure of those same cells to erlotinib + EGF kept the p-ERK levels near the 
level of unstimulated U87 EGFR vIII PTEN cells.   
A second advantage relates to the assessment of the single cell fluctuations, defined by 
the distribution of the levels of a given protein, measured across many SCBC assays. The 
measured biological variation that arises from the functional heterogeneity of a genetically 
identical cell population is significantly higher than the experimental error, and varies 
across proteins. These fluctuations provide a gauge of the heterogeneity of the cell 
population, and can be used to predict the thermodynamic stability of specific proteins 
towards perturbations
32
.  
The SCBC barcodes could potentially be expanded to 35-40 proteins, depending upon 
the availability of antibody pairs, but even for just 11 intracellular proteins, the correlation 
networks extracted from SCBC data already provide interesting parallels with the 
tumorigenecity and therapeutic resistance of EGFRvIII positive, PTEN null tumors. 
  
57 
Expanding the protein panel will permit a more complete mapping of the connectivity 
between known GBM signaling pathways, and how that connectivity may be influenced by 
molecular (i.e., therapeutic) or physical (i.e., hypoxia) perturbations. A further significant 
challenge will be to extend this platform towards the analysis of clinical specimens, and 
such work is currently underway. 
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2.6 APPENDIX A: SUPPLEMENTARY METHODS 
2.6.1 Synthesis of DNA-Antibody Conjugates 
As-received antibodies (Table 2.1) were desalted, buffer exchanged to pH 7.4 PBS and 
concentrated to 0.5 mg/mL using Zebba protein desalting spin columns (Pierce). 
Succinimidyl 4-hydrazinonicotinate acetone hydrazone in N,N-dimethylformamide (DMF) 
(SANH, Solulink) was added to the antibodies at variable molar excess of (300:1) of 
SANH to antibody. Separately, succinimidyl 4-formylbenzoate in DMF (SFB, Solulink) 
was added at a 16-fold molar excess to 5‘aminated 30mer oligomers in PBS. After 
incubation for 4h at room temperature, excess SANH and SFB were removed and both 
samples buffered exchanged to pH 6.0 citrate buffer using protein desalting spin columns. 
A 30-fold excess of derivative DNA was then combined with the antibody and allowed to 
react overnight at room temperature. Noncoupled DNA was removed using a Pharmacia 
Superdex 200 gel filtration column (GE) at 0.5 mL/min isocratic flow of PBS. The 
conjugates were then concentrated to 0.5 mg/mL by Amicon Ultra-4 Centrifugal Filter Unit 
with Ultracel-10 membrane (Millipore 10kDa) and stored at 4°C. The conjugation yield 
was determined by Nanodrop (Thermal Scientific). Detailed protocol can be found in the 
Protein-Oligo Conjugation Kit (Solulink).  
Table 2.1 Reagents Used. At top are the Sequences and terminal functionalization of 
oligonucleotides. All oligonucleotides were synthesized by Integrated DNA Technology (IDT) and 
purified via high performance liquid chromatography (HPLC). The DNA coding oligomers were 
pre-tested for orthogonality to ensure that cross-hybridization between non-complementary 
oligomer strands was negligible (<1% in photon counts).4  Next are listed the antibodies used for the 
multiplex protein assays. All antibody pairs except p-EGFR and p-VEGFR2 were purchased from 
commercial available ELISA kits (R&D systems, DuoSet® Elisa Development Reagents) 
containing capture antibodies, biotinylated detection antibodies and standard proteins. Capture 
antibodies bind both phosphoryalted and unphosphorylated proteins. Biotinylated detection 
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antibodies detect only phosphorylated proteins. p-EGFR antibodies specific for phosphorylation 
of EGFR at Y1173, Y1068 and Y845 were purchased from R&D systems as capture antibodies and 
biotin-labeled EGFR was used as detection antibody. p-VEGFR2 (Y1214) capture antibody and 
biotin-labeled VEGFR2 detection antibody were purchased from Abcam. 
Name DNA Sequence Melting Point 
A 5'- AAA AAA AAA AAA AAT CCT GGA GCT AAG TCC GTA-3' 57.9 
A' 5' NH3- AAA AAA AAA ATA CGG ACT TAG CTC CAG GAT-3' 57.2 
B 5'-AAA AAA AAA AAA AGC CTC ATT GAA TCA TGC CTA -3' 57.4 
B' 5' NH3AAA AAA AAA ATA GGC ATG ATT CAA TGA GGC -3' 55.9 
C 5'- AAA AAA AAA AAA AGC ACT CGT CTA CTA TCG CTA -3' 57.6 
C' 5' NH3-AAA AAA AAA ATA GCG ATA GTA GAC GAG TGC -3' 56.2 
D 5'-AAA AAA AAA AAA AAT GGT CGA GAT GTC AGA GTA -3' 56.5 
D' 5' NH3-AAA AAA AAA ATA CTC TGA CAT CTC GAC CAT -3' 55.7 
E 5'-AAA AAA AAA AAA AAT GTG AAG TGG CAG TAT CTA -3' 55.7 
E' 5' NH3-AAA AAA AAA ATA GAT ACT GCC ACT TCA CAT -3' 54.7 
F 5'-AAA AAA AAA AAA AAT CAG GTA AGG TTC ACG GTA -3' 56.9 
F' 5' NH3-AAA AAA AAA ATA CCG TGA ACC TTA CCT GAT -3' 56.1 
G 5'-AAA AAA AAA AGA GTA GCC TTC CCG AGC ATT-3' 59.3 
G' 5' NH3-AAA AAA AAA AAA TGC TCG GGA AGG CTA CTC-3' 58.6 
H 5'-AAA AAA AAA AAT TGA CCA AAC TGC GGT GCG-3' 59.9 
H' 5' NH3-AAA AAA AAA ACG CAC CGC AGT TTG GTC AAT-3' 60.8 
I 5'-AAA AAA AAA ATG CCC TAT TGT TGC GTC GGA-3' 60.1 
I' 5' NH3-AAA AAA AAA ATC CGA CGC AAC AAT AGG GCA-3' 60.1 
J 5'-AAA AAA AAA ATC TTC TAG TTG TCG AGC AGG-3' 56.5 
J' 5' NH3-AAA AAA AAA ACC TGC TCG ACA ACT AGA AGA-3' 57.5 
K 5'-AAA AAA AAA ATA ATC TAA TTC TGG TCG CGG-3' 55.4 
K' 5' NH3-AAA AAA AAA ACC GCG ACC AGA ATT AGA TTA-3' 56.3 
L 5'-AAA AAA AAA AGT GAT TAA GTC TGC TTC GGC-3' 57.2 
L' 5' NH3-AAA AAA AAA AGC CGA AGC AGA CTT AAT CAC-3' 57.2 
M 5'-Cy3-AAA AAA AAA AGT CGA GGA TTC TGA ACC TGT-3' 57.6 
M' 5' NH3-AAA AAA AAA AAC AGG TTC AGA ATC CTC GAC-3' 56.9 
DNA label Antibody Source 
A’ Human p-PDGFRβ (Y751) kit R&D DYC3096 
B’ Human p-Src (Y419) kit R&D DYC2685 
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C’ Human p-mTOR (S2448) kit R&D DYC1665 
D’ Human p-p70S6K (T389) kit R&D DYC896 
E’ Human p-GSK3α/β (S21/S9) kit R&D DYC2630 
G’ Human p-p38α (T180/Y182) kit R&D DYC869 
H’ Human p-ERK (T202/Y204) kit R&D DYC1825 
I’ Human p-JNK2 (T183/Y185) kit R&D DYC2236 
K’ Human total EGFR kit R&D DYC1854 
L’ Human total P53 kit R&D DYC1043 
J’ 
Capture antibody: rabbit anti-human p-VEGFR2 (Y1214) Abcam ab31480 
Detection antibody: biotin-labeled mouse anti-human VEGFR2 Abcam ab10975 
G’ 
rabbit anti-human EGFR (Y1173) R&D AF1095 
Detection antibody: biotin-labeled goat anti-human EGFR R&D BAF231 
I’ 
mouse anti-human EGFR (Y1068) R&D MAB3570 
Detection antibody: biotin-labeled goat anti-human EGFR R&D BAF231 
K’ or L’ 
rabbit anti-human EGFR (Y845) R&D AF3394 
Detection antibody: biotin-labeled goat anti-human EGFR R&D BAF231 
 
2.6.2 Microfluidic flow patterning of DNA barcode microarray 
    This procedure has been previously described in detail
10
, and so only a brief description 
is provided here. The PDMS elastomer-based microfluidic patterning chips were fabricated 
via a molding process from a silicon master with photolithographically-defined patterns. 
The mixture of GE RTV 615 PDMS prepolymer and curing agent (10:1) was stirred, and 
poured onto the silicon mold, which was pre-treated with trimethyl-chloro-silane (TMCS) 
vapor to facilitate mold release. The PDMS is then poured on the mold, degassed for 30 
min (house vacuum), and then cured at 80
o
C for 1 h. The solidified PDMS slab was cut 
from the mold, assess holes drilled and then bonded onto a poly-L-lysine glass slide 
(VWR). The microfluidic patterning chip contained 13 parallel microchannels patterned 
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such that they cover a large area (3cm×2cm) of the glass slide for creating the DNA 
barcode microarray. Each microchannel is approximately 0.5 meters long and 20 
micrometers wide. 
    For creating a DNA barcode array pattern, multiple DNA solutions (one for each 
barcode stripe), are each diluted in a mixture of DMSO and deionized water (v/v=1:2) with 
a final DNA concentration of 267 μM. These solutions are each flowed into a specific 
microfluidic channel. The solution-filled chip was placed in a desiccator to allow solvent 
(DMSO and water) to evaporate completely through the gas-permeable PDMS, leaving the 
DNA molecules behind. This evaporation process took 3-5 days to complete. Last, the 
PDMS elastomer was removed from the glass slide, and the barcode-patterned DNA was 
fixed to the glass surface by thermal treatment at 80
o
C for 4 hours. Residue crystals were 
readily removed by rapidly dipping the slide in deionized water. Each DNA barcode chip 
needs validation before bonding to bonding the single cell assay chip. A small area near 
edge was validated to check the DNA loading and uniformity. It was blocked with 1% 
Bovine Serum Albumin (BSA)/PBS for 1 hr, and then hybridized with fluorescent Cy3-
labeled complementary DNA for 1 hr. After washing three times with 1% BSA/PBS and 
PBS, the slide was dried by nitrogen gun and scanned by Axon Genepix 4400A . Under 
laser power of 15% and gain of 450, fluorescence intensity above 10,000 was acceptable 
for cytoplasmic protein detection at the single cell level.  
2.6.3 DNA spot microarrays for conjugate validation, cross-reactivity check and other 
bulk protein measurements. 
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The DNA-1
o
 antibody conjugate validation, check of cross-reactivity among 
antibodies and the measurement of EGFR phosphorylation states were performed on DNA 
spot microarrays printed by Institute of Systems Biology (Seattle, WA) using the same 
DNA oligos as those in microfluidic DNA barcode patterning
35
. For device assembly, a 12-
well PDMS slab was bonded to the glass slide with DNA spot microarrays, as shown in 
Fig. 2.13. Each well contains repeated 13 DNA spot microarrays. The diameter of each 
spot is 150 μm, and distance between neighboring spots is 400 μm.  
1) Conjugate validation. a) Block each well with 1% BSA for 1 h. b) Add 50 μl of 
conjugate (5 μg/ml) into the well and incubate at room temperature for 1 h. c) 
Aspirate each well and wash with 1% BSA, repeating the process two times for a 
total of 3 washes. d) Add 50 μl of standard protein in PBS and incubate at room 
temperature for 1 h. Meanwhile, add 50 μl of PBS in another well as the negative 
control. e) Wash each well with 1% BSA for three times. f) Add 50 μl of biotin-
labeled detection antibody and incubate at room temperature for 1 h. g) Wash each 
well with 1% BSA for three times. h) Add a mixture of Cy5 fluorescent dye-
labeled streptavidin and Cy3-labeled reference complementary ssDNA and 
incubate at room temperature for 1 h. i) Wash each well with 1% BSA for three 
times and PBS for two times. j) The PDMS device is removed from the glass slide, 
and is immediately dipped 3 times each in the following solutions in order, 1X 
PBS, 0.5X PBS, deionized Millipore H2O, and finally dried with a nitrogen gun. k) 
The slide was scanned by Axon Genepix 4400A. 5 μm of resolution is selected. 
Two color channels (the green Cy3 and the red Cy5 channel) are turned on to 
collect fluorescence signals.  
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2) Cross-reactivity check of antibodies. The experimental procedure is similar with 
the conjugate validation. In order to validate the cross-reactivity of antibodies, all 
conjugates and detection antibodies are added in each well, but only one standard 
protein is added in each well.  
3) Measurement of EGFR phosphorylation states. The experimental procedure is 
similar with the conjugate validation, except using cell lysate instead of standard 
proteins. The treated cells are washed with cold PBS to remove residual media. 
Cell lysis buffer (1X) is then added and the cells are incubated on ice for 10 
minutes. The cell extract is then collected and spun at 14,000 g in a 
microcentrifuge at 4
o
C for 10 minutes, and the supernatant is removed for use. p-
EGFR/ssDNA conjugates specific for phosphorylation of EGFR at Y1173, Y1068 
and Y845 are used as capture antibodies and biotin-labeled EGFR is used as 
detection antibody.  
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2.6.4 Step by step protocol of single-cell proteomic assay 
The use of an SCBC was as follows:  
 
Figure 2.13 Spot-based microarray platform utilized for multiplex protein assays from large 
numbers of cells, and application in monitoring EGFR phosphorylation and validation of 
conjugate cross-reactivity. The spot-based platform is a variant of ELISA. The sandwich 
immunoassays are identical to the DEAL-based assays used within the SCBC. (A) Layout of 
DNA spot microarrays. The inset shows a basic unit consisting of 13 DNA spots (#A to #M, 
comprised of the same ssDNA oligomers used for the DNA barcodes). Spot diameters are 150 
μm. The basic unit is repeated over 6 columns and 50 rows to make a DNA spot array 
containing 60X50 spots. (B) Photograph of a spot-based chip for multiplexed protein 
measurement from large numbers of cells, and for antibody cross-reactivity studies. This 12-well 
PDMS slab is bonded to the glass slide with the pre-printed DNA spot microarrays. Each well 
has a volume of 50 μl and contains a complete set of 13 DNA spots for simultaneously assaying 
the entire panel of proteins. (C) Spot-based EGFR phosphorylation measurements in U87, U87 
EGFRvIII and U87 EGFRvIII PTEN cells, under the conditions of standard culture, EGF 
stimulation, and erlotinib (eb) + EGF stimulation. The same numbers of cells were lysed in each 
condition for comparison. As a control, EGFR standard protein was used to validate the 
specificity of the phospho-specific antibodies. (D) Cross-reactivity of panel of assayed proteins. 
A pin-spotted microarray was used for the DEAL-based protein detection. Each row represents a 
different condition. For each row, the full cocktail of DEAL conjugates (for the 11 assayed 
proteins) was used, with one standard protein was tested per row. Red spots are signal from the 
standard proteins and the green spots alignment reference signals from Cy3-labeled DNA 
sequence #M’. 
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1) Blocking: All microfluidic channels were first blocked with the blocking 
buffer (3% w/v Bovine Serum Albumin + 0.1% N-Dodecyl-β-D-maltoside in 
1X PBS) for 60 min. N-Dodecyl-β-D-maltoside was reported to minimize 
non-specific protein adsorption on PDMS
36
.  
2) Forming capture antibody microarrays: A solution containing all DNA-
antibody conjugates was flowed through the assay channels of the SCBCs for 
60 min, which transformed the DNA barcode microarrays into antibody 
microarrays enabling the subsequent surface-bound immunoassay. The 
unbound conjugates were removed by flowing the washing buffer (3% BSA 
+ 1% phosphatase inhibitor) for 10 min. The DNA-antibody conjugate 
solution (100 μl) was prepared by mixing all synthesized conjugates in 3% 
BSA with a final concentration of 10 μg/mL of each conjugate.  
3) On-chip cell lysis and intracellular protein measurement: The concentrated 
cell lysis buffer (4X) was prepared by mixing Cell Lysis Buffer (Cell 
Signaling, containing 20 mM Tris-HCl, 150 mM NaCl, 1 mM Na2EDTA, 1 
mM EGTA, 1% Triton, 2.5 mM sodium pyrophosphate, 1 mM -
glycerophosphate, 1 mM Na3VO4, and 1 g/ml leupeptin), Complete 
Protease Inhibitor Cocktail (Roche) and Phosphatase Inhibitor Cocktail 2 
(Sigma). This lysis buffer can efficiently extract nuclear, membrane 
associated, and cytoplasmic proteins. The lysis buffer was loaded into the 
lysis buffer chambers (Fig. 2.3) while the valve 4 (Fig. 2.3 A) was kept 
closed by applying 18-20 psi constant pressure. After cell treatment, the 
treated cells were dissociated with trypsin and EDTA, centrifuged at 4
o
C and 
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suspended in cold PBS with a concentration of 1000 cell/μL. Then, cells 
were loaded into the pre-chilled microfluidic chips, and valve 3 (Fig. 2.3 A) 
were closed to compartmentalize cells, which converted the 8 channels into 
120 isolated microchambers. The cells on the chip were recorded by a CCD 
camera for cell counting at 4
o
C. Subsequently, the chip was sitting on the ice 
and the valve 4 was opened for on-chip diffusion of lysis buffer to the 
neighboring cell chambers (Fig 2.3 D-F). The chip was tilted to accelerate the 
lysis buffer diffusion. After 20 minutes of lysis buffer diffusion and on-chip 
cell lysis, the valve 4 was closed and the chip was incubated on ice for 20 
more minutes with shaking to complete the on-chip cell lysis. The chip was 
incubated at room temperature with shaking for 2 hours to allow capture of 
target proteins by antibody microarrays within the microchambers. 
Afterwards, the unbound cell lysate was quickly removed by flowing the 
washing buffer for 10 min.  
4) Applying detection antibodies: A mixture of biotin-labeled detection 
antibodies was flowed into the SCBC for 60 min at room temperature to 
complete the DEAL assay. The detection antibody solution contained 
biotinylated detection antibodies at ~3 μg/mL (or specified in the insert of the 
ELISA kit; the concentration varies from lot to lot) prepared in washing 
buffer. Then, unbound detection antibodies in the SCBC were removed by 
flowing the washing buffer for 10 min.  
5) Fluorescence probes: Cy5 fluorescent dye-labeled streptavidin (eBioscience, 
2μg/mL) and the reference, Cy3-labeled complementary ssDNA (DNA code 
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M/M’, 25 nM), were mixed together and were then flowed into the SCBC 
for 60 min. Afterwards, 3% BSA/PBS was flowed for 20 min to remove 
unbound Steptavidin-Cy5, and 1X Phosphate Buffered Saline Tween-20 
(PBST) was flowed for 40 min as the final wash step.  
6) Rinse: The PDMS chip device was removed from the DNA-patterned glass 
slide, and was immediately dipped 3 times each in the following solutions in 
order, PBST, 1X PBS, 0.5X PBS, deionized Millipore H2O, and finally dried 
with a nitrogen gun.  
7) Optical readout: The slide was scanned by Axon Genepix 4400A (Molecular 
Devices). The finest resolution (2.5 μm) was selected. Two color channels 
(the green Cy3 and the red Cy5 channel) were turned on to collect 
fluorescence signals.  
2.6.5 Protocols for immunoblot assays 
   Western blotting was as previously described. Cultured cells in 60 mm dish were 
lysed and homogenized using buffer containing 10 mmol/L Tris, pH 7.4, 100 mmol/L 
NaCl, 1 mmol/L EDTA, 1 mmol/L EGTA, 1 mmol/L NaF, 20 mmol/L Na4P2O7, 2 mmol/L 
Na3VO4, 0.1% sodium dodecyl sulfate, 0.5% sodium deoxycholate, 1% Triton X-100, 10% 
glycerol, 10 µg/mL leupeptin, 60 µg/mL aprotinin, and 1 mmol/L phenylmethanesulfonyl 
fluoride. Equal amounts of protein extracts were separated by using 8% or 10% SDS-
PAGE, and then transferred to a polyvinylidene difluoride membrane (Bio-Rad 
Laboratories Inc, Hercules, CA). After blocking for 1 hour in a Tris-buffered saline 
containing 0.1% Tween 20 and 5% nonfat milk, the membrane was probed with various 
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primary antibodies, followed by secondary antibodies conjugated to horseradish 
peroxidase. The immunoreactivity was revealed by use of an ECL kit (Amersham 
Biosciences Co, Piscataway, NJ). The antibodies were obtained from Cell Signaling (p-Akt 
Ser473, Akt, p-GSK3β Ser9, GSK3β, PTEN, phospho-EGFR), Sigma (α-actin) and Upstate 
(EGFR/EGFRvIII cocktail antibody). 
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2.7 APPENDIX B: SUPPLEMENTARY TABLES 
Table 2.2 Mean intensity, standard deviation and coefficient of variation (CV) of standard proteins 
in calibration experiments. (bottom rows) Parameters utilized for protein assay calibration curves. 
The calibration curves were well fit by a four-parameter Morgan-Mercer-Flodin (MMF) model, 
which is a common model for sigmoidal or S-shaped growth. Based on this model, the fluorescence 
intensity can be translated into concentration (pg/mL).   
d
d
ab cx
y
b x



 
  EGFR p-ERK p-p38α p-GSK3α/β p-p70S6K p-mTOR p-Src 
50 ng/ml 803.86±15.27 500.16±46.12 204.45±18.92 720.68±22.72 719.11±17.12 339.45±26.08 804.87±14.74 
CV 0.02 0.09 0.09 0.03 0.02 0.08 0.02 
10 ng/ml 733.32±8.43 191.47±11.93 87.40±6.64 321.67±14.40 283.54±14.35 117.64±6.01 736.16±18.34 
CV 0.01 0.06 0.08 0.04 0.05 0.05 0.02 
1 ng/ml 269.06±8.83 28.84±3.25 20.80±3.61 61.07±4.62 43.17±3.4 14.35±1.13 243.66±10.37 
CV 0.03 0.11 0.17 0.08 0.08 0.08 0.04 
100 pg/ml 67.14±4.3 5.86±0.93 9.74±1.44 7.09±0.85 8.02±0.88 5.29±0.59 52.16±4.66 
CV 0.06 0.16 0.15 0.12 0.11 0.11 0.09 
10 pg/ml 22.01±2.14 4.25±0.65 8.86±0.9 5.71±0.91 6.59±0.98 4.87±0.57 19.58±1.62 
CV 0.10 0.15 0.10 0.16 0.15 0.12 0.08 
0 12.45±1.5 4.34±0.71 7.2±0.95 5.11±0.69 6.87±0.59 4.43±0.37 8.97±0.86 
CV 0.12 0.16 0.13 0.13 0.09 0.08 0.10 
Parameters for Protein Assay Calibration Curves 
 a b c d r 
EGFR 1.230 667.38 1179.21 0.758 0.9999 
p-ERK 3.864 28142.75 884.84 0.970 0.9999 
p-p38α 7.911 11874.57 382.78 0.876 0.9999 
p-GSK3α/β 3.283 7972.09 1234.7 0.861 0.9999 
p-p70S6K 5.808 26921.69 1218.11 0.976 0.9999 
p-mTOR 4.280 101832 562.39 1.103 0.9999 
p-Src 10.618 1161.08 1173.15 0.821 0.9999 

Table 2.3 Mean intensity and standard deviation (std, red font) for proteins assayed from U87, U87 
EGFRvIII and U87 EGFRvIII PTEN cells, as a function of # of cells, and under the different 
conditions.  At the bottom (blue font) is presented the mean fold change and standard error of 
protein and phosphoprotein levels. For calculating the mean fold change values, unperturbed U87 
was set as the base line, and mean fold changes of protein levels in the cell lines and conditions 
were calculated. This mean fold change was calculated as follows: For a microchamber i containing 
n cells, the fluorescence levels recorded from the two barcode assays for a given protein   were 
averaged to yield 
,i n . The fluorescence intensity for  , averaged over all 0-cell measurements, 
was subtracted as background: )( 0,  ni . This value was then normalized against the background-
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subtracted, fluorescence levels of   averaged over all n cell measurements for unperturbed U87: 
1
, 0 , 87( ) ( ) 1i n n U  
   . These values for the fold-change in the levels of each assayed protein 
for each microchamber were then averaged over all microchambers containing 2-5 cells. Standard 
error of median (SEM) is calculated accordingly. Number of measurements is also listed. 
cell 
ref P53 EGFR 
p-
VEGFR 
p-JNK2 
p-
ERK 
p-
p38  
control 
p-
GSK3 
p-
p70S6K 
p-
mTOR 
p-Src p-PDGFR 
 
0 
403.8
1 
2.24 2.29 14.87 2.52 1.20 11.48 3.14 0.65 2.29 1.77 3.04 1.85 
U87 
1 
382.0
3 
19.80 384.80 19.94 3.49 3.78 22.47 2.84 16.48 5.42 5.01 7.51 2.65 
2 
396.5
2 
28.69 544.72 26.87 3.88 6.11 24.01 2.98 18.19 10.01 7.28 10.38 3.63 
3 
423.9
8 
40.12 595.11 28.03 4.03 7.10 27.17 3.06 18.82 12.95 7.70 13.83 3.16 
4 
402.4
2 
64.10 664.33 32.98 4.80 10.99 30.06 3.59 18.55 16.21 7.87 16.90 1.93 
5 
373.0
8 
92.42 706.23 58.71 5.63 13.76 31.76 3.20 22.43 18.16 10.15 13.87 3.19 
 
cell ref P53 EGFR 
p-
VEGFR 
p-JNK2 
p-
ERK 
p-
p38  
control 
p-
GSK3 
p-
p70S6K 
p-
mTOR 
p-Src p-PDGFR 
 
0 
415.7
0 
1.28 3.61 24.41 2.39 0.83 7.22 2.65 0.73 1.31 1.56 1.24 0.47 
U87 
+  
EG
F 
1 
420.9
5 
28.64 418.24 46.37 3.23 7.20 31.43 2.59 29.34 31.99 8.08 15.44 2.53 
2 
424.7
5 
48.68 578.54 51.67 3.55 10.61 33.95 2.57 31.12 40.95 10.65 25.94 3.55 
3 
414.1
5 
73.76 726.12 67.83 4.89 13.63 39.64 2.37 34.41 45.93 16.56 28.78 3.46 
4 
413.5
3 
118.7
9 
773.29 110.58 8.35 15.94 44.71 2.94 43.29 50.62 19.06 32.03 2.83 
5 
424.4
7 
136.4
9 
780.69 126.49 8.63 21.94 52.65 3.93 56.73 60.23 26.76 35.21 3.19 
 
cell ref P53 EGFR 
p-
VEGFR 
p-JNK2 
p-
ERK 
p-
p38  
control 
p-
GSK3 
p-
p70S6K 
p-
mTOR 
p-Src p-PDGFR 
 
0 
384.0
5 
2.11 3.13 29.50 2.20 1.34 10.18 0.88 0.55 2.76 1.70 2.14 0.80 
U87 
+  
EG
F 
+ 
eb 
1 
384.4
2 
18.67 374.74 45.24 5.53 8.64 19.45 3.73 12.02 22.08 10.51 13.21 5.56 
2 
381.3
5 
25.94 495.02 51.43 5.32 10.16 21.87 4.02 12.81 26.20 12.08 15.90 5.14 
3 
384.7
1 
39.22 566.42 56.64 5.57 11.42 22.58 3.74 13.43 26.16 13.15 18.84 5.29 
4 
386.4
9 
54.69 683.23 66.43 5.35 12.32 22.77 3.24 14.44 27.33 15.18 20.87 5.12 
5 
380.2
4 
87.64 733.72 79.67 5.16 13.39 23.37 4.16 16.80 35.69 17.91 22.45 6.09 
 
cell ref P53 EGFR 
p-
VEGFR 
p-JNK2 
p-
ERK 
p-
p38  
control 
p-
GSK3 
p-
p70S6K 
p-
mTOR 
p-Src p-PDGFR 
 
0 30.30 1.32 0.76 5.64 1.57 0.74 2.37 3.57 0.51 0.90 0.22 1.52 1.15 U87 
std 
1 38.66 14.51 123.07 7.29 1.36 1.82 10.41 1.33 5.47 2.65 2.54 7.18 1.40 
  
76 
2 51.31 12.62 96.37 13.87 1.48 2.88 6.75 1.35 5.36 5.19 4.88 9.10 1.72 
3 57.36 20.20 118.85 12.29 1.31 4.22 9.88 1.47 9.00 4.15 4.28 8.34 1.75 
4 35.00 39.63 97.98 16.35 1.00 4.36 6.69 1.58 7.55 11.40 5.14 10.84 1.07 
5 35.53 50.58 101.77 25.57 1.24 9.03 10.58 1.79 6.46 11.33 7.12 6.87 1.92 
 
cell ref P53 EGFR 
p-
VEGFR 
p-JNK2 
p-
ERK 
p-
p38  
control 
p-
GSK3 
p-
p70S6K 
p-
mTOR 
p-Src p-PDGFR 
 
0 22.30 0.63 0.83 5.19 0.81 0.29 1.40 2.29 0.24 0.68 0.13 0.89 0.24 U87 
+ 
EGF 
std 
1 42.69 12.96 145.74 15.27 1.41 4.91 13.76 1.48 11.19 9.84 4.43 8.51 1.33 
2 48.00 34.25 116.05 18.47 1.61 3.06 11.74 1.63 9.89 9.85 4.66 12.94 2.42 
3 32.29 28.70 71.26 32.32 2.21 4.13 7.43 1.32 8.52 9.00 10.12 7.05 1.50 
4 18.47 43.52 32.99 16.56 2.87 4.75 15.57 1.27 8.40 11.44 7.10 9.16 2.22  
5 38.37 41.30 33.32 46.91 0.89 15.81 16.73 2.26 21.09 17.43 10.40 7.34 2.54  
 
cell ref P53 EGFR 
p-
VEGFR 
p-JNK2 
p-
ERK 
p-
p38  
control 
p-
GSK3 
p-
p70S6K 
p-
mTOR 
p-Src p-PDGFR 
 
0 14.50 1.06 0.93 6.78 0.49 0.22 2.86 0.40 0.37 1.09 0.12 0.44 0.29 U87 
+ 
EGF 
+ 
eb 
(std) 
1 13.10 5.26 70.17 9.73 0.94 1.35 2.71 1.15 2.40 3.08 2.63 4.51 1.00 
2 10.21 10.18 79.79 11.04 0.76 1.32 2.94 1.17 1.75 3.18 2.29 4.33 0.48 
3 10.50 25.71 94.81 10.24 1.00 1.68 2.37 1.06 2.22 2.63 3.49 4.92 0.41 
4 11.34 25.70 72.01 6.13 1.16 1.41 2.67 0.86 2.48 6.37 2.82 6.69 0.72 
5 11.26 16.17 21.01 7.68 1.72 0.91 3.03 0.92 2.97 5.85 7.69 3.73 1.15 
  
cell ref P53 EGFR 
p-
VEGFR 
p-JNK2 p-ERK 
p-
p38  
control 
p-
GSK3 
p-
p70S6K 
p-
mTOR 
p-Src 
p-
PDGFR 
 
0 378.74 3.05 3.40 26.61 3.03 1.72 13.04 1.29 1.21 3.34 1.68 2.71 1.07 U87 
EGF
RVIII 
1 388.54 21.66 478.11 42.73 9.52 10.69 29.73 4.75 16.71 23.13 26.61 19.04 5.27 
2 386.66 27.32 567.97 52.53 12.53 14.39 30.08 4.94 17.91 26.31 35.86 21.50 5.28 
3 382.84 43.24 688.07 66.40 14.62 20.55 36.38 4.38 21.24 29.40 50.41 24.61 4.89 
4 387.14 57.77 735.43 76.10 15.73 23.22 41.96 5.06 24.66 36.88 60.61 34.79 5.98 
5 373.04 88.48 802.16 94.07 20.86 28.07 52.42 5.44 30.10 45.04 73.66 42.85 5.18 
 
cell ref P53 EGFR 
p-
VEGFR 
p-JNK2 p-ERK 
p-
p38  
control 
p-
GSK3 
p-
p70S6K 
p-
mTOR 
p-Src 
p-
PDGFR 
 
0 397.04 3.03 4.36 24.97 2.82 2.22 13.49 1.01 0.93 3.73 1.81 2.89 1.10 U87 
EGF
RVIII 
+ 
EGF 
1 413.40 19.25 476.95 59.57 15.50 26.92 47.99 2.66 25.87 39.32 43.89 22.05 5.01 
2 411.70 27.59 579.62 81.44 24.98 30.33 61.07 2.77 29.64 46.46 58.61 28.30 7.42 
3 416.12 43.10 721.14 122.76 29.63 37.57 71.37 3.16 34.59 54.16 75.14 33.90 7.88 
4 421.36 63.40 762.14 144.66 33.76 41.02 79.86 3.37 40.71 59.80 89.14 41.76 8.78 
5 398.36 83.97 801.47 164.69 36.45 49.82 95.95 3.20 51.10 67.18 103.44 50.34 9.11 
 
cell ref P53 EGFR 
p-
VEGFR 
p-JNK2 p-ERK 
p-
p38  
control 
p-
GSK3 
p-
p70S6K 
p-
mTOR 
p-Src 
p-
PDGFR 
 
0 384.74 2.75 3.95 26.24 2.81 1.65 11.84 1.43 1.35 2.69 1.68 3.19 1.05 U87 
EGF
RVIII 
1 399.74 17.94 453.10 61.89 12.45 24.27 29.58 4.05 20.64 26.95 39.78 15.23 1.77 
2 400.97 30.28 567.72 64.22 12.49 31.19 36.65 4.17 27.59 36.97 50.72 22.34 3.08 
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3 411.64 42.38 673.86 78.75 18.90 36.67 43.97 4.60 35.59 42.62 61.40 23.60 3.56 + 
EGF 
+  
eb 
 
4 414.72 67.17 724.37 85.05 13.69 43.11 53.92 5.08 38.90 56.30 73.36 33.72 5.49 
5 414.24 87.63 783.60 106.46 20.06 47.88 63.99 5.14 47.02 60.55 85.44 38.61 4.64 
cell ref P53 EGFR 
p-
VEGFR 
p-JNK2 p-ERK 
p-
p38  
control 
p-
GSK3 
p-
p70S6K 
p-
mTOR 
p-Src 
p-
PDGFR 
 
0 16.35 1.47 0.78 7.77 0.90 0.70 4.44 0.90 0.42 2.28 0.25 0.59 0.69 U87 
EGF
RVIII 
(std) 
1 13.32 5.60 89.41 6.61 3.59 3.10 4.60 1.19 3.06 3.01 6.96 4.17 2.06 
2 9.22 7.64 83.71 10.94 3.51 4.71 7.00 2.07 2.99 4.50 8.36 4.64 1.78 
3 16.46 9.58 36.77 12.41 3.27 4.57 6.39 1.48 3.66 4.66 7.60 4.85 1.55 
4 19.57 6.24 54.94 17.45 6.38 5.43 5.20 1.84 4.14 5.16 8.15 7.97 2.17 
5 12.94 16.61 13.30 14.15 5.20 3.75 9.95 1.67 3.26 5.58 8.89 12.37 1.09 
 
cell ref P53 EGFR 
p-
VEGFR 
p-JNK2 p-ERK 
p-
p38  
control 
p-
GSK3 
p-
p70S6K 
p-
mTOR 
p-Src 
p-
PDGFR 
 
0 21.09 1.35 0.78 6.59 0.73 0.88 3.19 0.30 0.43 1.86 0.11 1.17 0.70 U87 
EGF
RVIII 
+ 
EGF 
(std) 
1 33.42 5.13 84.21 17.17 6.39 6.09 14.42 1.57 7.54 10.47 10.76 9.44 2.61 
2 24.88 5.66 53.66 21.92 9.04 7.21 19.65 1.66 10.65 17.12 15.11 17.02 5.72 
3 25.84 6.22 46.98 50.42 7.44 8.05 20.51 1.87 9.30 14.76 20.83 18.29 6.57 
4 28.09 8.78 42.57 46.16 12.30 8.45 26.53 2.33 15.34 13.77 21.48 18.16 6.23 
5 26.02 20.46 68.48 56.14 5.66 7.59 29.04 1.37 18.14 19.27 37.54 28.27 10.53  
 
cell ref P53 EGFR 
p-
VEGFR 
p-JNK2 p-ERK 
p-
p38  
control 
p-
GSK3 
p-
p70S6K 
p-
mTOR 
p-Src 
p-
PDGFR 
 
0 20.46 0.81 1.16 8.90 0.68 0.75 2.93 0.73 0.59 1.34 0.15 0.74 0.36 U87 
EGF
RVIII 
+ 
EGF 
+  
eb 
(std) 
1 11.74 5.03 49.82 15.18 8.12 7.17 7.58 2.80 7.78 7.34 6.76 7.33 1.52 
2 13.41 7.39 56.69 8.32 9.91 5.18 9.58 2.55 9.48 10.18 11.16 7.99 2.90 
3 21.42 9.16 41.18 18.06 10.82 12.24 15.43 3.07 11.44 9.91 15.22 8.22 2.28 
4 19.28 6.26 37.52 20.58 7.75 16.65 21.53 3.57 14.95 21.57 21.22 13.80 3.44 
5 18.90 16.79 50.15 36.58 5.99 14.13 15.25 3.25 13.60 21.34 19.09 13.68 5.17 
 
cell ref P53 EGFR 
p-
VEGFR 
p-JNK2 
p-
ERK 
p-p38  control p-GSK3 
p-
p70S6K 
p-
mTOR 
p-Src 
p-
PDGFR 
 
0 384.61 3.25 2.88 20.10 3.44 1.10 12.88 0.87 0.96 1.41 1.73 3.47 0.36 U87 
EGFRVIII 
PTEN 
 
1 381.18 27.33 283.56 37.96 5.83 7.53 30.75 2.89 27.92 7.15 7.32 11.83 4.41 
2 369.80 36.31 363.47 42.77 5.58 8.36 34.88 3.26 30.67 7.33 7.55 12.98 4.03 
3 368.64 56.97 466.70 46.03 6.21 10.66 35.75 2.73 31.46 7.52 9.04 14.48 3.82 
4 383.82 68.22 545.53 52.54 6.74 12.67 39.44 2.71 32.61 9.10 10.76 14.48 4.27 
5 382.19 75.71 574.20 54.77 6.96 13.37 41.22 2.88 33.99 9.13 11.93 17.07 3.13 
cell ref P53 EGFR 
p-
VEGFR 
p-JNK2 
p-
ERK 
p-p38  control p-GSK3 
p-
p70S6K 
p-
mTOR 
p-Src 
p-
PDGFR 
 
0 385.52 2.86 3.87 26.30 2.72 1.53 9.63 0.80 0.72 2.58 1.74 1.90 0.58 U87 
EGFRVIII 
PTEN 
+ 
EGF 
 
1 412.33 25.18 262.04 54.41 2.71 24.29 32.12 2.01 23.84 19.58 15.64 23.02 2.24 
2 400.03 34.14 360.20 69.42 3.84 38.11 39.96 1.63 28.92 22.94 24.77 29.28 1.79 
3 395.77 49.89 472.01 73.00 4.74 41.88 43.11 2.43 30.30 25.24 27.60 31.28 1.90 
4 398.65 66.69 596.30 81.81 4.69 43.17 44.88 2.59 31.01 27.00 27.42 32.67 2.31 
5 390.22 90.98 623.85 85.15 6.44 46.63 47.75 2.39 32.39 31.21 30.47 33.48 2.39 
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cell ref P53 EGFR 
p-
VEGFR 
p-JNK2 
p-
ERK 
p-p38  control p-GSK3 
p-
p70S6K 
p-
mTOR 
p-Src 
p-
PDGFR 
 
0 369.50 1.75 4.97 23.63 2.50 1.05 8.19 2.84 1.19 2.43 1.62 1.85 0.85 U87 
EGFRVIII 
PTEN 
+ 
EGF 
+  
eb 
 
1 372.30 13.11 326.30 48.22 2.92 3.61 16.24 2.22 16.72 3.06 2.76 8.55 1.81 
2 371.09 27.80 415.36 57.37 3.17 5.88 17.46 2.82 19.43 3.31 3.88 10.83 2.75 
3 372.73 50.64 494.14 65.81 3.17 7.02 17.99 2.88 21.24 3.94 3.52 12.55 1.94 
4 363.36 61.77 573.10 66.83 4.26 8.84 20.16 3.19 22.26 4.11 3.52 13.05 2.78 
5 365.16 91.42 641.41 73.24 5.86 14.10 22.46 3.92 25.08 4.76 4.67 16.52 3.45 
 
cell ref P53 EGFR 
p-
VEGFR 
p-JNK2 
p-
ERK 
p-p38  control p-GSK3 
p-
p70S6K 
p-
mTOR 
p-Src 
p-
PDGFR 
 
0 20.64 1.09 0.80 2.70 1.19 0.51 2.29 0.52 0.89 0.71 0.14 0.72 0.25 U87 
EGFRVIII 
PTEN 
(std) 
 
1 47.40 11.84 61.25 13.69 2.92 6.38 9.14 1.54 11.50 2.99 3.31 5.43 2.90 
2 45.83 14.26 135.31 15.15 2.23 6.85 12.06 1.78 15.94 3.09 3.91 7.61 1.94 
3 55.28 21.83 108.94 16.52 1.62 5.25 12.18 1.70 9.85 3.30 3.84 6.17 2.89 
4 52.66 26.28 103.55 10.65 2.51 9.18 13.24 1.43 10.44 4.45 6.83 5.92 2.34 
5 49.54 22.53 137.77 14.42 2.32 7.13 11.18 1.64 12.87 3.19 4.32 6.29 2.60 
 
cell ref P53 EGFR 
p-
VEGFR 
p-JNK2 
p-
ERK 
p-p38  control p-GSK3 
p-
p70S6K 
p-
mTOR 
p-Src 
p-
PDGFR 
 
0 21.54 0.90 1.79 5.88 1.03 1.02 1.72 0.51 0.42 1.29 0.14 0.95 0.33 U87 
EGFRVIII 
PTEN 
+ 
EGF 
(std) 
 
1 16.96 5.31 54.66 13.53 1.43 9.91 10.23 1.19 7.98 3.09 5.83 5.21 1.50 
2 23.34 7.01 106.16 11.03 1.33 11.46 5.57 1.01 5.73 2.98 8.03 8.10 1.26 
3 16.90 16.34 77.90 12.78 2.22 11.49 5.16 1.65 7.67 3.63 7.30 6.68 1.05 
4 13.22 12.60 77.81 13.57 0.96 8.72 7.80 2.00 7.60 4.86 8.45 8.13 1.48 
5 23.63 19.13 39.10 16.58 1.66 12.37 3.93 1.53 6.16 5.53 6.59 8.37 1.25 
 
cell ref P53 EGFR 
p-
VEGFR 
p-JNK2 
p-
ERK 
p-p38  control p-GSK3 
p-
p70S6K 
p-
mTOR 
p-Src 
p-
PDGFR 
 
0 25.19 0.94 3.42 6.46 0.77 0.47 2.23 2.14 1.54 0.77 0.20 0.81 0.53 U87 
EGFRVIII 
PTEN 
+ 
EGF 
+ 
eb 
(std) 
 
1 23.68 7.16 59.41 11.59 1.16 2.06 4.56 0.93 3.19 1.66 1.07 3.88 1.07 
2 33.84 13.34 73.28 16.67 1.30 4.60 5.27 1.05 3.71 0.87 2.28 4.04 1.53 
3 23.88 10.81 62.81 15.33 1.25 5.13 6.02 0.67 3.60 1.76 1.04 3.05 1.02 
4 32.82 14.57 65.15 12.98 1.48 4.58 6.64 1.01 5.87 1.67 1.13 4.61 1.70 
5 33.56 22.56 44.35 12.00 2.16 9.65 6.41 1.01 5.02 1.44 1.59 6.96 1.62 
 
Mean Fold Change of Protein & Phosphoprotein  Levels 
Mean fold change 
Referen
ce 
P53 EGFR 
p-
VEGFR 
p-
ERK 
p-
p38  
p-
GSK3
 
p-
p70S6K 
p-
mTOR 
p-Src 
# of 
Measureme
nts 
 
U87 (EGF) 0.06 0.78 0.12 1.94 0.89 1.12 1.05 3.34 1.35 1.93 42  
U87 
(Erlotinib+EGF) 
-0.05 -0.07 -0.04 0.89 0.55 -0.20 -0.28 1.38 0.97 0.65 52 
 
U87 EGFRvIII -0.04 -0.05 0.10 1.32 1.56 0.54 0.12 1.70 6.69 1.63 55  
U87 EGFRvIII 
(EGF) 
0.03 -0.03 0.13 4.60 4.09 2.76 0.93 3.74 11.05 2.31 80 
 
  
79 
U87 EGFRvIII 
(Erlotinib+EGF) 
0.02 0.02 0.09 2.21 4.31 1.15 0.83 2.97 8.90 1.43 74 
 
U87 EGFRvIII 
PTEN 
-0.04 0.08 -0.24 0.48 0.27 0.53 0.64 -0.40 0.21 0.16 83 
 
U87 EGFRvIII 
PTEN 
(EGF) 
-0.01 0.15 -0.24 2.22 5.28 1.19 0.61 1.25 3.15 2.10 76 
 
U87 EGFRvIII 
PTEN 
(Erlotinib+EGF) 
-0.07 0.04 -0.19 1.53 -0.04 -0.31 0.09 -0.87 -0.63 0.12 63 
 
Standard Error of Protein & Phosphoprotein  Levels 
Standard Error of 
Median (SEM) 
Referen
ce 
P53 EGFR 
p-
VEGFR 
p-
ERK 
p-
p38  
p-
GSK3
 
p-p70S6K p-mTOR p-Src 
 
U87 (EGF) 0.03 0.21 0.04 0.59 0.23 0.22 0.16 0.48 0.38 0.53  
U87 
(Erlotinib+EGF) 
0.02 0.10 0.03 0.32 0.15 0.07 0.04 0.22 0.23 0.24 
 
U87 EGFRvIII 0.02 0.07 0.03 0.38 0.25 0.14 0.06 0.25 0.88 0.36  
U87 EGFRvIII 
(EGF) 
0.02 0.06 0.02 0.78 0.40 0.29 0.12 0.40 1.17 0.47 
 
U87 EGFRvIII 
(Erlotinib+EGF) 
0.02 0.07 0.02 0.44 0.46 0.18 0.12 0.33 0.97 0.31 
 
U87 EGFRvIII 
PTEN 
0.02 0.09 0.03 0.24 0.16 0.13 0.10 0.06 0.15 0.17 
 
U87 EGFRvIII 
PTEN 
(EGF) 
0.02 0.08 0.03 0.45 0.55 0.15 0.08 0.17 0.42 0.41 
 
U87 EGFRvIII 
PTEN 
(Erlotinib+EGF) 
0.02 0.09 0.04 1.16 0.20 0.10 0.06 0.04 0.08 0.31 
 

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Table 2.4 Correlation coefficients of cytoplasmic proteins measured by SCBC in all cell lines 
and conditions. Correlation coefficients were calculated based on 1-2 cells. The cut-off for 
correlation and anti-correlation is 0.4 and -0.4, respectively, and red font is used to indicate the 
above-threshold correlations, which was drawn in the correlation maps (shown in red in the 
following tables). The number of measurements is shown after the table. The proteins shown in blue 
are below the detection limit.   
 
p-
JNK2 
p53 EGFR p-VEGFR p-ERK 
p-
p38  
p-
GSK3  
p-p70S6K p-mTOR p-Src 
U87 
(63 
measurements) p-JNK2 1.00 0.05 0.24 0.14 0.17 0.08 0.09 0.16 0.14 0.41 
p53  1.00 0.50 0.34 0.16 0.05 0.02 0.04 -0.07 0.10 
EGFR   1.00 0.65 0.57 0.20 0.27 0.44 0.14 0.07 
p-VEGFR    1.00 0.53 0.35 0.49 0.39 0.25 -0.18 
p-ERK     1.00 0.32 0.40 0.70 0.37 0.03 
p-p38       1.00 0.72 0.32 0.56 0.00 
p-
GSK3  
 
     1.00 0.44 0.61 -0.19 
p-p70S6K        1.00 0.61 0.10 
p-mTOR         1.00 -0.01 
p-Src          1.00 
 
p-
JNK2 
p53 EGFR p-VEGFR p-ERK 
p-
p38  
p-
GSK3  
p-p70S6K p-mTOR p-Src 
U87 
+ 
EGF 
(54 
measurements) 
 
p-JNK2 1.00 0.16 0.26 0.16 -0.09 0.23 0.24 0.02 0.11 0.19 
p53  1.00 0.50 0.05 0.39 0.37 0.24 0.51 0.23 0.31 
EGFR   1.00 -0.12 0.44 0.46 0.20 0.61 0.03 0.51 
p-VEGFR    1.00 -0.04 -0.13 0.04 -0.11 0.32 0.03 
p-ERK     1.00 0.31 0.12 0.52 0.12 0.40 
p-p38       1.00 0.80 0.71 0.39 0.32 
p-
GSK3  
 
     1.00 0.54 0.46 0.27 
p-p70S6K        1.00 0.35 0.47 
p-mTOR         1.00 0.34 
p-Src          1.00 
 
p-
JNK2 
p53 EGFR p-VEGFR p-ERK p-p38  
p-
GSK3  
p-p70S6K p-mTOR p-Src 
U87 
+ 
EGF 
+ 
eb 
(62 
measurements) 
p-JNK2 1.00 0.15 0.28 0.36 0.29 0.00 -0.11 -0.04 0.20 0.46 
p53  1.00 0.58 0.41 0.37 0.33 0.10 0.42 0.27 0.30 
EGFR   1.00 0.60 0.34 0.22 0.06 0.27 0.21 0.50 
p-VEGFR    1.00 0.36 0.16 -0.13 0.22 0.36 0.66 
p-ERK     1.00 0.27 0.07 0.35 0.29 0.34 
p-p38       1.00 0.59 0.62 0.20 0.13 
p-
GSK3  
 
     1.00 0.51 0.16 -0.06 
p-p70S6K        1.00 0.46 0.22 
p-mTOR         1.00 0.47 
p-Src          1.00 
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p-
JNK2 
p53 EGFR p-VEGFR p-ERK 
p-
p38  
p-
GSK3  
p-p70S6K p-mTOR p-Src 
U87 EGFRvIII 
(68 
measurements) p-JNK2 1.00 0.10 0.08 0.18 0.33 0.17 0.16 0.22 0.39 0.23 
p53  1.00 0.65 0.51 0.50 0.09 0.19 0.30 0.19 0.35 
EGFR   1.00 0.55 0.39 -0.04 0.06 0.21 0.18 0.24 
p-VEGFR    1.00 0.41 0.15 0.30 0.26 0.39 0.37 
p-ERK     1.00 0.17 0.27 0.43 0.40 0.41 
p-p38       1.00 0.74 0.66 0.18 0.32 
p-
GSK3  
 
     1.00 0.64 0.31 0.32 
p-p70S6K        1.00 0.52 0.44 
p-mTOR         1.00 0.36 
p-Src          1.00 
 
p-
JNK2 
p53 EGFR p-VEGFR p-ERK 
p-
p38  
p-
GSK3  
p-p70S6K p-mTOR p-Src 
U87 EGFRvIII 
+ 
EGF 
(72 
measurements) 
p-JNK2 1.00 0.46 0.42 0.48 0.20 0.32 0.31 0.18 0.23 0.19 
p53  1.00 0.71 0.68 0.43 0.57 0.28 0.40 0.60 0.35 
EGFR   1.00 0.47 0.34 0.41 0.12 0.11 0.46 0.14 
p-VEGFR    1.00 0.58 0.66 0.56 0.47 0.57 0.54 
p-ERK     1.00 0.73 0.74 0.36 0.54 0.59 
p-p38       1.00 0.61 0.34 0.60 0.68 
p-
GSK3  
 
     1.00 0.49 0.52 0.71 
p-p70S6K        1.00 0.71 0.41 
p-mTOR         1.00 0.51 
p-Src          1.00 
 
p-
JNK2 
p53 EGFR p-VEGFR p-ERK 
p-
p38  
p-
GSK3  
p-p70S6K p-mTOR p-Src 
U87 EGFRvIII 
+ 
EGF 
+ 
eb 
(58 
measurements) 
 
p-JNK2 1.00 -0.03 0.08 0.02 -0.22 0.04 0.20 -0.20 0.14 -0.09 
p53  1.00 0.72 0.43 0.47 0.44 0.30 0.40 0.53 0.36 
EGFR   1.00 0.17 0.29 0.32 0.24 0.27 0.57 0.31 
p-VEGFR    1.00 0.33 0.16 0.22 0.11 0.21 0.22 
p-ERK     1.00 0.59 0.28 0.59 0.31 0.77 
p-p38       1.00 0.56 0.77 0.42 0.50 
p-
GSK3  
 
     1.00 0.59 0.45 0.14 
p-p70S6K        1.00 0.30 0.46 
p-mTOR         1.00 0.39 
p-Src          1.00 
 
p-
JNK2 
p53 EGFR p-VEGFR p-ERK 
p-
p38  
p-
GSK3  
p-p70S6K p-mTOR p-Src 
U87 EGFRvIII 
PTEN 
(72 
measurements) 
p-JNK2 1.00 0.19 0.03 0.22 -0.18 -0.12 0.07 0.01 -0.16 -0.13 
p53  1.00 0.31 0.31 0.16 -0.01 -0.08 -0.18 0.22 -0.01 
EGFR   1.00 0.09 -0.06 -0.03 0.13 -0.10 0.15 -0.05 
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p-VEGFR    1.00 0.01 0.00 0.28 0.28 -0.07 -0.33 
p-ERK     1.00 -0.13 -0.51 -0.08 0.11 0.04 
p-p38       1.00 0.54 0.42 0.15 0.26 
p-
GSK3  
 
     1.00 0.55 0.17 0.14 
p-p70S6K        1.00 0.26 0.12 
p-mTOR         1.00 0.54 
p-Src          1.00 
 
p-
JNK2 
p53 EGFR p-VEGFR p-ERK 
p-
p38  
p-
GSK3  
p-p70S6K p-mTOR p-Src 
U87 EGFRvIII 
PTEN 
+ 
EGF 
(82 
measurements) 
p-JNK2 1.00 0.34 0.16 0.27 0.30 0.36 0.39 0.23 0.34 0.29 
p53  1.00 0.32 0.61 0.32 0.44 0.44 0.29 0.46 0.57 
EGFR   1.00 0.33 0.26 0.25 0.03 0.18 0.28 0.13 
p-VEGFR    1.00 0.14 0.42 0.29 0.34 0.30 0.57 
p-ERK     1.00 0.36 0.53 0.29 0.75 0.48 
p-p38       1.00 0.67 0.52 0.48 0.31 
p-
GSK3  
 
     1.00 0.38 0.54 0.28 
p-p70S6K        1.00 0.41 0.30 
p-mTOR         1.00 0.65 
p-Src          1.00 
 
p-
JNK2 
p53 EGFR p-VEGFR p-ERK 
p-
p38  
p-
GSK3  
p-p70S6K p-mTOR p-Src 
U87 EGFRvIII 
PTEN 
+ 
EGF 
+ 
eb 
(73 
measurements) 
p-JNK2 1.00 0.24 0.10 -0.02 0.01 0.29 0.24 0.10 0.07 0.04 
p53  1.00 0.62 0.46 0.27 0.07 0.15 0.09 0.15 0.33 
EGFR   1.00 0.54 -0.03 -0.14 0.11 -0.11 0.06 0.49 
p-VEGFR    1.00 -0.32 -0.47 -0.08 -0.15 -0.04 0.33 
p-ERK     1.00 0.52 0.25 0.32 0.43 -0.02 
p-p38       1.00 0.50 0.39 0.40 -0.10 
p-
GSK3  
      1.00 0.21 0.40 -0.13 
p-p70S6K        1.00 0.22 -0.04 
p-mTOR         1.00 0.01 
p-Src          1.00 
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C h a p t e r  3  
Applications in fundamental cancer biology: hypoxia induces a phase 
transition within a kinase signaling network in cancer cells 
3.1 INTRODUCTION 
In most solid organ cancers, increased interstitial pressure, vascular constriction, 
abnormal leaky blood vessels, and edema result in a hypoxic microenvironment, 
particularly in the center of the tumor
1-5
. Hypoxia, in part by stabilizing the hypoxia 
inducible transcription factor (HIF), can increase the biological aggressiveness of tumors, 
promoting glycolysis, cellular proliferation, and angiogenesis. It can also make tumors less 
responsive to many therapies
6-9
.  
Signaling through mTOR is often a critical component of the hypoxic response
10-13
. 
Amplification and activating mutations of receptor tyrosine kinases, mutation of 
phosphoinositide 3-kinase (PI3K) and its regulatory subunits, and loss of the phosphatase 
and tensin homolog (PTEN) tumor suppressor protein can lead to elevated growth factor–
independent activation of mTOR signaling
10, 14
. The hypoxic microenvironment indirectly 
regulates mTOR, in part by regulating intracellular ATP levels
15
, to promote tumor cell 
growth and proliferation. This can occur via activation of hypoxia-inducible factor-1α 
(HIF-1α) dependent glycolysis, and by stimulating angiogenesis16. Most models of mTOR 
signaling in cancer assume a continuous relationship between the level of growth factor 
receptor pathway signaling, and/or ATP and nutrient levels, and the degree of mTORC1 
activation. However, most signaling cascades actually behave as excitable devices with 
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built in excitability thresholds, enabling them to integrate diverse temporal and spatial 
inputs to produce specific signaling responses
17
. It is not known how physical perturbations 
like altering pO2 can influence the excitability of signaling networks, and whether such 
effects yield continuous or discrete transitions. This question is important because if mTOR 
signaling becomes uninhibitable at levels of hypoxia that are frequently reached within the 
center of a tumor, a potentially targetable mechanism of drug resistance can be identified.  
We set out to study how varying pO2 from 21% (ambient) to 1% (hypoxia) influences 
mTORC1 and HIF-1α signaling within model GBM cancer cells that exhibit persistent 
mTORC1 activation
18, 19
. We used the Single Cell Barcode Chip (SCBC)
20, 21
 to investigate 
U87 EGFRvIII cells (which are GBM cells that stably express the epidermal growth factor 
receptor activating mutation (EGFRvIII)). The SCBC is an integrated microfluidics 
platform
22
 designed for the quantification of a panel of functional proteins from statistical 
numbers of single cells
21
. The panel, which was designed to capture key aspects of both 
HIF-1 and mTORC1 signaling9, 12, included 3 secreted proteins (vascular endothelial 
growth factor (VEGF), Interleukin-6 (IL-6) and Matrix Metalloprotease-1 (MMP1)), and 1 
cytoplasmic protein (HIF-1α) and 3 cytoplasmic phosphoproteins (phospho(p)-mTOR, p-
extracellular signal-regulated kinase 1 (p-ERK1), p-P70 ribosomal protein S6 kinase (p-
P70S6K)). Advantages of these proteins is the availability of high quality antibody pairs for 
our assays, and the fact that they are produced by single cells at a level that allows us to 
accurately convert single cell fluorescence signal into copy numbers per cell detected.  
An SCBC cell data set, which is comprised of a statistical number of single cell assays, 
yields three types of independent observables. The first are averaged levels of each assayed 
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protein from single cells. The second are the protein fluctuations, which are histograms 
of the observation frequency versus the measured protein levels. The third observations are 
the correlations between the various assayed proteins. The last two observables are unique 
to single cell multiplex proteomics assays, and all three observation types are employed to 
understand how changes in pO2 influence mTORC1 and HIF-1 signaling. We provide the 
interpretation in three stages of increasing level of detail, where the last stage is a theory 
with predictive capabilities. We first discuss a mean field, qualitative model that provides a 
context for discussing how the average effect of other proteins influences the fluctuations 
of a specific protein in question. The experimentally measured fluctuations, when 
interpreted within this model, point towards a pO2-dependent deregulation of mTORC1 
signaling, and imply that mTORC1 signaling will be difficult to inhibit near 1.5% pO2. 
This picture is shown to be correct through the use of the ATP-competitive mTOR inhibitor 
PP242
23
 on both the GBM cell lines, as well as a neurosphere culture model grown from a 
human-derived GBM xenograft tumor that also expresses the EGFRvIII mutation. We then 
attempt to understand the pO2-dependent deregulation of mTORC1 in two more detailed 
ways. We first present a steady state kinetic model to capture the relationships between O2, 
p-mTOR, HIF-1, and PP242. The kinetic approach indicates that there is a switch in 
mTORC1 signaling near 1.5% pO2, and that there is a value of pO2 near 1.5% for which 
mTOR is un-inhibitable. Finally we discuss a quantitative version of the Le Chatelier's 
principle that relies upon the single cell proteomics assays as input
24
, and, unlike the mean 
field model, allows for the explicit treatment of protein-protein correlations. The theory is 
validated by using it to predict the effect of changes of pO2 on the mean numbers of the 
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assayed proteins. This prediction fails between 2 and 1.5% pO2, which implies that 
changing pO2 through this range is a strong perturbation to the cells. The theory then shows 
that the deregulation of mTORC1 signaling is associated with a phase transition in the 
signaling network. The implication is that, near 1.5% pO2, the network switches from one 
set of protein-protein interactions to another. At the switching point, the network is 
unstable, and the coordinated signaling between mTOR and its effector proteins is lost.  
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3.2 EXPERIMENTAL METHODS 
3.2.1 Microchip design and fabrication 
The SCBC platform (Fig. 3.1) contains 240, 1.7 nanoliter volume microchambers. 
Each microchamber has an upper assaying compartment that contains a 9-element DNA 
barcode. A second compartment, separated by a valve, serves as a lysis buffer reservoir. 
Eight elements of the barcode are converted to a miniature antibody array for assaying a 
panel of proteins by loading a DNA-antibody conjugate cocktail, while one element 
provides an alignment marker (Fig. 3.2). 
 
Figure 3.1 The design the of single cell proteomic chip. The SCBC microfluidic chip is 
designed for enabling on-chip cell culture, cell lysis and multiplex protein detection. V1-V6 
represents inputs for activating specific valves. V3 isolated the chamber from the microchannels 
and V4 controls the diffusion between the cell compartments and the  lysis buffer reservoirs. 
The cartoon illustrates the immunoassays for detecting functional proteins from cell lysate. The 
optical images show a cell viability check by trypan blue diffusion. 
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DNA barcode arrays for the fabrication of SCBCs are flow patterned using molded 
polydimethylsiloxane (PDMS) microfluidics templates. This procedure has been previously 
described in Chapter 2. The PDMS microfluidic chip for the single cell assay was 
fabricated by two-layer soft lithography (Fig. 3.1). The fabrication of these chips has been 
previously described in Chapter 2, and with a few specific differences, as described here. 
The channel surface of the as-fabricated PDMS chip was coated with collagen type 1(BD 
Biosciences, 0.1mg/ml in DI water) before thermally bonded to the DNA barcode slide to 
form the working device. The collagen coating promoted cell adherence during the on-chip 
cell culture. 
3.2.2 Experiment setups and procedures 
A custom-build hypoxia setup is used for providing control oxygen environment with 
real time pO2 monitoring. Cells are loaded from an upstream inlet into the SCBC and 
distributed randomly among the microchambers. Controlling the cell loading density 
enables about half of the microchambers to contain a single cell while others may be empty 
or contain 2 or more cells. After cell loading and counting, the microchip is incubated in a 
controlled O2 environment for 7 hours (Fig. 3.2 A), followed by an on-chip cell lysis (Fig 
3.2 B). An O2 sensor (0.1% accuracy) measured both the level and the equilibration rate of 
the pO2. Secreted proteins are captured during incubation, and intracellular proteins are 
captured following lysis. A detection antibody cocktail and the fluorescent probes are 
loaded afterward to complete the on-chip immunoassay, which is read with a Genepix array 
scanner (See Fig. 3.2 B for detailed execution scheme) The incubation time was chosen to 
ensure cell viability at all pO2 explored (Fig. 3.1), and to enable capture of sufficient 
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numbers of secreted proteins. Refer to Chapter 2 for a step by step procedure of the 
single cell proteomic assay. 
3.2.3 Cell lines and reagents 
 
Figure 3.2 SCBC platform, hypoxia setup and experimental flowchart. This SCBC design 
permits incubation of the cells within controlled pO2 environments, followed by multiplexed 
and quantitative assays of functional (secreted, membrane, and/or cytoplasmic) proteins from 
quantized cell populations (A) Drawing of the custom-built hypoxia setup with real time pO2 
monitoring. The photograph is of an SCBC with the microchambers (red) and control valve 
layers (green) delineated with food dyes. Lower right drawing is a side-view of a single cell 
microchamber with a representative readout image from the SCBC device. Each barcode 
fluorescent stripe corresponds to a specific protein assay. Signals from three microchambers 
with different cell numbers are shown. (B) SCBC assay steps. DNA barcodes are converted into 
antibody barcodes using a cocktail of DNA-antibody conjugates. Cells are then loaded and 
isolated into the upper chamber and incubated at a desired pO2, during which time secreted 
proteins are captured on designated barcode stripes. The chip is then cooled to near 0oC, and the 
valve connecting the lysis buffer chamber is opened, leading to cell lysis within 15 minutes. 
The intracellular proteins are released and captured onto designated barcode stripes. (C) The 
equilibrium of the O2 content within the microfluidic device, over time, as measured by the O2 
sensor The O2 concentration reaches a mild hypoxic level (<3%) in less than 30 minutes. 
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U87 EGFRvIII cells were constructed as previously described
25
 and routinely 
maintained in Dulbecco's Modified Eagle's Medium (DMEM, American Type Culture 
Collection) containing 10% fetal bovine serum (FBS) in humidified atmosphere of 5% CO2 
and 95% air at 37°C. GBM39 human glioblastoma cells were generated as previously 
described
26
 and maintained in NeuroCult®-XF Proliferation Medium (STEMCELL 
Technologies, Inc.) containing 20ng/mL epidermal growth factor (EGF, Sigma) and 
fibroblast growth factor (FGF, Sigma) and 1µg/mL Heparin (Sigma) in humidified 
atmosphere of 5% CO2 and 95% air at 37°C. The DNA and antibody reagents are listed in 
the SI Appendix, Table S1. The DNA-antibody conjugates were synthesized as described in 
the Chapter 2 and validated with standard proteins by DNA spot microarray before use
27
. 
3.2.4 Protein assays on bulk cell culture 
The validation of the DNA-antibody conjugates involved separate calibrations for each 
of the different immunoassays, as well as quantitating the cross-reactivity between those 
immunoassays (Fig. 3.3). All bulk protein assays in this study started with spotted DNA 
microarrays that were obtained from the Institute for Systems Biology (Seattle, 
Washington). The spotted arrays and the flow patterned barcode arrays utilized the same 
DNA oligomer pairs (Appendix A: Supplementary Tables) for each detected protein. The 
description of the microwell-based multiplexed immunoassays from statistical numbers of 
cells followed the protocols described in Chapter 2.  
For mTOR kinase inhibition bulk assay, U87 EGFRvIII cells were cultured in DMEM 
with 1% FBS at a density of 150,000 cells/mL and at O2 levels controlled to be 21%, 3%, 
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2%, 1.5% or 1% for 7 hours, with or without addition of 3µM of the mTOR kinase 
inhibitor PP242 (2-(4-amino-1-isopropyl-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-1H-indol-5-
ol, Sigma-Aldrich). GBM39 neurosphere cells were dissociated with TriplE (Invitrogen) to 
form single cell suspension and then were cultured in laminin (Sigma) pre-coated dishes 
with NeuroCult®-XF Proliferation Medium at a density of 150,000 cells/mL and at various 
conditions identical to U87 EGFRvIII cells above. Following incubation, the treated cells 
were then washed by cold PBS to remove residual media. A mixture of Cell lysis buffer 
(Cell Signaling, containing 20mM Tris-HCl, 150mM NaCl, 1mM Na2EDTA, 1mM EGTA, 
1% Triton, 2.5mM sodium pyrophosphate, 1mM β-glycerophosphate, 1mM Na3VO4 and 
1µg/ml leupeptin), Complete Protease Inhibitor (Roche) and Phosphatase Inhibitor Cocktail 
2 (Sigma) was added, and the mixture was stored on ice for 10 minutes. The cell extract 
 
Figure 3.3 Antibody microarray utilized for the multiplex protein assays from statistical 
numbers of cells, as well as for cross-reactivity checks of the assayed protein panel. Layout 
(left-top) and photograph (left-bottom) of the microarray. The layout inset shows a basic 13-spot 
repeat unit. Locations #A to #M are spotted with the same ssDNA oligomers that are used for 
DNA barcode SCBC microarrays. Spot diameters are 150 µm. The basic unit is repeated over 
60 columns and 50 rows. The 12-well PDMS slab (left-bottom) is bonded to the array-spotted 
glass slide. Each well has a volume of 50 µl and contains 5 complete sets of 13 DNA spots for 
simultaneously assaying the entire panel of proteins. At right is presented the cross-reactivity 
data for the panel of assayed proteins. For each row in the figure, the full cocktail of antibody-
DNA conjugates (for the 7 assayed proteins, except p-EGFR due to lack of standard protein) 
was used. One standard protein was tested per row. The red spots are signal from the standard 
proteins and the green spots are alignment reference signals from Cy3-labeled DNA sequence 
complementary to spot #M. The p-EGFR antibody does not cross-react with other proteins in 
the panel. 
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was then collected and spun at 14,000g at 4°C for 10 minutes. The resulting supernatant 
was re-centrifuged to remove remaining cell debris. The cell lysate and media were then 
added into corresponding wells for profiling secreted and intracellular proteins. 
3.2.5 Protein calibration for bulk and SCBC assays 
1. Calibration curves for bulk protein measurement: The assay for generating 
calibration curves was performed under conditions identical to the mTOR kinase inhibition 
assay described earlier, except that standard proteins were used instead of cell lysate or 
medium. A cocktail of standard proteins was serially diluted in 1X PBS and added into 
different wells. Fluorescence signals were collected and plotted versus protein 
concentrations (Fig. 3.4). 
 
Figure 3.4 Calibrations of the assayed protein panel. The calibrations at left were carried out 
using SCBC barcodes within an SCBC, and under conditions similar to those single cell 
experiments, except that standard proteins were used. The calibration at right utilized the 
microwell format of the spotted arrays, and provides calibration data for the bulk cell assays. 
These curves are utilized to transform the fluorescence intensities into concentrations (or copy 
numbers) of proteins. The error bars represent the standard deviations of the measurements. 
Two dagger symbols, color coded for each curve, are drawn to delineate the upper and lower 
range of protein levels that were detected within the experiments. For both the SCBC and bulk 
assays, these ranges are generally within the linear response regime of the calibration curves. 
Note that p-EGFR was not included here due to lack of standard protein. 
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2. Calibration curves for SCBC measurement: These calibrations were performed 
within an SCBC and under exactly the same condition as the single cell proteomic assay 
described above, except that standard proteins were utilized, rather than cells. A mixture of 
standard proteins from the SCBC assayed panel was serially diluted in 1X PBS and flowed 
into the SCBC microchannels. Fluorescence signals were collected to generate the 
calibration curves (Fig. 3.4). Since the volume of the microchambers is known, these 
calibration curves enable a transformation from the fluorescence intensity to the number of 
molecules for each protein assayed, under the caveat that the standard proteins may not be 
exactly the same as their counterparts from the GBM cells. 
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3.3 PHYSICAL APPROACHES 
3.3.1 A mean-field model for understanding protein fluctuations 
Protein fluctuations can be highly informative toward understanding protein functional 
activity. Quantifying and linking the fluctuation profiles of each signaling node with 
different external perturbations will yield vast amount of information regarding the 
signaling transduction mechanism, stimuli effectiveness or drug efficacy. A mean-field 
model is applied here to provide a context for discussing how the average effect of other 
proteins influences the fluctuations of a specific protein in question. It offers predictive 
capacity of fluctuation profiles that a widely dispersed fluctuation can indicate a highly 
active protein that is involved in multiple functional processes. A narrow, sharp fluctuation, 
by contrast, represents a protein with limited interactions. 
To illustrate this point, we carried out Monte Carlo simulations to generate histograms 
for a hypothetical functional protein at several degrees of activity. The simulation is 
designed to capture the protein fluctuation profile for different degrees of protein activity 
and is programmed by R (r-project.org). The protein is assumed to be able to participate in 
up to four independent functional processes. Each process requires a range of protein copy 
numbers represented by a Gaussian distribution and an associated probability that it is 
active in any given single cell. If the protein does not carry out any process, its 
concentration is set as an inactive baseline. The more active the functional protein is, the 
more processes it will participate in (up to four in this simulation). 
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To be specific, the hypothesized processes and their required concentrations and 
fraction active values are listed in Table 3.1. 
In the Fig. 3.6, 1 active process means that protein is confined to be involved only in 
process-1 or doing nothing; 2 active processes represents that the protein can access both 
process-1 and process-2 and so on. Finally 4 active processes indicate the protein is able to 
participate into all four parallel functional processes listed above. The Gaussian 
distributions for representing the required range of protein copy number have been set to 
have a fixed coefficient of variation (CV) as 0.15. 200 single cell events are generated for 
each case and the corresponding histogram is plotted in Fig. 3.6 C. The averaged required 
protein copy number and fraction active value for each process are arbitrarily chosen for 
calculation convenience. They can be altered freely without affecting the final conclusion 
of the simulation. 
Table 3.1 Parameters used for the Monte Carlo simulation of the fluctuation profile of a 
hypothetical protein. 
Process Averaged required protein copy # Distribution type Fraction active 
Baseline 100 Gaussian  
Process-1 150 Gaussian 0.7 
Process-2 200 Gaussian 0.3 
Process-3 250 Gaussian 0.5 
Process-4 300 Gaussian 0.8 
 
3.3.2 Single-cell ensemble, a basis for making predictions 
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Here we describe a physically motivated approach based upon the maximum entropy 
formalism
28
, which is being increasingly used in biology
29-38
. However, we use entropy not 
as a statistical measure of dispersion, but as a physical quantity
39, 40
. This allows us to apply 
a thermodynamic-like approach and to derive a quantitative Le Chatelier's principle
41
.  
The system we consider is many independent replicas of a compartment containing a single 
cell in a nutrient solution at thermal equilibrium. Because the system is not large, different 
replicas of it can differ in the number, iN , of functional proteins of kind i. We seek to 
represent these fluctuations by taking the different replicas as different samples from an 
ensemble of single cell compartments where the mean number iN  of proteins of kind i 
over the ensemble is given. Another given quantity is the energy, (and volume that we do 
not indicate explicitly). We now seek the most probable distribution of protein numbers in 
different compartments. The solution is well known because if many compartments are 
measured, then the required distribution is the one whose entropy is maximal. In textbooks 
of statistical mechanics this search for the most probable distribution is sometime called the 
Boltzmann approach. It is possible to show 
42
 that this approach does not require the system 
to be macroscopic in size. It is sufficient if we measure enough replicas so that the 
distribution of proteins does not significantly change as we add more measurements. If 
each replica is macroscopic, the fluctuations will be small and rare. Repeated 
measurements will give the same results. If each replica is small we can observe the 
fluctuations, which is the unique information available to SCBCs. 
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The key point is that even if the fluctuations are not small it is possible to make 
predictions. The probability of a system in a particular composition can be shown to be 
given by a joint probability density function 
    1 2, ,.. exp i iiP N N N E     (3.1) 
This straightforward result is perhaps misleading in its simplicity. It is most directly 
derived by the method of Lagrange undetermined multipliers. The numerical value of these 
multipliers is determined at the final stage by imposing the condition that the distribution 
(Eq. 3.1) reproduces the given values of the means. There are as many multipliers as 
conditions. 
β is the Lagrange multiplier that is determined by the mean value of the energy and, as 
usual, is related to the temperature T as 1 kT  where k is Boltzmann’s constant. The 
'si  are the chemical potentials as introduced in the thermodynamics of systems of more 
than one component 
41, 43
. The Lagrange multipliers that correspond to the given (mean) 
number of species i are known as the Planck potentials and denoted as i . It is often more 
convenient to work with ,i i i   . If our system were macroscopic in size we would 
call i  ‘the chemical potential of protein i’. For convenience we retain the designation 
‘potential’ because, as we shall show, i  retains essential properties of the chemical 
potential even when fluctuations are finite.    is a function of all the Lagrange multipliers 
and its role is to insure that the sum of the probability over all possible compositions yields 
one. 
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There are at least two points where important details are not revealed by the notation 
used in Eq.  S1. Both are relevant in what follows. First is the condition that the numerical 
values of the chemical potentials are determined by the given mean numbers, the 'siN , of 
the proteins. Strictly speaking, we should write the chemical potentials as functions of the 
'siN . The other point arises when we want to treat the actual numbers 'siN  of the 
different proteins as continuous variables. This is needed, for example, to compute 
averages, normalize the distribution (Eq. 3.1), etc. The integration for each protein is over 
!dN N  where N!, the factorial of N, arises to account for the Gibb’s paradox. Therefore, as 
a function of the continuous variable N the distribution for one protein is  
 ( ) ! exp( )NP N Q N N   (3.2) 
Here Q is the factor that arises by summing over all the internal states of the protein that are 
occupied at the temperature T. 
3.3.3 Fluctuations describe the response to small perturbations 
We show that by measuring the fluctuations in the unperturbed system we can predict 
how the system responds to small perturbations 
41
. Proof: Say that we make a small change 
in the value of the chemical potential i  from its current equilibrium value to some new 
value i i   . We do so isothermally. This change in i  potentially changes the 
equilibrium mean concentration of all species from jN  to j jN N , for all j. To compute 
the change in concentrations, we need to consider the change in the ensemble as 
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represented by Eq. 3.1. In the algebraic developments in Eq. 3.4 below we make use of 
the definition of the mean concentration  
 1 2, ,..j jN N P N N  (3.3) 
The summation in Eq. 3.3 is over all the possible compositions, each weighted by its 
probability  1 2, ,..P N N  computed as the distribution of maximal entropy. The same 
meaning for the summation is used also in Eq. 3.4 below. We denote this averaging by an 
over bar. From Eq. 3.1, the variation of the distribution that occurs when a particular 
chemical potential is changed by a small amount is 
   1 2 1 2, ,.. , ,..iiP N N N P N N    . Note that it is in using this lowest term in the 
Taylor series that we assume that the change is small. It follows that on the average the 
proteins respond to the change as: 
 
   
   
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 

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  
  
 
 
 
  
  
 (3.4) 
Note that the conservation of normalization implies that the average change in the 
probability must be zero,  1 20 , ,..P N N  and we have used this result in the 
derivation above. In the last line in Eq. 3.4 we have avoided writing the summation over all 
compositions by the use of the over bar to designate an average over the probability 
 1 2, ,..P N N , which is the notation introduced in Eq. 3.3. 
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As a special case of Eq. 3.4, for a small change in 
i
  , it's readily to reach that 
    
2
i i i i i i ii i
N N N N N N N           . Because the variance is positive, a 
change in the mean copy number of protein i when its own potential is changed from 
i
  to 
+
i i
  is always in the same direction (positive or negative) as 
i
 itself. It is in this sense 
that we refer to 
i
 as the potential of the protein i. 
The key point that carries into the general case is that, to linear order in the 
perturbation, the change in the mean number of proteins due to a perturbation can be 
computed as an average over the unperturbed distribution of copy numbers. The change in 
the mean is proportional to the variance of the distribution of fluctuations. Therefore, the 
lesser the fluctuations (i.e., the narrower the histogram), the more resilient to change is the 
distribution
24
. This is wholly consistent with the conclusion derived from the mean-field 
model discussed above. 
3.3.4 A quantitative version of the principle of Le Chatelier 
Taylor theorem states that, in the leading order, the change of a function is the sum of 
the changes. Therefore the expression for an isothermal variation in all the chemical 
potentials leads to a change of the distribution of the form:  
   1 2 1 2, ,.. , ,..ii iP N N N P N N      (3.5) 
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The summation in Eq. 3.5 is an ordinary sum over the finite number S of signaling 
proteins, 1,2,..,i S . Then we have the general equation of change that is an extended 
form of Eq. S4 valid for all possible small isothermal changes in the chemical potentials 
  j j j i i iiN N N N N       (3.6) 
This is the result of the quantitative Le Chatelier's principle. 
The principle in its simplistic statement claims that the system responds to a 
perturbation in a direction that restores equilibrium. For example, when the temperature of 
a heat bath is increased, the mean energy of an immersed system goes up so that the 
distribution remains canonical. The proof for our case starts from Eq. 3.3. When the 
chemical potential of protein i is changed, for an ensemble at maximal entropy the mean 
value of protein j changes by 
 1 2, ,..j
j
i i
N P N N
N
 

 

 
 (3.7) 
where, as emphasized in Eq. 3.3, the distribution  1 2, ,..P N N  is not arbitrary, but is 
the one of maximal entropy as exhibited in Eq. 3.1. Eq. 3.4 is recovered when the 
derivative in Eq. 3.7 is evaluated. It appears trivial, but it is not without meaning. What we 
have proven is that computing a small change in the distribution  1 2, ,..P N N  when a 
particular chemical potential is changed from the value i  to a new value i i   is the 
same as computing the derivative of the distribution  1 2, ,..P N N  at the point where the 
value of the chemical potential is i . Then the change in the distribution is 
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  1 2, ,.. i iP N N    . Of course, this is what differential calculus is about. Yet the 
result is not pure mathematics. It shows that the new distribution is a distribution of 
maximal entropy of the functional form Eq. 3.1 as otherwise the result will not hold. It says 
that a small change in the chemical potential i , and no other change, leads to a new 
distribution which is also one of maximal entropy. 
Typically we do not see the theorem of Le Chatelier stated as in Eq. 3.6. This is 
because of the practical point that the number fluctuations are typically not easy to observe 
in a macroscopic system. Here however we deal with functional proteins released by a 
single cell in which the distribution is clearly observed and the covariance can be computed 
from the experimental data as long as that the number of replicas is not small. 
The (symmetric) square matrix   j j i iN N N N   is the covariance matrix of the 
copy number fluctuations in the steady state concentrations, the 'sjN . The covariance 
matrix has the dimensions of S by S where S is the number of signaling molecules that take 
part. In practice we have to compromise on this definition meaning that S is the number of 
signaling molecules that can be detected. If an important protein is not detected, then the 
network that we infer will be incomplete and the predictions may fail. However, if they do, 
this is informative, because it signals the presence of new constraints needed to capture 
reproducible behavior in the system, which had not been taken into account. 
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3.4 RESULTS AND DISCUSSION 
3.4.1 Single-cell data collected from SCBCs 
 
Figure 3.5 Representative SCBC data collected from U87 EGFRvIII cell lines. (A) Scatter 
plots of assayed protein levels measured from U87 EGFRvIII single cells at 21% and 1% pO2. 
The averaged fluorescence intensity with standard error of the mean (SEM) are overlaid for 
each protein. Statistical uniqueness is evaluated by two-tailed student's t test assuming unequal 
variance (NS: not significant; *P<0.05; **P<0.005; ***P<0.0005). (B) Western blotting 
results for several of the cytoplasmic proteins from U87 EGFRvIII cells assayed at 21% and 
1% pO2. (C) Scatter plots of the assayed levels of p-P70S6K and p-mTOR at 21% pO2 for 
individual microchambers containing 1, 2 or 3 cells, indicating the statistical uniqueness of data 
sets representing different quantized cell populations. (D) Complete single cell dataset of 
secreted and cytoplasmic proteins profiling from individual SCBC microchambers containing 
single or few cells at different pO2 values, presented as a heat map. Columns containing 1-, 2- 
and 3-cell data are indicated by the color code along the top row. The heat maps were 
generated by Cluster and Treeview (EisenSoftware). 
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For the U87 EGFRvIII cell line, we collected single cell data at 21%, 3%, 2%, 1.5% 
and 1% pO2. At each condition, we assayed ~100 single cells, 60 zero-cell chambers, and 
50 two-cell chambers. After background subtraction, scatter plots of the single-cell 
proteomic data (Fig. 3.5 A) can be compared against bulk cell population protein assays 
using western blotting or sandwich ELISA (Fig. 3.5 B and D). The statistical uniqueness of 
1-cell data was established via comparison against 2-cell data (Fig. 3.5 C). For each protein 
measured, the fluorescence intensity is converted into copy numbers detected using 
 
Figure 3.6 Measured single cell fluctuations for four cytoplasmic proteins as a function of 
pO2, and a simulation of fluctuations for a hypothetical protein. (A) Single cell fluctuation 
profiles for HIF-1α at various pO2. (B) Single cell fluctuations for p-mTOR, p-P70S6K and p-
ERK1 at various pO2. Note that these fluctuations exhibit a sharpening at 1.5% pO2. (C) 
Single cell fluctuation profiles from a Monte Carlo simulation that assumes a hypothetical 
protein participates in varying numbers of functional processes.  Note the comparison of this 
simulation to the measured fluctuations of HIF-1 
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calibration data (Fig. 3.4) that relied on standard proteins. For a given protein, a 
histogram of copy number versus frequency of observation reflects the fluctuations of that 
protein.  
3.4.2 Protein fluctuations reveals a deregulation in mTORC1 signaling near 1.5% 
oxygen partial pressure (pO2). 
 
Figure 3.7 The influence of the mTOR inhibitor PP242 on the assayed protein levels for GBM 
cell lines and xenograft neurosphere tumor models, as a function of pO2. (A,B) Bar graphs 
showing the changes in protein copy number, as measured from bulk-cell lysate of the U87 
EGFRvIII cells and the GBM39 tumor model . Protein level changes are normalized by the 
number listed below the corresponding protein name. The insets are fluorescence images of the 
developed assays of the highly expressed mTOR effector, p-P70S6K. (C) Plot of protein 
concentrations at various pO2 joined with spline fit for control and PP242 treated U87 EGFRvIII 
cells (upper) and GBM39 neurospheres (lower). Note that the drug treated and untreated levels 
coincide for p-mTOR, p-P70S6K and p-ERK1 for both model systems near 1.5-2% pO2. Error 
bars represent the standard deviations of the measurements. 
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Fig. 3.6 A and B show the single cell fluctuations for the four cytoplasmic proteins 
at different pO2 values. HIF-1α has a unique profile compared to the phosphoproteins 
related to mTORC1 signaling (mTORC1 designates mTOR and its effectors, which include 
P70S6K and ERK1
12
). As pO2 decreases, the HIF-1α fluctuations evolve from a narrow and 
peaked histogram into a widely dispersed profile, with the average shifting to higher copy 
numbers. By contrast, the three phosphoprotein fluctuations exhibit broad widths at 21%, 
3%, 2%, and 1% pO2, but are sharply peaked at 1.5% pO2 (Fig. 3.6). This has implications 
for a signaling network transition. 
Protein fluctuations can be highly informative toward understanding protein functional 
activity. A widely dispersed fluctuation can indicate a highly active protein that is involved 
in multiple functional processes. A narrow, sharp fluctuation, by contrast, represents a 
protein with limited interactions. To illustrate this point, we carried out Monte Carlo 
simulations to generate histograms for a hypothetical functional protein at several degrees 
of activity. The protein was assumed to participate in up to four independent functional 
processes. Each process required a range of protein copy numbers, and had an associated 
probability that it was active in any given single cell (See Materials and Methods for 
detail). The simulated histograms (Fig. 3.6 C) reveal that the fluctuations are increasingly 
dispersed, as the number of potentially active functional processes increases. This plot 
effectively emulates the fluctuations of HIF-1α as pO2 is lowered (Fig. 3.6 A). The 
implication is that HIF-1α is increasingly activated as the cells transition from normoxia to 
hypoxia. This conclusion may be drawn by simply inspecting the fluctuation profiles of 
HIF-1α, but it is also in strong agreement with the literature8, 9.  
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By analogy with the above discussion of HIF-1α, we hypothesized that the 
phosphoproteins associated with mTORC1 signaling (Fig. 3.6 B) become isolated from cell 
signaling processes around 1.5% pO2. This has implications, because mTORC1 is 
considered an important drug target in GBM (and other) tumors. The decoupling of 
mTORC1 from its effector proteins within this hypoxic window could account for a level 
of resistance to mTOR kinase inhibitors. We tested this prediction by assaying for the 
effects of the mTOR inhibitor PP242
23
 on the phosphorylation levels of mTOR, P70S6K, 
and ERK1, as a function of pO2, on bulk U87 EGFRvIII cell cultures, since those cells 
were the ones analyzed using the SCBC platform. We also tested our prediction on a tumor 
model by similarly analyzing neurosphere cultures derived from the human origin GBM39 
xenograft
26
. This model also carried the EGFRvIII mutation. GBM neurospheres can 
provide realistic tumor models relative to cell lines
44
, and have even been shown to exhibit 
stem-like behaviors under hypoxic stress
45
. Inhibition of mTOR by PP242 leads to down-
regulation of the phosphorylation of both mTOR and P70S6K, and increased 
phosphorylation of ERK1, due to the activation of a negative feedback loop downstream of 
mTORC1 that targets the PI3K pathway
46
. The protein assays used here were multiplexed 
sandwich ELISA immunoassays from statistical numbers of cells based upon a published 
technique
27
. The cells were assayed in the presence of a 3 M solution of PP242, or a 
DMSO control, under varying pO2. As shown in Fig. 3.7, the results clearly support the 
prediction. We found that mTORC1 signaling is inhibited by PP242 for both U87 
EGFRvIII cells and for the GBM39 neurosphere cultures at 21%, 3%, and 1% pO2, but is 
not inhibited between 2–1.5% pO2.  
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3.4.3 Steady-State kinetic model identifies a switch in mTORC1 signaling near 
1.5% pO2 
We now look towards achieving a better mechanistic understanding of the behavior of 
mTOR signaling near 1.5% pO2 via a steady state kinetic model. 
As master regulators of hypoxic GBM cells, HIF-1α and mTORC1 act in an 
integrated way
12
. Our data suggest that their interplay is critical for the signaling network 
transition. PP242, as an ATP competitive inhibitor, can directly inhibit mTORC1 activity. 
mTORC1 activity will also be inhibited by HIF-1α dependent transcriptional regulation, 
which can occur through REDD1 (regulated in development and DNA damage responses 
1) or BINP3 (BCL2/adenovirus E1B 19 kDa protein-interacting protein 3), when exposed 
to hypoxia
47-49
. Furthermore, our measurements (Fig. 3.7), and other reports
50
, indicate 
that the HIF-1α expression level can be suppressed by addition of PP242 under hypoxia. 
Thus, since HIF-1α can repress mTORC1, suppression of HIF-1α could potentially 
promote mTORC1 activity. This effect may compete against PP242 direct inhibition of 
mTORC1 during the course of hypoxia, thus providing a potential mechanistic 
explanation of the undruggability of mTORC1 signaling between 1.5–2% pO2. This is 
summarized by the network hypothesis illustrated in Fig. 3.8 A.  The network is a greatly 
simplified version of what is known from the literature, but we are able to work with it 
here because, as a steady-state kinetic model, it only requires that that the flux into and 
out of a particular protein channel equal a constant value, for a given set of physical 
conditions. Thus, we are accounting for the net influence of the network components on 
each other, but not necessarily the direct influence. The network of Fig. 3.8 A has the 
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nuance that the indicated protein-protein and protein-molecule interactions are not 
necessarily linear relationships.  
We first address the relationship between HIF-1α and pO2. Under normoxic 
conditions, HIF-1α is hydroxylated at conserved proline residues by HIF prolyl-
hydroxylases (PHD1-3), allowing its further ubiquitination and degradation
25
. But HIF-1α 
is stabilized in hypoxic environments because HIF prolyl-hydroxylase utilizes oxygen as a 
co-substrate, and so is inhibited at a low pO2
51
. It has also been reported that the formation 
of HIF-1α is directly regulated by NF-κB52, while the activation of NF-κB is strongly 
related to the production of reactive oxygen species (ROS)
53
. Therefore, it is reasonable to 
assume that the production of HIF-1α is partially related to oxygen concentration. 
Thus, at steady state of HIF-1α ([HIF-1] for short), 
 'HIF 2 HIF HIF 2
[HIF-1]
[O ][HIF-1] ( [O ]) 0
d
k P k
dt
                      (3.8) 
where HIFk is the rate constant for HIF-1α hydroxylation. The term 
'
HIF HIF 2[O ]P k represents the formation rate of HIF-1α that is partially dependent upon pO2. 
From Eq. 3.8, the steady-state HIF-1α concentration, which fits well with the 
experimental data (Fig. 3.8 B),  is given by: 
 
'
HIF HIF 2
HIF 2
[O ]
[HIF-1]
[O ]
P k
k

                                                     (3.9) 
The level of p-mTOR in non-drug treated sample at a fixed pO2 is written as: 
 phos dephos
[p- mTOR]
[mTOR] [p- mTOR] 0
d
k k
dt
             (3.10) 
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where phosk is the phosphorylation constant of mTOR by phosphorylases or kinases and 
dephosk  is the de-phosphorylation constant of p-mTOR by phosphatases in a cell. Thus, as 
expected, the steady-state concentration of p-mTOR for non-drug treated sample is simply 
proportional to total mTOR concentration 
 phos dephos[p- mTOR] ( / )[mTOR]k k                          (3.11) 
Introduction of PP242 inhibits mTORC1 activity and down regulates mTOR S2448 
phosphorylation
54
, which is equivalent to reducing phosk to a smaller value, 
PP242
phosk . Thus we 
have 
 
PP242 p-mTOR
phos phos PP242[p- mTOR]'/ [p- mTOR] /k k    (3.12) 
Since the oxygen dependent mTORC1 regulation and the drug inhibition of mTOR are 
independent processes, we take the inhibition constant 
p-mTOR
PP242 as independent of pO2, and 
so it can be readily calculated from experiment data. 
We now turn towards quantifying the dependence of [p-mTOR] on [HIF-1] for non-
drug treated samples (Fig. 3.8 C). These two proteins exhibit a clear (inverse) linear 
relationship, and so the plot is fitted using:  
 
p-mTOR 0
HIF[p- mTOR] [HIF-1] [p- mTOR]                  (3.13) 
where [p-mTOR]
0
 is the extrapolated concentration of p-mTOR at zero concentration of 
HIF-1α, and p-mTORHIF captures the strength of the inhibition of p-mTOR by HIF-1α 
dependent transcriptional regulations. 
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Eq. 3.13 describes the increase in p-mTOR with decreasing HIF-1α.  PP242 further 
inhibits HIF-1α, which thus tends to promote p-mTOR.   
 
p-mTOR p-mTOR
HIF PP242Promotion [HIF-1]                     (3.14) 
 where PP242 PP242[HIF-1] [HIF-1] [HIF-1]   is the inhibitory influence of the mTOR 
inhibitor PP242 on HIF-1α. To determine this value, we note that, for our experiments, 
PP242 concentration was either 0 (the DMSO control) or 3µM, while HIF-1α (through the 
influence of hypoxia) varied from around 800 to 2800 pg/ml. Over range, the suppression 
of HIF-1α by PP242 appears to quadratic with respect to HIF-1α concentration for non-
drug treated samples (Fig. 3.8 D). 
 
HIF 2
PP242 PP242[HIF-1] [HIF-1]                                  (3.15) 
As a result, according to the proposed mechanism, the p-mTOR concentration at 
different pO2 for PP242 treated cells is given by 
 
p-mTOR p-mTOR
242[p- mTOR] [p- mTOR] Inhibition PromotionPP       (3.16) 
where
p-mTOR p-mTOR
pp242Inhibition ([p-mTOR] [p-mTOR]') (1 )[p- mTOR]    represents the 
direct inhibition on mTORC1 by PP242. 
We combined steady state chemical kinetic analysis with the fitting of data from 
calibrated microwell-based sandwich ELISA assays on proteins collected from lysed U87 
EGFRvIII cells (Fig. 3.7 A and C; Appendix A: Supplementary Tables). The parameters 
used in the model are extracted from fits to the experimental data (Fig. 3.8 B–D), and are 
provided in the table below. With these relationships, it is straightforward to calculate the 
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p-mTOR concentrations from only the pO2 values, the presence or absence of PP242, 
and the fitted parameters through Eq. 3.16 (Fig. 3.8 E). 
Table 3.2 Parameters used in the steady-state kinetic model. 
parameters values 
PHIF 1877.8 pg/mL·s 
kHIF
 
100 s-1 
k'HIF
'
 
83580 pg/mL·s 
[p-mTOR]0
 
3242 pg/mL 
p-mTOR
HIF  
0.47 
p-mTOR
PP242  
0.88 
HIF
PP242  
9.8e-5 mL/pg 
In Fig. 3.8 B–D we present the relationships between HIF-1 and pO2, p-mTOR and 
HIF-1, and the influence of PP242 on HIF-1α. With these relationships in hand, we can 
calculate the dependence of the p-mTOR level on pO2 using, as input, only the measured 
pO2 values, the presence or absence of PP242, and the fitted parameters (Fig. 3.8 E; 
Table 3.2). This result is of interest in three ways. First, the kinetic model accurately 
captures the p-mTOR levels in the absence of PP242 inhibition, for all values of pO2. 
Second, it predicts a pO2 level for which p-mTOR is not influenced by PP242. For the 
parameters fitted here this level is near 1.25% pO2, but can be shifted to slightly higher 
pO2 levels by altering some of the fitting parameters, while keeping them within their 
statistical margins of error. However, for any of the fitted parameters, the kinetic model 
also predicts PP242 inhibition of mTOR at pO2 levels above the crossing point, and 
PP242 activation of mTOR below the crossing point. This is clearly not observed 
experimentally. The implication is that new regulators of mTOR, not included in the 
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model of Fig. 3.8 A, would have to be invoked to account for the observed behavior at 
very low pO2 levels.  
The influence of hypoxia and PP242 on the GBM39 model exhibits many similarities 
to that observed for U87 EGRFvIII cells, but only certain aspects of the kinetic model 
translate to that system. For example, HIF-1α exhibits a clear hyperbolic dependence upon 
decreasing pO2 in both models, but the other relationships are not as clear for GBM39. This 
 
Figure 3.8 The network hypothesis and accompanying steady state kinetic model describing 
relationships between HIF-1α, p-mTOR, PP242, and pO2 in U87 EGFRvIII cells reveal a switch 
in mTOR regulation below 1.5% pO2. (A) The network drawing indicates (net) effective 
activating (arrow) and inhibiting (bar) interactions. The functional forms of those interactions 
represent the fitted or predicted parameters, using steady-state kinetic relationships. (B) The 
levels of HIF-1α fit well to a steady state kinetic model predicting a hyperbolic increase in HIF-
1α with decreasing pO2. (C) [p-mTOR] exhibits an inverse linear relationship with [HIF-1α]. 
(D) The change in HIF-1α levels upon addition of a 3µM solution of PP242 exhibits a quadratic 
dependence upon [HIF-1α]. (E) The fitted parameters from the model are used to calculate [p-
mTOR] in terms of pO2 in the presence and absence of PP24, and compared against experiments 
(the points connected by lighter lines). The calculation predicts a pO2 level where the solid red 
and blue lines cross, or where PP242 doesn’t inhibit p-mTOR. However, the model also predicts 
PP242 activates p-mTOR at pO2 levels above this crossing point, which is clearly not observed. 
This disagreement implies that new regulators of mTOR are important in the regime of 
moderate-to-severe hypoxia. 
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is not surprising, given that the GBM39 protein assays are sampling a neurosphere model 
of a tumor, which is comprised of a heterogeneous mixture of cellular phenotypes.  
The kinetic model gives some mechanistic insight into the switch in mTORC1, partly 
through its failure to predict the influence of PP242 below 1.5% pO2. This failure 
presumably arises because certain protein-protein interactions are neglected in this range. 
 
Figure 3.9 The use of a quantitative Le Chatelier principle reveals an oxygen partial pressure-
dependent phase transition in the mTORC1 signaling network within model GBM cells. (A) 
Measured and predicted changes for the panel of assayed proteins, as pO2 is changed between 
specified levels. The agreement between experiment and prediction for 21–3% and 1.5–1% 
implies that these pO2 changes constitute only a weak perturbation on the signaling network. The 
change from 3–2% pO2 represents a somewhat stronger perturbation, while for the range 2%-
1.5% pO2, a strong perturbation is indicated by the qualitative disagreement between prediction 
and experiment. (B) The coordination of mTOR associated signaling modes, as a function of 
pO2, is reflected in an analysis of the relevant eigenvalues (mode strength) and their composition 
of the protein-protein covariance matrix (mode composition). The coordination of mTOR with 
its effectors, p-ERK and p-P70S6K, dominates the composition of the 3 lowest amplitude 
eigenvectors, which exhibit singular behavior between 2–1.5% pO2. Experimentally determined 
points are connected by solid lines, the dashed lines imply that the amplitudes of the three 
eigenvectors will reach a (shallow) minimum (loss of mTOR signaling), which is indicative of a 
phase transition. Each column of the pie charts represents the compositions of 3 lowest 
amplitude eigenvectors at the corresponding pO2. They reflect a shift in the coordination of 
mTOR signaling across the phase transition. Note the importance of HIF-1α in these 
eigenvectors at pO2 ≥ 2%, and the importance of p-ERK below 2%. 
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Those interactions are implicit in the protein fluctuations. Thus, we turn to the 
quantitative Le Chatelier’s principle, because it explicitly recognizes individual protein-
protein correlations, and the predictive nature of this theory may help shed light on the 
uninhibitability of mTORC1 between 1.5–2% pO2.  
3.4.4 Quantitative Le Chatelier's Principle identifies a phase transition in mTORC1 
signaling between 2% and 1.5% pO2 
For the Le Chatelier approach, the goal is to understand whether a change in pO2 
constitutes a strong or a weak perturbation to the U87 EGFRvIII cells. We previously 
reported on the development and validation of this approach
24
. In that earlier work, we used 
the theory to predict how the levels of a panel of secreted proteins from a human 
macrophage cell line, stimulated with lipopolysaccharide to emulate gram(-) bacteria, 
would respond to the addition of neutralizing antibodies. The theory requires single cell 
data as input, and can predict how the levels of certain proteins will respond to a weak 
perturbation. A strong perturbation is implied when the theoretical prediction and the 
experimental measurement are in strong disagreement.  
For the theory, we first use the measured data to compute the mean number iN  of 
molecules for each protein i per cell, and the mean of the joint numbers of proteins i and j, 
i jN N . Thereby we compute the covariance matrix  , which is a symmetric P × P matrix 
where P is the size of the protein panel assayed, and the matrix elements Σij represent the 
covariance between proteins i and j (Appendix A: Supplementary Tables). Given the 
protein-protein covariance matrix  , we write the quantitative Le Chatelier's principle as 
  
116 
the matrix equation ΔN = Σ Δμ , where   is a column vector whose P components 
give the change in the chemical potentials of the P proteins due to the change in external 
conditions. 1/ Bk T  , where T is the temperature and kB is Boltzmann’s constant 
(Theoretic details can be found in Chapter 3.3). This relates the change N  in the mean 
number of molecules of each protein to external perturbations, such as O2 pressure changes, 
or addition of a drug. Applying this approach to the single cell data, we found that the state 
of the signaling network at 3% pO2 was only weakly perturbed from that at 21% pO2 (Fig. 
3.9 A). The change between 3 and 2% pO2 was a stronger perturbation (we correctly 
predict the signs of the changes in protein levels, but the predicted levels for proteins IL6 
and MMP1 deviate significantly from experiment). We could not predict the measured 
changes between 2% and 1.5% pO2. We could, however, describe the changes between 
1.5% and 1% pO2. We do not show a prediction for VEGF at low pO2 because, in this 
range, VEGF appears decoupled from the other proteins (Fig. 3.10). 
Based upon these observations we hypothesized that the states corresponding to ~2–
21% pO2 represented one phase of the signaling network, while those between 1–1.5% pO2 
represented a second phase, with a phase transition occurring in between. We tested this 
hypothesis by analyzing the protein-protein covariance matrix to view the coordination of 
mTORC1 signaling, as pO2 was varied. This approach goes beyond measuring specific 
protein-protein pairwise interactions, because it accounts for all of the proteins that are 
simultaneously assayed from each single cell. For the analysis, the eigenvalues (Fig. 3.9 B) 
of covariance matrix describe the amplitude of the coordinated protein-protein interaction 
modes, while the eigenvectors (Fig. 3.9 C) describe the composition of those modes. Such 
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an analysis draws from the Gibbs phase rule
55, 56
, which states that, at a phase transition, 
a degree of freedom is lost for each coexisting phase. Consider the water liquid/solid phase 
transition. Away from the transition, temperature can be readily varied by warming or 
cooling, but at the transition when ice and water coexist, it is not possible to change the 
temperature.  
The nature of the hypoxia-induced transition is that, at the phase transition, the 
signaling network undergoes a switch in connectivity during which the functional 
phosphoproteins related to mTORC1 signaling are isolated and inactivated. This is 
reflected in how the fluctuations of Fig. 3.6 B sharpen at 1.5% pO2, but more rigorously in 
Fig. 3.9 B and C. Above 2% pO2, these eigenvectors capture 75–95% of the covariance, 
and hence signaling network coordination, between the proteins HIF-1α, p-P70S6K, and p-
mTOR; below 1.5% pO2, they capture 80–100% of the covariance between p-P70S6K, p-
mTOR, and p-ERK1. The amplitudes of these eigenvectors are strongly influenced by pO2 
and they each point to a minimum between 1.5% and 2% pO2 (Fig. 3.9 B). Because the cell 
is a finite system, the minimum will likely not be sharp. This eigenvalue singularity 
indicates a loss of degrees of freedom (or the loss of mTORC1 signaling coordination) and 
thereby points to the existence of a phase transition associated with mTORC1 signaling 
between 1.5% and 2% pO2. Recall the quantitative Le Chatelier's principle ΔN = Σ Δμ  
where the vector  DN  of change in protein numbers has P components. The matrix 
equation tells us that we can identify P linearly independent ways in which an external 
perturbation can influence the response of the proteins within the network. If the matrix   
is singular (i.e. it has one or more zero eigenvalues), there are fewer independently 
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allowable variations. This is the loss of degrees of freedom. This analysis leads to the 
surprising prediction that mTORC1 signaling will be intrinsically uncontrollable in the U87 
EGFRvIII cells between 1.5% and 2% pO2, but may be influenced at higher or lower pO2 
values. The proof follows from the near zero eigenvalues of the covariance matrix; the 
associated eigenvectors are those localized on the phosphoproteins associated with 
mTORC1 signaling. Near the transition, even large changes in the chemical potentials of p-
mTOR and its effector proteins p-ERK and p-70S6K result in very small changes in their 
mean numbers.  
 
Figure 3.10 The protein compositions of the 7 eigenvectors of the covariance matrix, as a 
function of pO2. Note that below 2% pO2, VEGF is almost completely decoupled from the 
other proteins, as indicated by its dominance within the 1st (highest amplitude) eigenvector. 
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The hypoxia induced phase transition is a multi-dimensional transition that behaves 
in a complementary manner to a regular transition of the inverse 
relation 1 1 N     . The latter implies that near a phase coexistence where 1 has 
a low eigenvalue, large changes of the number of molecules (extensive variables) will 
barely influence the chemical potential (the conjugated intensive variables). This bears an 
analogy to the liquid/solid transition of water where finite changes of the internal energy 
(the extensive variable) via the addition of heat do not alter the temperature (the conjugated 
intensive variable). Given that intensive and extensive variables come in conjugate pairs 
and are interchangeable through Legendre transforms
56
, both transition manners can be 
appreciated. 
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3.5 CONCLUSION 
We found that in model GBM cell lines and in a mouse GBM xenograft neurosphere 
model, the change in mTOR signaling from normoxia to hypoxia involves a discontinuous 
transition between two phases - i.e. changing pO2 induces a switch in mTORC1 signaling. 
These results point to a fundamentally different approach towards understanding and 
predicting certain cellular behaviors. They may also provide a clue towards understanding 
the clinical failure of mTOR inhibitors on GBM tumors
57, 58
. Our measurements were 
guided by the existing biological literature, but our concern was not with capturing the 
detailed biomolecular interactions within the cells, but rather on understanding how the 
state of the signaling network is influenced by physical (pO2) or molecular (therapeutic) 
perturbations. The approach is driven by new experimental tools for quantitating the levels 
of a panel of functional proteins from single cells, while the theory is grounded in well-
established physico-chemical principles. 
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3.7 APPENDIX A: SUPPLEMENTARY TABLES 
Table 3.3 Reagents Used in this study. The upper table provides the sequences of the 
oligonucleotides used in the protein immunoassays. All oligonucleotides were synthesized by 
Integrated DNA Technology (IDT) and purified via high performance liquid chromatography 
(HPLC). The DNA coding oligomers were pre-tested for orthogonality to ensure that cross-
hybridization between non-complementary oligomer strands was negligible (<1% in photon 
counts). Below the oligonucleotides is a list of the antibodies and standard proteins used for the 
multiplex protein assay. 
Name DNA Sequence Melting Point 
B 5'-AAA AAA AAA AGC CTC ATT GAA TCA TGC CTA -3' 57.4 
B' 5' NH3-AAA AAA AAA ATA GGC ATG ATT CAA TGA GGC -3' 55.9 
C 5'-  AAA AAA AAA AGC ACT CGT CTA CTA TCG CTA -3' 57.6 
C' 5' NH3-AAA AAA AAA ATA GCG ATA GTA GAC GAG TGC -3' 56.2 
D 5'- AAA AAA AAA AAT GGT CGA GAT GTC AGA GTA -3' 56.5 
D' 5' NH3-AAA AAA AAA ATA CTC TGA CAT CTC GAC CAT -3' 55.7 
E 5'- AAA AAA AAA AAT GTG AAG TGG CAG TAT CTA -3' 55.7 
E' 5' NH3-AAA AAA AAA ATA GAT ACT GCC ACT TCA CAT -3' 54.7 
G 5'-AAA AAA AAA AGA GTA GCC TTC CCG AGC ATT-3' 59.3 
G' 5' NH3-AAA AAA AAA AAA TGC TCG GGA AGG CTA CTC-3' 58.6 
H 5'-AAA AAA AAA AAT TGA CCA AAC TGC GGT GCG-3' 59.9 
H' 5' NH3-AAA AAA AAA ACG CAC CGC AGT TTG GTC AAT-3' 60.8 
K 5'-AAA AAA AAA ATA ATC TAA TTC TGG TCG CGG-3' 55.4 
K' 5' NH3-AAA AAA AAA ACC GCG ACC AGA ATT AGA TTA-3' 56.3 
L 5'-AAA AAA AAA AGT GAT TAA GTC TGC TTC GGC-3' 57.2 
L' 5' NH3-AAA AAA AAA AGC CGA AGC AGA CTT AAT CAC-3' 57.2 
M 5'-AAA AAA AAA AGT CGA GGA TTC TGA ACC TGT-3' 57.6 
M' 5' Cy3-AAA AAA AAA AAC AGG TTC AGA ATC CTC GAC-3' 56.9 
DNA label Antibody Source 
 
B' 
Capture: Human VEGF Antibody R&D MAB293 
Detection: Human VEGF 165 Biotinylated Antibody R&D BAF293 
Standard: Recombinant Human VEGF 165 R&D 293-VE 
C' Human p-mTOR (S2448) DuoSet® ELISA kit R&D DYC1665 
D' Human p-P70S6Kinase (T389) DuoSet® ELISA kit R&D DYC896 
 
E' 
Capture: Human IL-6 Antibody R&D MAB206 
Detection: Human IL-6 Biotinylated Antibody R&D BAF206 
Standard: Recombinant Human IL-6 R&D 206-IL 
G' Capture: Rabbit anti-human phospho-EGF R (Y1173) R&D AF1095 
Detection: Biotinylated Goat anti-human EGF R R&D BAF231 
H' Human p-ERK1 (T202/Y204) DuoSet® ELISA kit R&D DYC1825 
 
K' 
Capture: Human MMP-1 Antibody R&D AF901 
Detection: Human MMP-1 Biotinylated Antibody R&D BAF901 
Standard: Recombinant Human MMP-1 R&D 901-MP 
L' Human total HIF-1α DuoSet® ELISA kit R&D DYC1935 
 
Table 3.4 Data and parameters used in protein calibration curves. Mean intensities and standard 
deviations of standard proteins and fitting parameters for bulk (upper half) and SCBC (lower half) 
calibration curves. The calibration curves for bulk protein measurements were fit by fourth order 
polynomials and those for SCBC protein measurements were well fit by a four parameter Morgan-
Mercer-Flodin (MMF) model.  
Calibration curves for bulk protein measurement 
 p-ERK p-mTOR p-S6K HIF-1α MMP-1 VEGF IL-6 
50ng/ml 6433± 93.2 5216± 5758.2± 9586± 99.5 11224± 40209± 29293± 
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208.5 558.8 1020.7 2289.7 1273.5 
10ng/ml 1608± 110.5 800.6± 
41.7 
1185± 
61.2 
1945.5± 78.7 1535.9± 78.3 6015± 
1201.3 
3525.4± 
133.4 
5ng/ml 743.8± 44.3 409.2± 
69.8 
456.7± 
32.7 
805.5± 33.2 660± 31.8 2417.8± 
141.6 
1250.5± 
50.6 
1ng/ml 149.2± 13 51.4± 11.2 105.4± 
16.4 
127.6± 24.4 129.7± 10.6 452±16.1 248.7± 
25.2 
500pg/ml 63.5± 12.5 29.5± 3.5 72.3± 7 53.3±6.7 74.8± 4.5 255.7± 32.7 132.8± 
13.5 
100pg/ml 20.6±1.6 13.8±0.4 37±7.3 11±1.1 21.2±2.5 79.6± 17.4 45±4.9 
10pg/ml 17.2± 2 12.4± 0.5 34.7± 4.2 7±0.8 8.6±2.4 66.3± 23.2 30.4± 7.7 
2 3 4y a bx cx dx ex      
 a b c d e r 
p-ERK 9.04 0.13 3.71E-6 -7.5E-11 0 0.9999 
p-mTOR 12.1 2.35E-2 1.8E-5 -1.47E-9 2.29E-14 0.9999 
p-S6K 32.6 7.39E-2 -2.87E-7 5.47E-10 -1.05E-14 0.9999 
HIF-1α 1.59 0.11 1.19E-5 -3.92E-10 3.72E-15 0.9999 
MMP-1 9.03 0.123 -5.56E-7 4.24E-10 -7.45E-15 0.9999 
VEGF 69.6 0.328 3.09E-5 -4.28E-10 0 0.9999 
IL-6 24.7 0.226 -6.84E-6 2.33E-9 -4.11E-14 0.9999 
 
Calibration curves for SCBC protein measurement 
 p-ERK p-mTOR p-S6K HIF-1α MMP-1 VEGF IL-6 
50ng/ml 189.5± 7.7 170.6± 8.1 215.7± 5.1 248.6± 15.2 218.7± 14.8 254± 16.6 251.7± 4.3 
10ng/ml 81.3± 3.1 65.9± 3.5 85.1± 4.3 97.9± 5.4 83.5± 4 182.3± 6.8 240.7± 14.9 
1ng/ml 11.3± 0.63 12± 0.64 13± 1.02 16.8± 1.1 23.1± 1.6 70.7± 3.01 105.2± 6.05 
100pg/ml 2.76± 0.15 6.31± 0.77 2.41± 0.26 4.3±0.28 8.4±1.05 18.7±2.3 14.3± 1.31 
10pg/ml 2.28± 0.24 6.09± 0.64 1.98± 0.29 2.62± 0.28 5.1±0.47 5.1±0.33 8.12±0.81 
 
0 2.2± 0.24 6.08± 0.72 1.5± 0.17 2.05± 0.18 4.11±0.53 1.29±0.14 7.9±0.77 
d
d
ab cx
y
b x



 
 a b c d r 
p-ERK 2.134 28.005 267.22 1.077 0.9999 
p-mTOR 5.997 41.482 261.08 1.105 0.9999 
p-S6K 1.518 31.53 370.82 0.965 0.9999 
HIF-1α 2.27 31.667 478.25 0.901 0.9999 
MMP-1 4.162 227.94 4267 0.637 0.9999 
VEGF 1.239 3.552 316.86 0.68 0.9999 
IL-6 8.124 1.524 253.24 1.443 0.9999 
 
Table 3.5 Mean intensities and standard deviations for the SCBC protein assays from U87 
EGFRvIII cells as a function of number of cells, and under different oxygen contents. 
cell ref p-
EGFR 
p-ERK p-mTOR p-S6K MMP-1 HIF-1α VEGF IL-6 Copy 
# 
Normoxia condition at 21% O2, 7 hours incubation 
1 81.4±
5.9 
154.6±4
9.5 
12.2±4 18.8±9.1 13.5±4.3 33.8± 
16.8 
16.9±4.
2 
50.1±16 67.7±
38.6 
113 
2 81.2±
5.1 
190.6±3
8.6 
16.4± 6.4 28.5±19.
4 
17.3±7.6 38.2± 
14.1 
24.7±7.
1 
105.5±2
4.1 
123.8
±50.2 
43 
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3 82.1±
6.2 
204.1±5
9.6 
23.7±9.5 38.4±19.
7 
23.5±9 44.8± 
28.9 
28.7±8.
1 
158.2±2
2.7 
179.3
±28.2 
40 
Hypoxia condition at 3.0% O2, 7 hours incubation 
1 80.6±
4 
150.9±5
2.6 
11.9±3.6 18.4±7.1 12.7±2.8 30.8± 9.9 24.9±7.
4 
85.4±32
.5 
79.6±
34.7 
77 
2 80.6±
4.8 
184.8±5
3.4 
17± 8.04 27.4±12.
8 
17.3±6.9 34.7±14.
9 
31±8.8 149.6±3
0.7 
141.9
±58.9 
61 
3 80.9±
4.2 
199.5±4
6.4 
23.2± 9.6 37.8±18.
9 
21.5±6.9 39.5±11.
4 
37.3±8.
2 
183.2±1
1.6 
192.9
±51.5 
23 
Hypoxia condition at 2.0% O2, 7 hours incubation 
1 80±4.
4 
161.4±5
1.6 
11.2±3.6 19.2±6.3 9.2± 2.3 27.3±5.1 30.1±4.
4 
116.8±3
6.8 
43.9± 
18.9 
86 
2 80±3.
7 
186.8±5
3.5 
15.4±4.8 27.4±11.
7 
12.2±3.9 44.4±48.
4 
40.7±6.
6 
161.5±4
2.6 
96±2
8.7 
96 
3 80.7±
3.4 
206.3±3
5.2 
20.4±5.7 37.8±15.
3 
15.7± 3.7 58.4±62 45.8±7.
9 
196.2±3
3.6 
154.6
±35.4 
48 
Hypoxia condition at 1.5% O2, 7 hours incubation 
1 80.7±
6.1 
150.6±4
9.1 
10.4± 1.5 18.4±4.6 11.3±3.1 31.1± 15 40.5±7.
9 
116.8±4
7.2 
63.3±
41 
92 
2 80.4±
3.7 
180.9±4
2.6 
15.1±5.2
5 
25.8±13.
1 
18±  3.5 34.9±21.
7 
50.4±10
.1 
170.4±3
9 
118.4
±52.3 
77 
3 81.3±
4.1 
201.1±3
5.1 
20.5±11.
5 
36.2±15.
1 
19.1±9.8 39.±19.3 61.9±11
.1 
204.5±1
6.1 
167± 
56.7 
34 
Hypoxia condition at 1.0% O2, 7 hours incubation 
1 81±5.
1 
153.8±5
7.1 
10.2±3.4 18±5.9 12.3±5.1 28.2±9.5 47.5±11
.6 
108.6±2
8.5 
84.3± 
36.2 
157 
2 80.3±
5 
181.9±5
8.7 
14.7±5.9 26.1±11 17.4±8.3 31.5±8.2 62.9± 
16.1 
174.1±3
2.3 
136.4
±51.9 
101 
3 80.8±
4.9 
199.5±4
1.7 
20.7±9.1 36.3±15.
1 
19.7±6.6 35.9±13.
1 
75±17.3 209± 
20.5 
188.2
±40.1 
58 
 
Table 3.6 Fluorescence intensities and change in number of molecules of the mTOR kinase 
inhibition assay on U87 EFGRvIII bulk cell populations. The mean intensities and standard 
deviations (SD) are shown with or without addition of PP242, and at different O2. The molecular 
weights (in kDa) used in the calibrations are 120, 289, 44, 70, 52, 20 and 20.3 for HIF-1α, p-
mTOR(Ser2448), p-ERK1(T202/Y204), p-P70S6K(T389), MMP-1, VEGF and IL-6, respectively. 
Protein    +         PP242 (3µM)       - Change in # of molecules 
(PP242+)  -  (PP242-) 
 mean SD mean SD mean SD 
U87 EGFRvIII normoxia condition at 21% O2, 7 hours incubation 
HIF-1α 94.9 13.4 107.0 13.3 -2.35E+07 3.7E+07 
  
131 
p-mTOR 160.8 6.3 191.7 4.8 -3.59E+07 9.34E+06 
p-ERK1 247.0 4.4 194.1 6.5 2.56E+08 3.8E+07 
p-P70S6K 78.1 4.7 547.6 77.9 -2.23E+09 3.0E+08 
MMP-1 437.3 7.2 415.2 10.6 9.63E+07 5.6E+07 
VEGF 4858.6 189.5 4944.9 178.1 -1.70E+08 5.2+08 
IL-6 525.9 10.9 468.9 13.1 3.72E+08 1.1E+08 
U87 EGFRvIII hypoxia condition at 3.0% O2, 7 hours incubation 
HIF-1α 164.9 12.4 194.8 7.7 -5.29E+07 2.62E+07 
p-mTOR 143.3 5.9 163.3 4.3 -2.43E+07 9.06E+06 
p-ERK1 390.2 58.9 269.4 38.2 5.65E+08 3.29E+08 
p-P70S6K 204.3 18.2 389.8 65.9 -8.98E+08 3.13E+08 
MMP-1 546.2 23.4 463.6 17.2 3.50E+08 1.23E+08 
VEGF 7726.9 208.1 7980.9 360.4 -4.30E+08 7.07E+08 
IL-6 894.5 41.9 542 21.8 2.13E+09 2.75E+08 
U87 EGFRvIII hypoxia condition at 2.0% O2, 7 hours incubation 
HIF-1α 200.8 9.9 234.4 11.3 -5.73E+07 2.58E+07 
p-mTOR 149.7 5.4 152 5.8 -2.79E+06 9.75E+06 
p-ERK1 217.1 19.3 171 13.7 2.25E+08 1.16E+08 
p-P70S6K 121.6 18.4 256.4 34.5 -7.29E+08 2.07E+08 
MMP-1 540.3 18.6 402.1 26 5.94E+08 1.39E+08 
VEGF 7467.2 155.4 8137.6 110.4 -1.14E+09 3.26E+08 
IL-6 1066.9 69.1 452.7 31.7 3.64E+09 4.19E+08 
U87 EGFRvIII hypoxia condition at 1.5% O2, 7 hours incubation 
HIF-1α 210.8 9.6 285.4 14.4 -1.24E+08 2.87E+07 
p-mTOR 136.9 3.2 135.7 2.4 1.47E+06 5.13E+06 
p-ERK1 178.3 5.8 166.4 3.1 5.82E+07 3.25E+07 
p-P70S6K 115.9 7.6 373 92 -1.31E+09 4.32E+08 
MMP-1 337.4 16.8 313.8 11.8 1.07E+08 9.28E+07 
VEGF 8414.4 461.1 9851.6 495.1 -2.33E+09 1.10E+09 
IL-6 528 28.2 468.1 26.2 3.91E+08 3.01E+08 
U87 EGFRvIII hypoxia condition at 1.0% O2, 7 hours incubation 
HIF-1α 261.8 18.4 375.2 21.7 -1.78E+08 4.48E+07 
p-mTOR 99.8 4.3 119.7 3.8 -2.74E+07 7.99E+06 
p-ERK1 164.7 1.96 147.5 1.5 8.51E+07 1.22E+07 
p-P70S6K 54.3 7.9 338.8 53.8 -1.52E+09 2.61E+08 
MMP-1 289 12.9 316.3 17.1 -1.24E+08 9.76E+07 
VEGF 7567.1 179.1 10991.9 683.7 -5.54E+09 1.11E+09 
IL-6 1102.3 45.2 762.7 29.5 1.87E+09 2.91E+08 
 
Table 3.7 Protein-protein covariance matrices at various pO2 levels from U87 EGFRvIII single cell 
data. The covariance matrices are symmetric, so only the upper half parts are shown. 
21% pO2 p-mTOR p-ERK1 p-p70S6K HIF-1α VEGF IL-6 MMP1 
p-mTOR 2.52E+07 2.11E+07 1.09E+07 1.19E+05 3.98E+07 2.29E+07 8.11E+06 
p-ERK1  9.84E+07 2.37E+07 2.61E+06 -1.26E+07 -3.75E+06 1.24E+08 
p-p70S6K   3.77E+07 6.46E+05 5.66E+07 1.98E+07 -9.52E+05 
HIF-1α    8.82E+06 3.66E+07 3.36E+06 3.82E+07 
VEGF     2.17E+09 5.68E+08 1.27E+08 
IL-6      4.32E+08 -1.39E+07 
MMP1       3.74E+09 
3% pO2 p-mTOR p-ERK1 p-p70S6K HIF-1α VEGF IL-6 MMP1 
p-mTOR 1.74E+07 9.48E+06 6.62E+06 3.54E+06 1.96E+07 4.00E+06 1.06E+07 
p-ERK1  7.69E+07 6.28E+06 9.49E+06 1.57E+08 2.27E+07 9.07E+06 
p-p70S6K   1.48E+07 7.96E+06 3.47E+07 1.90E+07 4.55E+07 
HIF-1α    3.42E+07 8.72E+07 5.73E+06 2.23E+07 
VEGF     5.49E+09 6.09E+08 5.49E+08 
IL-6      4.08E+08 1.42E+08 
MMP1       6.75E+08 
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2% pO2 p-mTOR p-ERK1 p-p70S6K HIF-1α VEGF IL-6 MMP1 
p-mTOR 1.19E+07 1.08E+07 2.85E+06 1.54E+06 6.55E+07 3.65E+06 1.09E+07 
p-ERK1  7.94E+07 1.03E+07 7.63E+06 5.18E+08 2.41E+07 3.15E+07 
p-p70S6K   1.07E+07 5.76E+06 3.73E+08 1.23E+07 8.22E+06 
HIF-1α    1.16E+07 2.96E+08 7.32E+06 1.98E+07 
VEGF     6.13E+10 6.33E+08 2.87E+08 
IL-6      7.95E+07 9.79E+06 
MMP1       1.17E+08 
1.5% pO2 p-mTOR p-ERK1 p-p70S6K HIF-1α VEGF IL-6 MMP1 
p-mTOR 6.04E+06 6.27E+06 5.36E+06 9.68E+05 1.51E+08 3.67E+06 3.10E+07 
p-ERK1  1.37E+07 6.18E+06 2.83E+06 2.73E+07 8.39E+05 4.34E+07 
p-p70S6K   1.86E+07 7.04E+06 1.73E+08 2.92E+07 1.07E+08 
HIF-1α    5.27E+07 2.48E+08 6.03E+07 1.01E+08 
VEGF     6.51E+10 6.37E+09 2.89E+07 
IL-6      1.25E+09 2.02E+08 
MMP1       1.52E+09 
1% pO2 p-mTOR p-ERK1 p-p70S6K HIF-1α VEGF IL-6 MMP1 
p-mTOR 1.03E+07 1.67E+07 1.27E+07 7.24E+06 3.75E+06 1.47E+06 9.11E+06 
p-ERK1  6.96E+07 1.96E+07 2.06E+07 3.56E+07 2.19E+07 2.09E+07 
p-p70S6K   5.37E+07 6.61E+06 4.52E+08 2.28E+07 3.21E+07 
HIF-1α    1.19E+08 1.14E+08 2.02E+07 3.48E+07 
VEGF     8.66E+10 9.64E+08 9.25E+07 
IL-6      3.14E+08 7.93E+07 
MMP1       7.37E+08 
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C h a p t e r  4  
Applications in preclinical cancer research: collective behaviors in 
signaling coordination––signaling modes––identifies adaptive network 
dynamics and defines effective targeted therapy strategies 
4.1 INTRODUCTION 
For almost all patients with advanced cancer, targeted therapies yield modest clinical 
benefit, as tumors rapidly become resistant
1
. Resistance to any single therapy can occur 
when drug-resistant tumor cell subpopulations expand to drive recurrence
2
 in a process 
akin to Darwinian-type evolution under the selection pressure of the drug. The timescale of 
the appearance of resistance may be governed by several factors, one of which is long term 
cell-cycle selection of the resistant subpopulation. Deep sequencing of clinical tumor 
samples can potentially detect that rare cell subpopulation, and thus help guide the selection 
of a therapy that includes a second drug that forestalls resistance by targeting that 
population
3-6
. 
An alternative resistance mechanism is one in which cancer cells targeted by the 
inhibitor adapt, altering their protein signaling networks so as to maintain the signal flux 
through those networks that is required for tumor maintenance and growth
7-9
. In this 
mechanism, the drug is a perturbation that shifts the cancer cells from one steady state to 
another. Such resistance can develop quickly, and would not be detectable by sequencing. 
Instead, the challenge is to measure the structure and response dynamics of the protein 
signaling networks that are influenced by the drug
10, 11
. Anticipating how those networks 
will respond to the drug might then provide insights for identifying effective therapy 
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combinations.  
To test this idea, we exploited a clinically relevant model of acquired cancer drug 
resistance, with the goal of understanding the general nature of the resistance, and of 
identifying combinations of targeted therapies for effective treatment. GBM39 is a human-
derived model of glioblastoma multiforme (GBM) that is maintained by serial 
transplantation in xenografts
12
. It retains tumor heterogeneity, an invasive growth capacity, 
and a drug response profile that are representative of clinical behavior
13
. GBM39 expresses 
high levels of the epidermal growth factor receptor (EGFR) variant(v)III oncogene, which 
sensitizes tumor cells to the mechanistic target of rapamycin (mTOR) kinase inhibitor 
CC214-2
14
. Here, we determined the structure of the hyperactivated phosphoprotein 
networks, including those associated with mTOR signaling, using multiplex assays of 
phosphoproteins from statistical numbers of single cancer cells
15, 16
 that were untreated, 
responding to CC214-2, and resistant to CC214-2. The evolution of that structure, between 
the untreated and responsive states, provides guidance for selecting targeted therapy 
combinations that can successfully arrest tumor growth. It also provides guidance for 
identifying those therapies and therapy combinations that will not be effective.   
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4.2 EXPERIMENTAL METHODS 
4.2.1 Establishment of in vivo mouse xenograft model recapitulating the clinical 
scenario of acquired resistance 
Mice bearing GBM39 flank xenografts treated for 19 days with CC214-2 (100mg/kg, 
once every two days by gavage), demonstrated significant inhibition of glucose uptake as 
measured by 
18
F-fluorodeoxyglucose (FDG) positron emission tomography (PET) (Figs. 
4.1 a, b and 4.2), reduced mTOR Complex(C)1 and mTORC2 signaling, reduced cellular 
proliferation as measured by Ki67 staining (Fig. 4.1 c, Appendix A: Supplementary Figures 
and Appendix B: Supplementary Table) and a reduction in tumor volume relative to 
 
Figure 4.1 Characterization of GBM 39 in vivo mouse model. (a) Tumor growth curve for 
control (sample size n=11), responsive (n=7) and resistant (n=7) xenografts (variations 
expressed as s.d.), (b) 18F-FDG PET scanned images, PET-CT, and CT scanned images for 
the three conditions (Right, n=4 for each condition). The arrow indicates the localization of 
the tumor. (c) Immunohistochemistry results for the three conditions (n= 8, 6, 6 respectively 
for vehicle, responsive and resistant groups). *P<0.05 (Student’s T-test); scale bar: 100 μm. 
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untreated mice (Fig. 4.1 a). Minor tumor cell death was observed. By day 27, rapid tumor 
regrowth was appreciated with concomitant increases in glucose uptake, mTOR signaling, 
cellular proliferation and tumor volume, thus modeling the clinical scenario of acquired 
resistance (Fig. 4.1 a–c).  
GBM39 primary neurospheres were provided by Prof. David James (UCSF, San 
Francisco, U.S.A.) and authenticated by luciferase reporter expression before the beginning 
of the in vivo experiments. GBM39 cells were tested for pathogens, including mycoplasma, 
by IDEXX RADIL and all tests results were negative. GBM39 cells were cultured in 
NeuroCult (StemCell Technologies) supplemented with Heparin (1 μg/mL), Epidermal 
Growth Factor (EGF, 20 ng/mL) and Fibroblast Growth Factor (FGF, 20 ng/mL; SIGMA) 
and 100 U/mL penicillin and streptomycin (Gibco) in a humidified 5% CO2 (vol/vol) 
incubator, at 37°C. CC214-1 and CC214-2 were provided by Celgene Corporation (San 
Diego, U.S.A.)
17
. GBM39 flank xenografts were obtained in full compliance with the 
 
Figure 4.2 18F-FDG Positron Emission Tomography (PET) on GBM39 xenografts. Statistical 
analysis of the Standardized Uptake Value (Suv) registered by imaging; *P<0.05 (Student's 
T-test; n= 4 for each time point; data represents the average of 4 independent measurements 
for each time point with variations expressed as s.d.); Tp= Time points. 
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UCLA-Division of Laboratory Animal Medicine (DLAM) regulation and with the 
UCSD-Institution of Animal Care and Use Committee (IACUC) regulations. GBM39 cells 
were resuspended in PBS (Cellgro) plus Matrigel (BD Biosciences), 1:1 solution (vol/vol), 
at 1×10
7 
cells/ml density. One million of GBM39 cells were injected in the flank of each 4 
weeks old female athymic mouse. Tumor sizes were measured using automated caliper. For 
the drug treatments, CC214-2 was administered by oral gavage, 100mg/kg, once every two 
days, in a suspension containing 0.5% carboxymethylcellulose (Sigma), 0.25% Teewn-80 
(Sigma) in nanopure water. 
4.2.2 MicroPET/CT characterizations 
Four mice for each group were anesthetized with isoflurane (2% in 100% oxygen), 
warmed and injected with 20µCi [F
18
]-FDG. After an uptake period of 60 minutes, mice 
were placed in a dedicated imaging chamber designed for use for the CT and both PET 
systems. Data were acquired using an Inveon scanner (Siemens Preclinical Solutions), a 
Gensiys4 (Sofie Biosciences, Culver City, CA) and a MicroCAT II CT (microCAT; Imtek 
Inc.) instrument. Acquisition of PET images was performed for 10 min on each scanner 
followed by 8 min CT acquisition
18
.  
PET and CT Images were analyzed using OsiriX Imaging Software (version 3.8; 
OsiriX). MicroCT and PET images were reviewed blinded to detect tumor burden. 
Consecutive 2-dimensional regions of interest (ROI) were drawn on tumor on coronal and 
axial to detect the maximum FDG uptake. These regions encompassed the entire 
metabolically active tumor. Display of representative images was done according the 
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shown color scale proportional to tissue concentration, with red being the highest and 
lower values in yellow, green, and blue (Figs. 4.1 b and 4.2). Student’s T-test was used to 
assess statistical significance. The variation between groups was similar and expressed as 
standard deviation. 
4.2.3 Immunohistochemistry (IHC) and immunoblotting 
For IHC assays, Paraffin embedded GBM39 xenografts blocks were sectioned at the 
UCLA Pathology Histology and Tissue Core Facility and at the UCSD Histology and 
Immunohistochemistry core followed by immunohistochemistry stains performed as 
described in Mellinghoff et al.
19
. Three images at 40x magnification per IHC slide were 
captured using DP 26 camera mounted on an Olympus BX43 microscope. Quantitative 
analysis of the IHC stained slides was performed with Microsuite Five software (Olympus; 
Figs. 4.1 c and 4.14 and Appendix B: Supplementary Tables). In the IHC quantification, 
the following number of xenografts was considered for each group: n= 8 for controls, n= 6 
for CC214-2 responsive group, n= 6 for CC214-2 resistant group, n= 4 for Dasatinib group, 
n= 4 for U0126 group, n= 4 for U0126 plus Dasatinib group, n= 2 for each combination 
with CC214-2, n= 2 for each drug removed group. Student’s T-test was used to assess 
statistical significance. 
Western blot (Figs. 4.3 a, 4.7 a and 4.11 b) was done loading 10 μg of protein lysates. 
Lysates were collected in RIPA buffer (Boston BioProducts) with addiction of protease 
plus phosphatase inhibitor cocktail, 10μL/mL each (Thermo Scientific). Gradient 4-15% 
pre-casted gels were used for the electrophoretic protein separation in mono-dimension 
(Bio-Rad). Proteins were transferred on nitrocellulose membranes using Trans-blot Turbo 
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Transfer system (Bio-Rad). Blots were then blocked in Tris-buffered saline, 0.1% 
Tween20 (vol/vol) and 5% BSA (Fischer Scientific, vol/vol) for 1 hour. The primary 
antibodies were incubated overnight, at 4ºC. After washing, the membranes were incubated 
with secondary HRP conjugated antibodies for 1 hour at room temperature. West Femto 
Trial kit (Thermo Scientific) was used to develop the immunoreactivities.  
4.2.4 Preparing single-cell suspension from solid tumors. 
Freshly resected xenografts were finely cut in sterile conditions and digested for 3 
hours at 37°C, under constant rotation (200 rpm), in a solution containing 1.5% BSA 
(g/mL, Gemini), 0.3% collagenase type 2 (g/mL, Worthington), 0.3% collagenase type 4 
(g/mL, Worthington) and 10 μg/mL DNAse I enzyme (Sigma). Single cell suspensions 
were then filtered with a 40 μm cell strainer and pellets were treated for 2 minutes with 3 
mL ACK buffer (Lonza). Solutions were neutralized with DMEM medium (Gibco) and cell 
viability assessed by trypan blue exclusion. Frozen stocks were made re-suspending cell 
 
Figure 4.3 Cell preparation and validation for the SCBC test. (a) Western blot results for the 
cells that were sorted, plated and harvested at three different time points: 0, 12, 24 hours. The 
fact that the levels of key functional proteins do not change over time validates the cell plating 
step for the test. (b) EGFR expression level of sorted U87/EGFR cells and GBM39 cells. After 
sorting, cells were stained with PE-conjugated rat anti-human EGFR antibodies. It's readily to 
see that GBM39 cells are smaller in size and more heterogeneous in terms of EGFR expression 
on the cell surface. 
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pellets in Bambanker (Wako) and storing cryovials at – 80°C (Fig. 4.11 a). 
4.2.5 Magnetic-activated cell sorting (MACS) and plating 
A solid tumor is composed of many different types of cells including immune cells, 
stromal cells, and cancer cells. In order to analyze the main characteristics of the cancer 
cells, it is required to sort out cancer cells, even specific subset of the cancer cells of a 
tumor sample. There are several challenges for cell sorting. First, the technique should be 
very specific, robust, and reproducible. Second, it should be able to handle small amount of 
sample. Third, cells after sorting should be healthy in order to provide representative 
information of the tumor. We chose to use magnetic bead-activated cell sorting (MACS) 
targeting EGFR cell surface marker. EGFR is one of the major cell surface markers for 
GBM which is over expressed in approximately 50–60% of glioblastoma (GBM) tumors20. 
Cell sorting was carried out with Human EGF R/ErbB1+ Cancer Cells PlusCellect kit from 
R&D systems (Catalog # PLS1095) and followed the manufacturer's protocol. Typical cell 
number available from the mouse tissue sample ranges from 500,000 to 1,000,000 and the 
yield of the EGFR+ cell sorting is sample specific with a range of 60–70% for most of our 
cases. Cell variability after sorting is another critical issue here since primary cells are 
normally fragile. A short time (2 hours) incubation step on a laminin pre-coated petri dish 
was introduced to enable only healthy cells to attach to the plate and subsequently to be 
transferred to the SCBC test. The cell viability was greater than 95% after employing the 
surface plating step. Immunoblot analyses (Fig. 4.3 a) also confirm that the additional short 
time culturing does not induce significant physiological changes in the primary cells. After 
2 hours of incubation, dead suspended cells were removed by aspirating the media. Cells 
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that attached to the surface were trypinized and re-suspended in the cell media 
(NeuroCult®-XF Proliferation Medium, STEMCELL Technologies, Inc.) at 1,000 cells/μL 
for loading to the SCBC.  
4.2.6 Microchip design, fabrication and experimental procedures. 
We utilized the single cell barcode chip (SCBC) platform to quantify the levels and 
correlative interactions of 9 proteins and phosphoproteins
15, 16
 from statistical numbers of 
single EGFR+ tumor cells (Figs. 4.4 and 4.5). GBM39 cells from harvested tumor were 
processed into a single cell suspension. The EGFR+ cells (which include the 70% 
EGFRvIII+ subset) were sorted and applied to the SCBC platform (Fig. 4.4). An SCBC 
contains 320 1.5 nanoliter volume microchambers, each designed for cell lysis, and each 
equipped with a full antibody array. Following cell lysis, the proteins are captured on the 
antibody array, which is developed so that specific protein levels are encoded as a 
fluorescence signal on particular array spots. A one-chip data set includes the digitized 
 
Figure 4.4 Protocols and single-cell data of SCBC assays on GBM39 xenograft cells. EGFR+ 
cancer cells are separated from the GBM39 models in the control, responsive, or resistant states 
and loaded onto an SCBC. To ensure adequate statistical power, two SCBC replicates were run 
in parallel for each test condition. 
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fluorescence signals from 9 proteins measured from each of ~100 1-cell microchambers 
(Fig. 4.11 a) and 100 0-cell microchambers (providing a measurement of signal 
background). Two SCBCs were typically used for each condition studied.  
The fabrication of SCBC, the protein panel validation and calibration and the 
experimental procedures of the single-cell proteomic assay follow the same protocol 
described in Chapter 2.  
4.2.7 DEAL based cell capturing and viability test 
EGFR + and EGFRvIII + cells were sorted from GBM39 neurospheres by DEAL 
technology
21
. DEAL arrays were blocked with 1% BSA in PBS solution (g/mL) for 30 
minutes, washed in PBS and deionized water and incubated with oligo-Cetuximab (Bristol-
Myers) conjugate for 30 minutes, at 37°C. Single cell preparation of GBM39 cells, 
 
Figure 4.5 Design and working scheme of SCBC. (a) Picture of SCBC. (b) Picture of one 
chamber unit: valves for chamber formation (red), valve for lysis buffer control (green), 
cell chamber compartment (blue), and lysis buffer (yellow) reservoir are delineated by food 
dyes. (c) Optical image of a single cell chamber. 
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suspended in the culture medium, were applied to the array for 40 minutes, on ice. The 
DEAL arrays were then washed with BSA 0.1% in PBS (g/mL), a solution 1:2 of trypan 
blue in PBS (vol/vol) was applied on the captured cells that were then covered with a cover 
slip. Dead cells were visualized and counted as the number of trypan blue positive cells, 
with a Nikon Eclipse TS100 scope (Fig 4.7). 
Fifteen thousand of GBM39 cells were seeded in 12 well plates and, after 24 hours, 
treated with CC214-1 2 μM, U0126 5 μM, Dasatinib 100 nM, for 24 hours. Cell viability 
and cell death were evaluated using Bio-Rad TC-20 cell counter. Representative images of 
the cells were taken using a Nikon Eclipse TS100 scope equipped with Canon S51S camera 
(Fig. 4.8). Student’s T-test was used to assess statistical significance. The variation between 
the sample sets was similar and expressed as standard deviation. 
 
Figure 4.6 Calibration curves of the assayed protein panel. The calibrations were carried out 
using SCBC under the same condition to those single cell experiments, except that standard 
proteins were used. The calibration curve for p53 couldn’t be generated due to the non-
specific binding of recombinant standard protein. 
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4.2.8 Single Nucleotide Polymorphism (SNPs) analysis 
Two controls and two CC214-2 resistant xenografts were used for the DNA 
extractions, using the Qiagen QIAamp DNA Mini kit protocol. Few microgram (1.5-2 μg) 
of DNA from control and resistant samples were analyzed by Affymetrix SNP 6.0 array 
(200kb filter, 50 markers) at the Clinical Microarray Core, University of California Los 
Angeles. The DNA sequences used for the Genome-wide Affymetrix SNP6.0 array 
sequence analysis have been deposited to Gene Expression Omnibus (GEO). The accession 
code is GSE53042. 
4.2.9 In vivo drug treatment 
 
Figure 4.7 In vitro GBM39 combinatory treatment with CC214-1, U0126 and dasatinib. (a) 
Biochemical analysis of the drug targets down-regulation upon single or combinatory 
treatments. All of the drugs successfully hit their targets. (ERKi: 5uM U0126, Dasat.: 100nM 
dasatinib, E+C: U0126+ 2μM CC214-1, D+C: dasatinib+CC214-1; 24 hours treatment). (b) 
DEAL sorting of GBM39 EGFR+ cells after single or combinatory treatments, followed by 
trypan blue assay. Cells were treated with CC214-1, U0126 and dasatinib for 4 days at the 
concentration specified in (a). The percentages of dead cells are listed on the right side of the 
images. Cell death percentages resulted significantly different (P<0.05; Student's T-test) from 
DMSO in the combinatory treatments. Variations are expressed as s.d. Data are representative 
of three independent experiments. 
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For the drug treatments, CC214-2 was administered by oral gavage, 100mg/kg, once 
every two days, in a suspension containing 0.5% carboxymethylcellulose (Sigma), 0.25% 
Teewn-80 (Sigma) in nanopore water. Dasatinib (Selleckchem) was administered by oral 
gavage, 30mg/kg, once every two days, dissolved in the CC214-2 suspension. U0126 
(Selleckchem) was administered by intra-peritoneal injection, 25 μmol/kg, once every two 
days, in a suspension containing 40% DMSO (vol/vol, Fisher) in PBS (Cellgro). The 
injection of 1mL saline 0.9% NaCl (Baxter) was used if signs of weight loss were 
 
Figure 4.8 In vitro proliferation assay for mono- and combination therapies. (a) In vitro 
GBM39 proliferation assay after combinatory treatments with CC214-1, U0126 and dasatinib 
(3 days treatment). Representative images of the GBM39 cells under treatment are shown. (b) 
Bar graphs of the percentage of viable and dead cells and the total viable cell number for the 
treated cells depicted in A; *P<0.05 (Student’s t-Test, variations are expressed as s.d. Data are 
representative of three independent experiments). 
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registered. Mice were euthanized when tumors reached 15 mm diameter. To determine 
the number of animals requested, we carried out power calculations using STATA software 
(version 8), performed the Monte Carlo simulation command (simpower) and determined 
the sample size to detect a significant difference in our tumor size comparison study. To 
ensure statistical significance of drug effects, we used a sufficient, but not excessive, 
sample size: for vehicle treated controls, CC214-2 responsive and CC214-2 resistant mice n 
= 11, 7, 7 respectively for each group; for Dasatinib, U0126, either alone or in 
combination, and for the combinatory treatments with CC214-2, n = 4 for each group. 
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4.3 PHYSICAL APPROACHES 
4.3.1 Collective behaviors in signaling coordination: singling modes hypothesis 
The typical topological structure of the signaling networks is comprised of many 
different wires interconnecting various signaling proteins (nodes). Each wire represents a 
protein-protein pairwise interaction between two signaling nodes (Fig. 4.9). The structure 
can be very complicated if many signaling protein are involved, which makes it hard to 
 
Figure 4.9 A comparison between the procedure of decomposing strongly-coupled atom-atom 
interaction in a crystal lattice into a set of distinct vibration normal modes and the procedure of 
decomposing a protein signaling network into a set of independent signaling modes. 
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quantitatively trace and predict the exact outcome from a signaling input. Physical and 
computational models are therefore needed to structure the deluge of data and to make 
them accessible to meaningful interrogation and analysis
22
.  
By analogy with the study of atomic interactions in a crystal lattice where the atom-
atom pairwise interactions can be greatly simplified by diagonalizing the system potential 
matrix to decompose the strongly coupled atomic interactions into a series of independent 
normal vibrational modes (Fig. 4.9), a simplified picture of signaling network coordination 
can also be achieved by diagonalizing protein-protein correlation or covariance matrices to 
decompose the pairwise interactions into a set of distinct linear combinations of signaling 
proteins (i.e., independent signaling modes). The protein-protein covariance matrices are 
the strength measure of the protein interactions. The composition of each mode is a linear 
combination of a panel of proteins that are the key nodes of the signaling network under 
study (i.e., eigenvectors) and the strength of each mode is the corresponding eigenvalue 
(Fig. 4.9). Interrogating how the strength and composition of the dominative signaling 
modes evolve with the tumor progression (treatment naïve, drug responding and resistant) 
and/or respond to external perturbations (different drug treatments) will lead a conceptual 
advance of viewing and simplifying the protein signaling network and provides the basis of 
developing physico-chemical theory for single cell proteomics with predictive capacity. 
4.3.2 Principal component analysis (PCA) 
An optimal tool for extracting the dominative signaling modes from the single cell 
proteomic dataset is principal component analysis (PCA). In this chapter, PCA is carried 
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out carried out for single cell data from tumors at all three stages, as well as the three 
clustered subgroups identified in control sample. Each column of the dataset is mean-
centered and divided by the standard deviation to form a standardized dataset first. A 
normalized PCA (coded in R) is used to peel off layer after layer of systematic co-
variations from the data, in terms of principal components (PCs). Different principal 
components typically capture different parts of the cell responses—for example, one might 
correlate best with cell division, whereas another correlates best with cell death
22
. The 
correlations between functional protein levels and PCs are calculated to quantify the 
dominative protein pattern of the signaling network coordination and its response to 
external perturbations such as drug treatment. The square of a protein projection on a PC 
defines the contribution of that protein to that PC. The contributions of each functional 
protein to the first three PCs for control sample are calculated and shown in the pie charts 
of Fig. 4.13. In the subgroup with most mTOR activity, different groups of functional 
protein preferentially occupy different PCs and become orthogonal to one another (Figs. 
4.12 c and 4.13), which implies potentially independent signaling modes are active within 
the same cellular subpopulations. 
4.3.3 Quantifying the functional heterogeneity 
Cancer cells are stable populations existing in the presence of large heterogeneity. The 
population is stable exactly because it is heterogeneous. Single cell proteomic 
measurements capture the protein fluctuations, while simultaneously providing a measure 
of the stability of a tumor that is comprised of those cells, and providing a bridge to 
statistical physics models with predictive capacity. The heterogeneity can be quantified in 
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many different ways. In this chapter, we apply agglomerative hierarchical clustering 
(AHC) analysis that is applied by XLSTAT software (Addinsoft) on the single cell data 
extracted from control, responsive and resistant tumors respectively (Fig. 4.13). The 
proximity among single cell observations is measured by the dissimilarity coefficients of 
Euclidian distance. Ward's minimum variance method is employed as a strategy to 
calculate the dissimilarity in order to minimize the total within-cluster variance and thus 
keep each clustered group as homogeneous as possible
23
. The truncation level is 
determined automatically by the software based upon the entropy and tries to create 
homogeneous groups. The calculated dissimilarity coefficients are used as indices for 
quantifying the functional heterogeneity of the tumor. As we can see in Fig. 4.12 b, this 
heterogeneity index correlates pretty well with the tumor progression during the course of 
CC214-2 treatment. 
4.3.4 Partial least square (PLS) modeling of immunohistochemical data 
To demonstrate the relationships between single cell proteomic data and tumor 
response to different therapy combinations, we use a PLS model to ask whether an IHC 
tissue analysis of the mouse models explored in Fig. 4.14 b could yield a deeper 
understanding of the SCBC data analysis.  
The digitized IHC data under different drug combinations was used to establish the 
explanatory metrics X (independent metrics) (Figs. 4.10 and 4.15). Prior to establishing the 
corresponding dependent metrics Y, two characteristic terms that can be directly extracted 
from the tumor growth curves were introduced. One is the transitory growth rate (TGR) at 
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the time of sacrifice, which is defined as the average percentage of tumor volume 
change per day of the last three time points available on the growth curves, except for cases 
C+U DR, C+D DR and V2 where last two time points were used instead of three. The other 
term is the cell cycle measure (time constant τ) that can be extracted by fitting the growth 
curves (Fig. 4.15 a) with the exponential growth function. The tumor volume in the growth 
curves was modeled by the exponential growth function 
' /
0 0
t
tV V V e
   , where Vt is the 
normalized tumor volume over time. V0 can be understood as the portion of the solid tumor 
that was not engaged in tumor growth and V0
'
 was the portion that was engaged in the 
tumor growth
24
. ε~N(0,σ) is an error term from a normal distribution with mean zero and 
SD σ. At the initial state (t=0), '0 0 =1-tV V V   . The application of effective drug 
combinations can significantly shut down the tumor progression and thus lead to large 
values of the cell cycle measure τ as expected (Fig. 4.10). Please note that the functional 
form used here is an oversimplified model without separately considering the 
initial/consistent cell death caused by the drugs or any phenotypical switch and emergence 
of resistance during the treatment. Only the single metric τ was used to roughly assess the 
drug effect. But it still captures the essential information to disclose the independent 
signaling modes as discussed in the paper. 
The PLS model was constructed in XLSTAT software (Addinsoft) according to the 
following iterative formulae
25
: 
 first eigenvector of ( ) ' 'a i-1 i-1 i-1 i-1w E F F E  
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where the Ei represents the residue of the ith principal component of the explanatory 
metrics with the score vector ti, loading vector pi while Fi represents the residue of the ith 
principal component of the dependent metrics with score vector ti and loading vector qi. 
wi is the loading weight that strikes a balance between modeling X and modeling Y. The 
prime represents the matrix transpose. The residue matrices E0 and F0 just contain the 
mean-centered X- and Y- variables. The regression coefficient matrix that leads out the 
functional form between X and Y can be calculated as ' -1 '
h h h h h
B = W (P W ) Q , where h is 
the number of principal components used in the model. 
Eight observations (V1, C, D, U, C+D, D+U, C+U and C-R) were employed to 
establish the calibration phase of the model. The stability and predictive quality of the 
model were assessed by calculating Q
2
cum index that involves the predicted residual sums 
of squares (PRESS) statistic and sum of squares of error (SSE) for a model with one less 
component
26
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PRESS statistic requires a leave-one-out cross-validation. The Q
2
cum index 
measures the global contribution of the h first principal components to the predictive 
capacity of the model. As a result, the optimal number of principal components used in the 
model can be determined with respect to this index. The first two PCs yielded the highest 
Q
2
cum index for this model and thus were employed in the subsequent calculations.  
In the prediction phase, the established model was used to predict the TGR at sacrifice 
and cell cycle measure τ for the observations C+D DR, C+U DR and V2. The predicted 
values were compared against the observed values extracted from the growth curves and 
 
Figure 4.10 Explanatory and dependent matrices used for PLS modeling. The explanatory 
matrix is composed of numerical IHC data for samples treated under different drug 
combinations, including V1 for vehicle, C for CC214-2 treated, D for dasatinib treated, U for 
U0126 treated, U+D for combinatory treatment of U0126 and dasatinib, C+D for CC214-2 and 
dasatinib, C+U for CC214-2 and U0126, C-R for resistant stage of CC214-2 treated sample, 
C+D DR for C+D treated samples after drug removal, C+U DR for C+U treated samples after 
drug removal and V2 for the control sample in the first CC214-2 only mouse experiment. The 
values of TGR at sacrifice and cell cycle measure are directly extracted from the corresponding 
growth curves under different drug treatments. The orange part of the table represents the 
calibration phase of the model and blue part represents the prediction phase. 
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shown in Fig. 4.16 a. The good match between observation and prediction further 
validates the model reliability and stability.  
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4.4 RESULTS AND DISCUSSION 
4.4.1 Single-cell proteomic analysis  of three drug treatment stages 
The  single cell proteomic data is shown in Fig. 4.11. Comparing the SCBC 
measurements with immunohistochemical (IHC) and immunoblot analyses performed on 
 
Figure 4.11 Single-cell proteomic data for three drug treatment stages (a) SCBC data 
represented as one-dimensional scatter plots (n=133, 62, 143 for control, responsive resistant 
groups) for each protein at each test condition. The averaged fluorescence intensity with 
standard error of the mean (SEM) is overlaid for each protein. Statistical uniqueness is 
evaluated by two-tailed Mann-Whitney test for pairwise comparison (black stars) and Kruskal-
Wallis ANOVA for comparison among three groups (blue stars, NS, not significant; *P < 0.05; 
**P < 0.005; ***P < 0.0005). (b) Immunoblots of various proteins from bulk assays for the 
control and resistant states of GBM39.  
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bulk tumor samples confirmed that CC214-2 significantly suppressed mTORC1 and 
mTORC2 signaling, which became reactivated during acquired resistance (Figs. 4.1 c and 
4.11 b and Appendix B: Supplementary Tables).  
The SCBC data set enabled statistical analyses of the functional protein correlations in 
tumor cells for all three states. This analysis provides insight into how changes in signaling 
coordination, rather than just protein levels, might be implicated in acquired resistance. 
During response, CC214-2 profoundly diminished the levels of most proteins (Fig. 4.11 b 
 
Figure 4.12 Prediction of therapy strategies by statistical analysis of single-cell data. (a) 
Protein-protein correlation networks for the three states, extracted from SCBC data. Average 
protein levels are reflected in the sphere diameters, while correlation strengths are reflected in 
the thickness of the edges (see key). For the resistant state, existing, new, and lost correlations, 
relative to control, are indicated (see key). (b) Quantification of  the heterogeneity of GBM39 
xenograft cells at the three stages. AHC analysis based upon Ward’s method was utilized to 
perform a clustering analysis for the three states of GBM39. The dissimilarity level obtained 
from that analysis provides the heterogeneity index. (c) Correlations between key functional 
proteins and the first principal component for the control and responsive states from in vivo (i) 
and in vitro (ii) drug treatment tests. In both cases, two independent signaling modes are 
identified. 
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and the sphere sizes in Fig. 4.12 a), as well as the protein signaling coordination (the 
loss of network edges of Fig. 4.12 a). This is reflected in a near 10-fold drop in the 
functional heterogeneity of the cell population (Fig. 4.12 b). The functional heterogeneity 
index, defined as the dissimilarity value in the agglomerative hierarchical clustering (AHC) 
analysis based upon Ward's minimum variance method (See Chapter 4.3.3), is a metric of 
the dispersion of the functional protein levels across all single cell assays
23
. Note the 
appearance of 9 new interactions (green edges in Fig. 4.12 a), 8 of which are associated 
with phospho(p)- extracellular-signal-regulated kinases 1 (p-ERK1) and p-proto-oncogene 
tyrosine-protein kinase (p-Src). These results point to the possibility that a gain of function 
through ERK/Src might be leading to CC214-2 resistance by promoting downstream 
mTOR signaling
27-29
. Additionally, acquired resistance was associated with a sharp 
increase in functional heterogeneity, an outcome inconsistent with clonal selection of a 
resistant subpopulation, suggesting that mTOR kinase inhibitor resistance may be mediated 
by signaling network adaptation. 
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4.4.2 Signaling modes extraction by PCA predicts effective therapy strategies 
To clarify how the protein coordination was altered by mTOR kinase inhibition, we 
performed principal component analysis (PCA), using the two-dimensional matrix of 
measured protein-protein covariances as input. The PCA analysis of the protein-protein 
covariance matrix reflects protein signaling coordination, rather than absolute protein 
 
Figure 4.13 Clustering and PCA of single-cell data for control and responsive tumor 
samples. Agglomerative Hierarchical Clustering (AHC) based upon Ward’s method was 
used for the clustering analysis. (a) Three major subpopulations with different functional 
phenotypes were observed for control sample. The subpopulation with magenta color shows 
the highest mTOR activity. (b) The AHC and PCA analysis for responsive sample. The 
greatly elevated p-ERK1/p-Src partition in PC1 implies that ERK/Src signaling, that has less 
prominent regulatory activity in control (PC3), takes over the signaling in responsive stage 
due to the repression of the previously dominant regulatory proteins associated with 
mTORC1/C2. 
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levels. The pie charts at the top of the plot represent the composition of the 3 top principal 
components (PCs) of the full single cell dataset. The 1st PC contains many contributions, 
reflecting the highly interconnected correlation network of Fig. 4.12 a. However, the 2nd 
and 3rd PCs are dominated by mTORC1 signaling (p-mTOR and p-P70S6K) and ERK/Src 
signaling, respectively. PCA analysis of the subpopulation most characterized by mTOR 
 
Figure 4.14 In vivo validation of 7 mono- or combination therapies. (a) In vivo test results for 
the 7 mono- or combination therapies based upon the predictions from the SCBC data analysis. 
All 7 predictions proved correct. P values derived from Student’s T-test (variations expressed 
as s.d.; n= 11 for controls, n= 6 for CC214-2 group, n= 4 for Dasatinib group, n= 4 for U0126 
group, n= 4 for each combinatory treatment group) (b) IHC images of drug targets for the 
combinatory treatments of CC214-2 and ERK and/or Src inhibitors, attesting the successful 
down-regulation of all of the drug targets (digitized results and statistical analysis shown in the 
Appendix B: Supplementary Tables). Scale bar: 100μm. 
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signaling (purple) is striking. PC1 (capturing 26% of the total variance) is dominated by 
mTORC1 signaling (p-mTOR and p-P70S6K); PC2 (21% of the variance) is dominated by 
mTORC2 signaling (p-Akt S473) and PC3 (16% of the variance) is dominated by p-ERK1 
and p-Src signaling.  This implies potentially independent signaling modes are active 
within the same cellular subpopulations.  
We then calculated the correlations between the assayed proteins and the first principal 
component (PC1) in response to CC214-2. PC1 captures the most essential feature of the 
signaling network, and so this analysis estimates the influence of a given protein on 
signaling coordination. For the control tumor, PC1 is populated by p-ERK1, p-Src, p-Akt1, 
 
Figure 4.15 Single Nucleotide Polymorphism (SNPs) analysis that shows no substantial 
karyotype variation between vehicle and resistant genomes. Two control and two CC214-2 
resistant samples were analyzed by Affymetrix SNP array 6.0, using a filter of 200kb and 50 
markers for the copy number variation analysis. Although all of these samples show a very 
unstable genome, there is no obvious difference among these groups. Four karyotyping pictures 
are shown. 
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p-mTOR, and p-P70S6 kinase (p-P70S6K, Fig. 4.12 ci). In response to CC214-2, these 
5 proteins split into 2 groups, or modes (a term we use to imply collective behavior). The 
influence of p-Akt1, p-mTOR, and p-P70S6K (red mode of Fig. 4.12 ci) on signaling 
coordination, relative to p-ERK1 and p-Src (blue mode), is diminished. Among the proteins 
whose levels are altered by treatment with CC214-2, the signaling coordination associated 
with mTORC1/C2 signaling was repressed while the signaling coordination associated with 
MAPK/ERK and Src signaling were increased. This observation suggested that the latter 
may have gained the ability to maintain signal flux to key downstream mTOR effectors 
(Fig. 4.13). These data suggest that targeting any one of the 5 proteins is unlikely to exhibit 
a strong effect, as would targeting two proteins from the same mode. However, 
simultaneously targeting 1 protein from each mode would be predicted to constitute an 
effective therapy. Correspondingly, we treated mice implanted with GBM39 using 
combinations of CC214-2 (C), dasatinib (D, Src inhibitor), and U0126 (U, MEK/ERK 
inhibitor) to test four therapies or therapy combinations expected to be ineffective, and 3 
therapy combinations expected to be effective. 
4.4.3 In vivo validation of predicted therapy strategies 
Consistent with our model, treatment with C, D, U or D + U could not induce long 
term tumor growth inhibition (Figs. 4.7, 4.8 and 4.14 a). In contrast, combining C with 
either D and/or U completely suppressed tumor growth in vivo, with no adverse effects of 
either the tumor or the treatment. Treatment was stopped after 47 days with no sign of 
recurrence (Fig. 4.14 a). Removal of combination therapy resulted in rapid tumor regrowth 
(Fig. 4.14 a). This was concomitant with reactivation of signaling pathways (Fig. 4.14 b, 
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Appendix A: Supplementary Figures and Appendix B: Supplementary Tables). These 
results demonstrate that in a therapeutically representative in vivo model of one of the most 
aggressive and treatment resistant of all human cancers, GBM39
12
, long-term disease 
remissions can be induced and sustained if independent signaling modes are sufficiently 
inhibited. 
4.4.4 In vitro perturbation identifies the fast network adaptation mechanism 
We next addressed the question of whether the resistance to CC214-2 that appears to 
be mediated by ERK/Src signaling arose from a clonal subpopulation of tumor cells, or 
from an adaptation of the signaling networks within those same tumor cells that responded 
to CC214-2. For that experiment, we treated the EGFR+ cells resected from a GBM39 
control with 2μM solutions of CC214-1 (in vitro use) for 60 hours. We reasoned that 60 
hours of in vitro treatment was sufficient for the tumor cells to establish a new steady state. 
The treatment did not induce significant cell death, and the GBM39 tumor cells do not 
divide during the 60 hour exposure to CC214-1 (Fig. 4.8). The results, shown in Fig. 4.12 c 
(ii), are consistent with the in vivo observations, and clearly indicate that resistance arises 
from adaptation of the cancer cells to the drug, rather than from the emergence of a 
subpopulation of drug-resistant cells. Single Nucleotide Polymorphism (SNP) analysis of 
the vehicle and resistant genomes detected no substantial karyotype variation between the 
two, providing further evidence of an adaptive mechanism (Fig. 4.15). The in vitro 
recapitulation of in vivo observations implies such an analysis for identifying effective 
therapy combinations could potentially be carried out on biopsied tissue from GBM 
patients, within a clinically relevant time-scale.  
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4.4.5 PLS modeling on tissue analysis independently confirms the signaling modes 
hypothesis.  
We used a Partial Least Squares (PLS) model to ask whether an IHC tissue analysis of 
the mouse models explored in Fig. 4.14 b could yield a deeper understanding of the SCBC 
 
Figure 4.16 PLS modeling confirms the independent signaling modes as effective combination 
therapies. (a) Validation of the PLS modeling: The calibration phase of the model was 
constructed by using part of observations (orange part). The first two PCs were used to perform 
a leave-one-out cross-validation to assess the model stability. The established model was then 
employed to predict the TGR at sacrifice and cell cycle metric τ for the remaining observations 
(blue part). The prediction from the model matches well with the observed values extracted 
from the growth curves in Figure 4a, showing the validity of the model. (b) The correlations of 
the IHC assayed proteins, as well as the functional observations, with PC1 and PC2. TGR 
strongly correlates with oncogenic kinases such as p-P70S6K, p-Akt1 and p-4EBP1. p-Src and 
p-ERK1 largely dominate PC2, constituting an independent signaling mode that accounts for 
the resistance of mTOR kinase inhibitor. (c) PLS modeling shows that, for effective drug 
combinations, it projects qualitatively differently from linear superposition of individual drugs, 
which in turn implies that synergistic drug combinations do not simply act in a linearly additive 
manner. 
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data analysis of Figs. 4.12 c and 4.13. (See Chapter 4.3.4). Such an analysis can 
demonstrate biological relationships between different classes of information
30, 31
. The 
approach is similar to PCA, but seeks to identify those PCs of one data set (the IHC 
analysis) that can best predict a second data set (functional observations of the tumor). 
Quantitative IHC assays of a panel of functional proteins assayed from resected tumor 
tissues from the control model and for all 7 tested therapy combinations, at the time points 
of sacrifice, were loaded into an explanatory matrix (Figs. 4.10 and 4.16). The dependent 
matrix was constructed from two characteristic parameters of tumor growth under different 
therapies in Fig. 4.14 a. One is transitory growth rate (TGR) at sacrifice, defined as the 
average percentage of tumor volume change per day of the last three time points measured 
before the sacrifice. The other one is a cell cycle metric that is the time constant τ extracted 
by fitting the growth curves with the exponential growth function (see Chapter 4.3.4 and 
Fig. 4.10 for detail).  
The PLS model was developed using a subset of the treatment and treatment 
combinations (Figs 4.10 and 4.16 a, orange shaded data sets), and then validated through 
predictions of the remaining measurements (Figs 4.10 and 4.16 a, blue shaded data sets). 
The agreement between predictions and observations supports the validity of the model. In 
Fig. 4.16 b we plot the correlations of the assayed proteins, as well as the functional 
observations, with the x- and y-axis as the 1
st
 and 2
nd
 PCs, respectively. The mTORC1/C2 
associated proteins that constitute mode 1 of Fig. 4.12 c lie principally along PC1, as does 
the TGR. This means that the TGR is largely predicted using just the IHC measurements of 
the mTORC1/C2 proteins. Importantly, the TGR correlates with the phosphorylation of 
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ribosomal protein S6 (p-S6), the eukaryotic translation initiation factor 4E-binding 
protein 1 (p-4EBP1) and the oncogenic protein kinase Akt (p-Akt), which are key factors 
regulating protein translation and cellular proliferation. The cell cycle measure τ is anti-
correlated with the TGR and the mTORC1/C2 associated proteins, but also lies largely 
along PC1. These relationships indicate that mTORC1/C2 and their effectors are the 
primary drivers that account for tumor growth. The functional proteins p-ERK1 and p-Src 
constitute a second group largely aligned along PC2, with only weak relationships to 
proteins in the first group. This is consistent with a resistance mechanism associated with 
MAPK/ERK1 signaling and Src signaling. It also provides independent confirmation of the 
two signaling modes that are pointed to in the single cell analysis.  
The PLS model also allows for a comparison of the therapy combinations, with each 
combination represented by its respective IHC data set (Appendix B: Supplementary 
Tables). Examination of the projections of C, U and C+U (Fig. 4.16 c) on the first two PCs 
indicate that C+U projects qualitatively differently from the linear superposition of single-
input C and U, as does the therapy combination C+D, indicating cooperative effect of the 
two drugs that are non-linear. The therapeutically ineffective combination of D+U, 
however, is very close to the linear superposition of D and U. 
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4.5 CONCLUSION 
Our data provide evidence that tumor cells can respond to a therapy by adopting a new 
steady state that restores the tumor growth characteristics temporarily disrupted by the 
therapy. This resistance mechanism is pre-existing; the same cells that respond to the 
therapy also adapt and develop resistance to it. For the human-derived GBM39 model 
explored here, a single cell proteomics analysis of the phosphoprotein signaling networks 
associated with tumor growth can resolve the independent signaling modes that drive tumor 
growth in both the untreated and drug resistant states. Such analyses can be rapidly carried 
out using untreated tumor biopsies, and so may represent a new approach for guiding the 
selection of targeted combination therapies that can anticipate resistance, and thereby lead 
to the induction of sustained long term disease remission.  
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4.7 APPENDIX A: SUPPLEMENTARY FIGURES 
 
 
 
 
 
 
Figure 4.17 IHC on GBM39 xenograft samples. Statistical analysis of the quantitative IHC 
graphs for the mTOR, Erk and Src biomarkers and biological response markers (quantitative 
values mentioned in Table S2; C: CC214-2 responsive samples; R: CC214-2 resistant samples; 
D: dasatinib; U: U0126; stop: xenografts collected after interruption of the treatments); *P< 
0.05; **P<0.005; ***P≤0.0005, N.S., Not Significant; (Student’s T-test, values represent the 
average of three independent section's fields). 
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Figure 4.18 IHC on GBM39 xenograft samples. Statistical analysis of the quantitative IHC 
graphs for additional mTOR biomarkers (quantitative values mentioned in Table S2; C: CC214-
2 responsive samples; R: CC214-2 resistant samples; D: dasatinib; U: U0126; stop: xenografts 
collected after interruption of the treatments); *P< 0.05; **P<0.005; ***P≤0.0005, N.S., Not 
Significant; (Student’s T-test, values represent the average of three independent section's 
fields). 
  
173 
4.8 APPENDIX B SUPPLEMENTARY TABLES 
Table 4.1 Reagents Used. The upper part of the table provides the sequences of the 
oligonucleotides used in the protein immunoassays. All oligonucleotides were synthesized by 
Integrated DNA Technology (IDT) and purified via high performance liquid chromatography 
(HPLC). The DNA coding oligomers were pre-tested for orthogonality to ensure that cross-
hybridization between non-complementary oligomer strands was negligible (<1% in photon 
counts). Below the oligonucleotides is a list of the antibodies and standard proteins used for the 
SCBC multiplexed protein assay as well as the immunoblotting and the immunohistochemistry. 
Name DNA Sequence Melting Point 
B 5'-AAA AAA AAA AAA AGC CTC ATT GAA TCA TGC CTA -3' 57.4 
B' 5' NH3AAA AAA AAA ATA GGC ATG ATT CAA TGA GGC -3' 55.9 
C 5'- AAA AAA AAA AAA AGC ACT CGT CTA CTA TCG CTA -3' 57.6 
C' 5' NH3-AAA AAA AAA ATA GCG ATA GTA GAC GAG TGC -3' 56.2 
D 5'-AAA AAA AAA AAA AAT GGT CGA GAT GTC AGA GTA -3' 56.5 
D' 5' NH3-AAA AAA AAA ATA CTC TGA CAT CTC GAC CAT -3' 55.7 
E 5'-AAA AAA AAA AAA AAT GTG AAG TGG CAG TAT CTA -3' 55.7 
E' 5' NH3-AAA AAA AAA ATA GAT ACT GCC ACT TCA CAT -3' 54.7 
F 5'-AAA AAA AAA AAA AAT CAG GTA AGG TTC ACG GTA -3' 56.9 
F' 5' NH3-AAA AAA AAA ATA CCG TGA ACC TTA CCT GAT -3' 56.1 
G 5'-AAA AAA AAA AGA GTA GCC TTC CCG AGC ATT-3' 59.3 
G' 5' NH3-AAA AAA AAA AAA TGC TCG GGA AGG CTA CTC-3' 58.6 
H 5'-AAA AAA AAA AAT TGA CCA AAC TGC GGT GCG-3' 59.9 
H' 5' NH3-AAA AAA AAA ACG CAC CGC AGT TTG GTC AAT-3' 60.8 
K 5'-AAA AAA AAA ATA ATC TAA TTC TGG TCG CGG-3' 55.4 
K' 5' NH3-AAA AAA AAA ACC GCG ACC AGA ATT AGA TTA-3' 56.3 
L 5'-AAA AAA AAA AGT GAT TAA GTC TGC TTC GGC-3' 57.2 
L' 5' NH3-AAA AAA AAA AGC CGA AGC AGA CTT AAT CAC-3' 57.2 
M 5'-AAA AAA AAA AGT CGA GGA TTC TGA ACC TGT-3' 57.6 
M' 5' Cy3-AAA AAA AAA AAC AGG TTC AGA ATC CTC GAC-3' 56.9 
DNA Label Antibody for Conjugation in SCBC Source 
B’ Human/Mouse Phospho-Akt1 (S473) DuoSet® IC ELISA kit R&D DYC2289B 
C’ Human Phospho-TOR (S2448) DuoSet® IC ELISA kit R&D DYC1665 
D’ Phospho-p70 S6 Kinase (T389) DuoSet® IC ELISA kit R&D DYC896 
E’ Human Total p21/CIP1/CDKN1A DuoSet® IC ELISA kit R&D DYC1047 
F’ Human Total p53 DuoSet® IC ELISA kit R&D DYC1043 
G’ Human/Mouse Cleaved Caspase-3 (Asp175) DuoSet® IC ELISA kit R&D DYC835 
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H’ Human/Mouse/Rat Phospho-ERK1 (T202/Y204) DuoSet® IC ELISA kit R&D DYC1825 
K’ Human Phospho-Src (Y419) DuoSet® IC ELISA kit R&D DYC2685 
L’ Human total HIF-1α DuoSet® IC ELISA kit R&D DYC1935 
Catalog # Antibody for Immunoblotting and Immunohistochemistry Source 
4060 p-Akt Ser473 (D9E) Cell Signaling 
9275 p-Akt Thr308 Cell Signaling 
4857 p-S6 Ser235-236 (91B2) Cell Signaling 
9205 p-P70S6K Thr389 Cell Signaling 
2855 p-4E-BP1 Thr37-46 (236B4) Cell Signaling 
4370 p-ERK Thr202-204 (D13.14.4E) Cell Signaling 
2971 p-mTOR Ser2448 Cell Signaling 
2976 p-mTOR Ser2448 (49F9) Cell Signaling 
2972 mTOR Cell Signaling 
2101 p-Src Tyr416 Cell Signaling 
3217 p-NDRG1 Thr346 Cell Signaling 
5482 p-NDRG1 Thr346 (D98G11) Cell Signaling 
2280 raptor (24C12) Cell Signaling 
06-847 EGFR Millipore 
36-9700 p-EGFR Tyr1086 Invitrogen 
2997 p-PRAS40 Thr246 (C77D7) Cell Signaling 
441100G p-PRAS40 Thr246 Invitrogen 
9541 cleaved PARP Asp214 Cell Signaling 
ABM-2052 PTEN (6H2.1) 
Cascade 
Bioscience 
VP-RM04 Ki67 (SP6) Vectorlabs 
SMC-184D HIF-1α StressMarq 
16314-015 TUNEL Invitrogen 
NB-600-501 Actin (AC15) Novus Biologicals 
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Table 4.2. IHC quantification of the GBM39 xenograft stains. Statistical significant differences 
(P<0.05, student’s T-test) vs. vehicle samples highlighted in green (C= CC214-2 responsive 
xenografts; R= CC214-2 resistant xenografts; D= Dasatinib; U= U0126; C+D= CC214-2 + 
Dasatinib; C+U= CC214-2 + U0126; DR= Drug Removed). Values represent the average of three 
independent section's fields. 
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C h a p t e r  5  
Translating single-cell functional proteomics into the clinic 
5.1 INTRODUCTION 
There exists a sufficient pharmacy to treat many patients with advanced cancers, such 
as GBM. Resolving the functional heterogeneity to determine the signaling network 
coordination within an individual patient's tumor can potentially inform an effective 
therapy strategy to treat the patient
1
. In Chapter 4, we have shown that functional 
proteomics assays, executed on statistical number of single cells in patient derived models 
that we perturb with the drugs we would use in the clinic to treat the patient, yield deep 
insight towards identifying independent drug targets within the tumor, which in turn inform 
therapy combinations that are highly effective in treating the tumors in GBM mouse model. 
We have also shown that, such analysis can be performed ex vivo on tumor biopsy samples 
within in a clinically relevant time scale. It therefore provides the rationale to extend our 
current work into the clinic, which will enable us to interrogate GBM tumor samples in a 
way that could potentially yield a straightforward, rapid interpretation to give therapeutic 
guidance to the attending physician. 
Our approach centers on resolving the heterogeneity within a GBM tumor biopsy 
sample at the level of the activated, functional protein signaling networks that are 
associated with the aberrant nature of the tumor. However, such translation is not 
straightforward. The first challenge is that primary cells directly from tissues contain 
significantly lower copy number of a given functional protein than do cultured cells. Thus, 
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assay sensitivity is an important factor here, which demands improvement on 
engineering design and surface chemistries of the microchip. A reliable 
measurement/decision protocol is also required to streamline the single-cell proteomic 
assays and to ensure a robust and highly reproducible data collection and analysis, so that 
meaningful comparison can be made between datasets collected across time points, patient 
samples and assay conditions. Additionally, a challenge with any clinical study that 
attempts to match patients with appropriate therapies and therapy combinations, and for 
which the disease is highly heterogeneous, is that we don’t know, prior to analysis, what 
drugs will be required, and so we need to design a trial that can potentially accommodate 
multiple drugs from different manufacturers and select the appropriate dose smartly. 
In this chapter, we first discuss the advances in engineering and surface chemistry that 
address the technical challenges for translating SCBCs into the clinic. We further present 
some preliminary data collected from a pediatric GBM patient bearing an EGFR amplified 
tumor to demonstrate the workflow of the clinical translation.  
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5.2 EXPERIMENTAL METHODS 
5.2.1 Surface chemistry optimization for clinical applications 
Primary cells are smaller in size and have a higher dynamic range in terms of 
oncogenic signaling compared to the genetic modified cell lines. An antibody microarray 
with high sensitivity is therefore critical in this context, which in turn requires a higher 
DNA loading for patterning the ssDNA microarray. To increase the loading and overall 
uniformity, we developed a method based upon covalent binding between ssDNA and 
poly-L-lysine (PLL) in place of the original evaporation method (See Chapter 2). An 
additional PLL coating step is also included (Fig. 5.1).  
Specifically, after bonding of PDMS device to the PLL slide, 0.1% PLL solution 
(Sigma Aldrich) is flowed through the microchannels followed by air blow drying. Then a 
library of amine modified ssDNAs, diluted in a mixture of DMSO and deionized water 
(v/v=3:2) with a final concentration of 300μM and mixed with 2mM BS3 solution (a linker 
molecule that contains an amine-reactive N-hydroxysulfosuccinimide (NHS) ester at each 
 
Figure 5.1 The reaction scheme for covalent DNA patterning. Accessible α-amine groups 
present on the amine-terminated ssDNA and ε-amines on lysine residues react with NHS-esters 
and form amide bonds. A covalent amide bond is formed when the NHS-ester crosslinking 
agent reacts with a primary amine releasing N -hydroxysuccinimide 
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end of an 8-carbon spacer arm, v/v=1:1), is flowed into each of the microfluidic channels. 
The solution-filled chip is then placed in a sealed petri-dish with controlled moisture for 90 
minutes to immobilize amine-terminated ssDNAs to the PLL surface. After incubation, the 
PDMS elastomer is removed from the glass slide in water containing 0.02% SDS followed 
with intensive washing in 0.02% SDS in water.  
Fig. 5.2 shows how different surface chemistries will affect the DNA barcode 
patterning with respect to DNA loading and overall uniformity. Comparing with other 
methods, covalent binding method gives out highest loading and best over uniformity 
(lowest CV, Fig. 5.2 b). It also shorten the original 3-5 days process by evaporation method 
to only 1 day. The high DNA loading achieved plus other surface chemistry optimizations 
 
Figure 5.2.  The surface chemistry of DNA barcode patterning, and its importance for 
quantitative single-cell protein immunoassays.  a. The microfluidic flow patterning template 
used to prepare barcodes on poly-L-lysine(PLL)-coated glass slides. i. The elastomer flow 
patterning mold contains 1 channel for each barcode stripe – a mold for a 20 element barcode is 
drawn.  The channels meander across the glass surface, and are on the order of 1 meter long and 
10-20μm wide, depending upon the design.  ii. ssDNA oligomers are initially patterned, and the 
quality of those DNA barcodes is assessed by hybridizing each strand with a complementary, 
dye-labeled ssDNA’ oligomer.  iii. The digitized fluorescence micrograph shows the uniformity 
of a 10-element barcode, across the region indicated by the yellow bar in ii.  b. Digitized 
fluorescence data reflects the DNA loading of 20μm wide barcode stripes, based on various 
patterning chemistries.  “O” and “X” mean that the indicated chemistry was or was not used, 
respectively; CV (coefficient of variation) values through the entire slide were listed, showing 
the loading uniformity from various patterning strategies.  c. Calibration data for the protein p-
ERK, measured using the various chemistries.  Note that surface chemistry improvements yield 
more than a 10-fold increase in assay sensitivity, enabling single cell assays of both highly 
challenging primary cells (the GBM patient sample), and model cell lines.   
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such as matching best antibody ELISA pairs and using brighter dyes finally transfer to a 
more than 10-fold increase in assay sensitivity and more than 50-fold in signal to noise 
ratio (Fig. 5.2 c). 
5.2.2 High throughput solutions 
Single-cell functional proteomic microchips are the diagnostic workhorse for clinical 
applications. The nature of the single-cell biology is that statistical numbers of single cells 
must be analyzed for any given assay to generate a meaningful result
2
. Although our first 
microchip prototype contained only 120 microchambers
3
, the SCBC has been consistently 
developed and optimized since then and now it contains 320 microchambers per chip. Two 
chips have to be run in parallel each time to ensure enough statistics, which is not yet 
 
Figure 5.3 Illustration of the two-layer cross-stripe DNA microarray construction. (a, top) 
Schematic illustration of the chemical patterning to produce the high density cross-stripe 
ssDNA arrays. Stripes of DNA are first patterned onto a PLL coated glass slide using a flow 
patterning mold . A second flow patterning step, orientated perpendicular to the first, is used to 
create unique addresses at the intersections of the cross stripes. The color coded DNA 
oligomers illustrate the patterning/hybridization sequence to produce the final array. (a, 
bottom) Validation of the cross-stripe barcode microarray. Each square unit of fluorescent 
spots represents many copies of a 3×3 array. The plot at right provides the fluorescence 
intensity profile of the vertical line through the two square unit. (b) The microfluidic flow 
patterning template used to prepare high density 10μm × 10μm cross-stripe DNA array 
throughout the entire slide by covalent method. It will generate more than 240,000 array spots 
in the whole slide after patterning.  
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optimal. Another valve-free SCBC design
4
 developed for assessing cell-cell 
communications has around 10,000 microchambers and allows around 1,000 single cell 
assays per chip (Fig. 5.3 a). But it requires subtle operations and is less robust, which is not 
acceptable for analyzing precious clinical materials. A high throughput proteomic 
microchip that is robust and easy to handle is therefore desired for the clinical translation. 
The density of integration of SCBCs depends on the density of the antibody 
microarray and thus the density of ssDNA barcode. The two layer DNA patterning strategy 
is developed to achieve a significantly high density DNA microarray. Previously, we 
started with an n-element stripe-structured ssDNA microarray (Fig.5.2 a) that was further 
converted to an n-element antibody microarray by DNA hybridizations. In the new 
patterning approach, a second set of ssDNA are flow patterned at the right angle to the first 
set which yield an addressable n×m array, where n and m are the numbers of 
microchannels utilized for the two flow patterning steps (Fig. 5.3). This approach has been 
successfully demonstrated as a 3×3 array with 20μm × 20μm feature size in the central area 
of a standard microscope glass slide by traditional evaporation method
4
. A higher density 
array with 10μm × 10μm feature size throughout the entire slide by covalent binding 
method is still under developing with promising preliminary results (Fig. 5.3 b). 
Two layer DNA flow patterning yields microarray slides that are similar to 
commercial products, but with much extremely higher density and a much smaller feature 
size (10μm vs. 150μm). This in turn provides us great flexibility to design the SCBCs with 
much more microchambers per chip to ensure sufficient statistics. The smaller chamber 
volume, as a byproduct, will further increase the assay sensitivity. The multiplexity can 
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also be easily expanded from assaying 9–20 functional proteins per chamber to 16–36 
functional proteins. 
5.2.3 The protocol and workflow of analyzing patient biopsy samples 
Fig. 5.4 illustrates the general workflow from collecting patient's tissue biopsy samples 
to single-cell proteomics test and finally down to give out therapeutic guidance. Briefly, 
immediately following tissue resection, we use standard protocols to dissociate the solid 
tissue into single cell suspension (See Chapter 4.2 for detail). We select EGFR+ cells from 
the population, which apparently permits capture of other relevant cellular subsets from the 
tumor. Those cells are extracted using either MACS or FACS, and then cultured for a short 
period of time (2 hours), which allows for the removal of inviable cells. The remaining 
cells are loaded into an SCBC (or Betabox) and immediately analyzed. For investigating 
drug perturbations, the EGFR+ cells are cultured for a set of time in the presence of a 
 
Figure 5.4 Protocol for analyzing resected tumor tissue to identify effective therapy 
combinations. 
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targeted inhibitor at a relevant dosing level, prior to analysis. The time between the 
tumor resection and SCBC or Betabox assay completion is about one day.  
The Betabox
5
 is a combined microchip/Beta particle camera device which is an in vitro 
equivalent of [
18
F]FDG Positron Emission Tomography (PET) scans
6
. It only requires 
about 100 cells per assay and can simultaneously test up to 4 different conditions. Betabox 
assays yield metabolic assessments of drug target engagement, drug responses, as well as 
pharmacokinetic information within a few hours. 
Once the SCBC assay is complete, a genepix array scanner is utilized to digitize the 
fluorescent signal. A custom algorithm is applied to transfer the scanned image into a data 
table for analyzing the signaling network, and to reveal protein signaling modes (See 
Chapter 4.4.2 for detail). Comparing single cell proteomics data of the EGFR+ tumor cells 
with and without drug treatment and integrating information from Betabox and other 
pathological/molecular characterizations will help identify the effective drug combinations 
to treat the tumor.  
The period from surgical resection to completion of all the experiments is about 2-3 
days. Two additional days are required for data analysis. By the end of the fifth day, the 
analyzed data is discussed with the attending physician(s), with suggestions for effective 
therapy emerging from those conversations. These predictions will be first evaluated in 
vitro through a set of functional assays such as cell viability and proliferation tests. The 
patient can potentially start the therapy as soon as a week after the surgery. 
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5.3 RESULTS AND DISCUSSION 
5.3.1 Fast signaling adaptation of a pediatric GBM tumor to lapatinib: a patient 
sample case study 
The resected GBM tumor was pathologically characterized as EGFR amplified. As a 
result, Lapatinib, as an FDA approved EGFR inhibitor, was suggested by the physicians in 
the first place to treat the patient. We then utilized SCBC platform to quantify the levels 
and correlative interactions of 10 proteins and phosphoproteins from statistical numbers of 
single EGFR+ tumor cells in both treatment naïve and 48 hours Lapatinib perturbed
7
 (with 
a clinically relevant dosage, 2000nM) stages. We tested p-mTOR, p-P70S6K and p-4EBP1 
 
Figure 5.5 Single-cell scatter plots and correlation networks on pediatric GBM cells. (a) SCBC 
data represented as one dimensional scatter plot for vehicle and Lapatinib treated sample. The 
averaged fluorescence intensity with standard error of the mean (SEM) is overlaid for each 
protein. Statistical uniqueness is evaluated by two-tail Mann-Whitney test for pairwise 
comparison(*P<0.05; **P<0.005;***P<0.0005, NS: not significant). (b) Protein-protein 
correlation networks for control and Lapatinib treated samples, extracted from SCBC data. The 
correlation strengths are reflected in the thickness of the edges (see keys). For Lapatinib treated 
sample, new correlations, relative to control, emerge between p-ERK1 and core mTOR 
effectors. 
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associated with mTORC1 signaling; p-Akt1, p-NDRG associated with mTORC2 
signaling; p-ERK1, p-Src and three p53 related functional proteins. Both mTORC1/C2 
associated proteins and p-ERK/p-Src are downstream effectors of EGF Receptor tyrosine 
kinase signaling
3
 (Fig. 5.5). The results, however suggested that Lapatinib neither induced 
a considerable cell killing nor shut down the oncogenic signaling as it is supposed to, 
although it has successfully hit the target by evaluating the phosphorylation level of two 
 
Figure 5.6 Prediction of therapy strategies by statistical analysis of the single-cell data. (a) 
Correlations between key functional proteins and the first principal component (PC) for control 
and Lapatinib perturbed samples. Most of the mTOR effectors still dominate the signaling 
coordination in the drug treated sample. The influence of p-ERK1 on the signaling 
coordination significantly rise up in drug treated stage compared to control. The composition 
of the first three PCs for control sample reveal the decoupling between mTOR signaling and 
ERK/Src signaling. (b) The down regulated p-EGFR phosphorylation levels indicate Lapatinib 
has successfully engaged its target. (c) Quantification of the heterogeneity of the cancer cells at 
control and Lapatinib perturbed stages. The heterogeneity index is obtained from calculating 
the dissimilarity level of the AHC analysis (Ward's method, see chapter 4 for detail). (d) The in 
vitro validation shows that adapted tumor cells is more resistant to Lapatinib treatment. 
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related EGFR phosphorylation sites Tyr1173 and Tyr1068 (Fig. 5.6 b)
8, 9
.  
The expression level and spread of fluctuation of p-ERK1 greatly up-regulated in 
Lapatinib treated sample suggested a potential gain of function of MAPK/ERK signaling 
(Fig 5.5 a). By comparing the correlation networks of the tumor cells with and without drug 
treatment, it's readily to see that the drug actually triggered p-ERK1 to take over the 
signaling coordination and at the same time, the interactions among the core mTORC1/C2 
effectors became even stronger (Fig 5.5 b). In other words, the cancer cells quickly adapted 
to EGFR inhibition by activating ERK/Src signaling and mTOR signaling, suggesting that 
mTOR and ERK/Src signaling might provide two independent druggable pathways, which 
is in accord with our findings in the GBM 39 mouse model (See Chapter 4 for detail). The 
calculation of the influence of functional proteins on signaling coordination, as well as the 
population heterogeneity, further confirmed that Lapatinib did seem to be a bad player here 
(Fig. 5.6 a and c). The analysis of the composition of the first 3 principal components also 
implied the decoupling between mTOR signaling and ERK/Src signaling is present in this 
tumor (Fig. 5.6 a).  
Integrating the information above, we predicted that the inhibition of EGFR by 
Lapatinib would not be likely to suppress the tumor growth. In contrast, the adapted tumor 
cells may progress even faster due to the highly elevated mTOR signaling which drives the 
tumor to grow. We validated our prediction in vitro by assessing the cell viability and 
proliferation after 2 days Lapatinib treatment for both fresh tumor cells and adapted tumor 
cells (2000nM Lapatinib 2-day pretreated cells). We started with two sets of petri-dishes (3 
repeats in each condition) with identical cell number representing fresh or adapted tumor 
cells respectively. After 2-day Lapatinib treatment at 2000nM o.p.d., slight cell death was 
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observed in fresh tumor samples while a cell growth was observed in the adapted tumor 
samples, which is wholly consistent with our predictions (Fig 5.6 d). 
5.3.2 Prediction on effective therapy combination 
The single cell analysis on treatment naïve samples showed a highly activated mTOR 
signaling and thus suggested that mTOR is a reasonable drug target for treating this tumor. 
 
Figure 5.7 Validation of therapy predictions via SCBC and functional tests. (a) SCBC data 
represented as one dimensional scatter plot for control and drug combination, XL-765 plus 
Trametinib (XL765+T) treated sample. The averaged fluorescence intensity with standard 
error of the mean (SEM) is overlaid for each protein. Statistical uniqueness is evaluated by 
two-tail Mann-Whitney test for pairwise comparison(*P<0.05; **P<0.005;***P<0.0005, NS: 
not significant). (b) Protein-protein correlation networks for control and Lapatinib treated 
samples, extracted from SCBC data. The correlation strengths are reflected in the thickness of 
the edges (see keys). For XL-765+T treated sample, the interaction among core mTOR 
effectors has been diminished. (c) Quantification of the heterogeneity of the cancer cells at 
control and XL-765+T treated stages. (d) Cell viability assay for control and XL-765+T treated 
samples. The drug combination successfully induces considerable cell death. 
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The data on Lapatinib perturbed samples further implied that ERK signaling may 
emerge to serve as a resistant mechanism through fast signaling network adaptation. As a 
result, we suggested that a combination of mTOR inhibitor (XL-765)
10
 and  MEK/ERK 
inhibitor (Trametinib)
11
 could potentially repress the oncogenic signaling and halt the 
tumor progression. We tested our prediction via  in vitro cell viability assay as well as 
single cell proteomics assay. The results were encouraging (Fig 5.7). 
Analysis on the signaling coordination reveals that the combination of XL-765 (1μM) 
and Trametinib (100nM) has successfully weakened the interactions among the core 
mTOR effectors without triggering ERK signaling to compensate. Although p-Src shows 
slightly increased interactions with mTOR effectors, the correlations are not strong. The 
functional heterogeneity of drug treated samples is also significantly reduced (Fig. 5.7 b 
and c). Cell viability assays shows that the predicted drug combination (XL-
765+Trametinib) can induce a considerable cell death during the course of treatment, which 
in part validates our prediction (Fig. 5.7 d). The single-cell analysis also implies that a 
clinically available drug that can hammer mTOR signaling harder would be desired.  
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5.4 CONCLUSION 
Our data clearly illustrates the point that, via that single-cell functional proteomics 
analysis, we can rapidly determine the signaling network coordination within an individual 
patient's tumor and gain new insight into combining existing therapies together in much 
more effective ways. That knowledge can then be used to design a combinatorial therapy to 
treat the patient. The results and protocol discussed here are preliminary. Additional tests 
for intracranial xenograft models and GBM patient samples are required to further refine 
the measurement protocols as well as the analytical approaches to integrate the information 
from different sources to reach a robust decision strategy. 
Drug dosage and dosing schedule are also important factors that need further 
investigation. It has been shown that varied dosing schedules determined based upon the 
information such as maximum tolerated dose and pharmacokinetic processes of the drugs 
have great impact on the dynamics of the acquired resistance to Erlotinit in EGFR-mutant 
lung cancer. High-dose pulses with low-dose continuous therapy impede the development 
of resistance to the maximum extent compared with constant dose therapy
12
. It has 
implications in our scenario as well. If the fast network adaption induced therapy resistance 
is also a reversible dynamic switch, as we believe so, matching effective drug combination 
with smart dosing strategy for individual patient could potentially yield stronger synergetic 
effect with respect to tumor suppression and tumor killing. 
  
190 
5.5 REFERENCES 
1. Cloughesy, T.F. & Mischel, P.S. New strategies in the molecular targeting of 
glioblastoma: how do you hit a moving target? Clin Cancer Res 17, 6-11 (2011). 
2. Welch, C.M., Elliott, H., Danuser, G. & Hahn, K.M. Imaging the coordination of 
multiple signalling activities in living cells. Nat Rev Mol Cell Biol 12, 749-56 
(2011). 
3. Shi, Q. et al. Single-cell proteomic chip for profiling intracellular signaling 
pathways in single tumor cells. Proc Natl Acad Sci U S A 109, 419-24 (2012). 
4. Wang, J. et al. Quantitating cell-cell interaction functions with applications to 
glioblastoma multiforme cancer cells. Nano Lett 12, 6101-6 (2012). 
5. Wang, J. et al. Fast metabolic response to drug intervention through analysis on a 
miniaturized, highly integrated molecular imaging system. J Nucl Med 54, 1820-4 
(2013). 
6. Dooraghi, A.A. et al. Betabox: a beta particle imaging system based on a position 
sensitive avalanche photodiode. Phys Med Biol 58, 3739-53 (2013). 
7. Vivanco, I. et al. Differential sensitivity of glioma- versus lung cancer-specific 
EGFR mutations to EGFR kinase inhibitors. Cancer Discov 2, 458-71 (2012). 
8. Zwick, E., Hackel, P.O., Prenzel, N. & Ullrich, A. The EGF receptor as central 
transducer of heterologous signalling systems. Trends Pharmacol Sci 20, 408-12 
(1999). 
  
191 
9. Rojas, M., Yao, S. & Lin, Y.Z. Controlling epidermal growth factor (EGF)-
stimulated Ras activation in intact cells by a cell-permeable peptide mimicking 
phosphorylated EGF receptor. J Biol Chem 271, 27456-61 (1996). 
10. Prasad, G. et al. Inhibition of PI3K/mTOR pathways in glioblastoma and 
implications for combination therapy with temozolomide. Neuro Oncol 13, 384-
92 (2011). 
11. Flaherty, K.T. et al. Improved survival with MEK inhibition in BRAF-mutated 
melanoma. N Engl J Med 367, 107-14 (2012). 
12. Foo, J., Chmielecki, J., Pao, W. & Michor, F. Effects of pharmacokinetic 
processes and varied dosing schedules on the dynamics of acquired resistance to 
erlotinib in EGFR-mutant lung cancer. J Thorac Oncol 7, 1583-93 (2012). 
 
  
192 
Published materials included in the thesis 
1. Shi, Q. et al. Single-cell proteomic chip for profiling intracellular signaling 
pathways in single tumor cells. Proc Natl Acad Sci U S A 109, 419-24 (2012). 
(Included in Chapter 2, http://www.pnas.org/content/109/2/419.short) 
2. Wei, W. et al. Hypoxia induces a phase transition within a kinase signaling 
network in cancer cells. Proc Natl Acad Sci U S A 110, E1352-60 (2013). 
(Included in Chapter 3, http://www.pnas.org/content/110/15/E1352.short) 
 
 
 
 
 
 
 
 
 
 
 
 
 
